The role of genetic and epigenetic mechanisms as modifiers of age-at-onset (AO) in familial amyloid polyneuropathy (FAP ATTRV30M) by Diana Isabel da Silva Santos
 
 
 
DIANA ISABEL DA SILVA SANTOS 
 
 
THE ROLE OF GENETIC AND EPIGENETIC MECHANISMS AS MODIFIERS OF AGE-
AT-ONSET (AO) IN FAMILIAL AMYLOID POLYNEUROPATHY 
(FAP ATTRV30M) 
 
 
Tese de Candidatura ao grau de Doutor em 
Ciências Biomédicas submetida ao Instituto de 
Ciências Biomédicas Abel Salazar da 
Universidade do Porto.  
 
Orientadora – Prof. Doutora Alda Maria Botelho 
Correia de Sousa  
Categoria – Professora Associada com 
Agregação 
Afiliação – Instituto de Ciências Biomédicas Abel 
Salazar  
 
Co-orientadora – Prof. Doutora Carolina Luísa 
Cardoso Lemos 
Categoria – Professora Auxiliar Convidada 
Afiliação – Instituto de Ciências Biomédicas Abel 
Salazar  
 
Co-orientadora – Prof. Doutora Isabel da 
Conceição Moreira Pereira Alonso  
Categoria – Professora Afiliada 
Afiliação – Instituto de Ciências Biomédicas Abel 
Salazar  
 
Porto, 2017
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial support 
This study was supported by Fundação para a Ciência e Tecnologia, FCT, (PTDC/SAU-
GMG/100240/2008) and PEsT, co-supported by ERDF and COMPETE, and by 
Financiamento Plurianual de Unidades de Investigação and through a PhD grant 
(SFRH/BD/91160/2012) financed by Programa Operacional and União Europeia. 
 
 
 
 
  
 
 
 
  
  
 
 
 
“I am unable to find answers  
to my questions, precisely  
because I am a man of questions” 
 
Corino de Andrade 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ACKNOWLEDGMENTS/AGRADECIMENTOS 
 
A realização deste projecto só foi possível devido à contribuição e colaboração de várias 
pessoas e instituições. Portanto, gostaria de expressar o meu profundo e sincero 
agradecimento a todos aqueles que directa ou indirectamente contribuíram para a sua 
concretização. 
 
À Prof. Doutora Alda Sousa, minha orientadora, os meus sinceros agradecimentos por ter 
aceite orientar-me neste projecto, pelo apoio, disponibilidade e confiança em todos os 
momentos e pelos sábios conselhos e sugestões nos momentos que mais precisei. Muito 
OBRIGADA! 
À Prof. Doutora Carolina Lemos, minha co-orientadora, um agradecimento muito especial por 
tudo…por ter aceite orientar-me, por me ajudar a acreditar em mim, pelo constante 
acompanhamento, disponibilidade, apoio e incentivo ao longo de todo o projecto, por todas as 
oportunidades, pelo espírito de equipa, pela amizade e pela enorme confiança depositada em 
mim e no meu trabalho. Muito OBRIGADA “chefinha”! 
À Prof. Doutora Isabel Alonso, um agradecimento também por ter aceite ser minha co-
orientadora, pelos valiosos conselhos, disponibilidade e auxilio com o seu conhecimento 
científico. Muito OBRIGADA! 
Ao Miguel Alves Ferreira, por todo o apoio e sugestões que ajudaram a enriquecer o meu 
projecto, pelos preciosos conselhos, pela amizade e companheirismo e pelas fantásticas 
viagens aos congressos. OBRIGADA! 
Ao Professor Doutor Jorge Sequeiros por me ter dado a oportunidade de integrar o seu grupo 
de investigação, UnIGENe, o que me permitiu posteriormente prosseguir com o meu projecto 
de doutoramento. Agradeço todo o apoio e conselhos ao longo destes anos. 
À Prof. Doutora Denisa Mendonça, por ter aceitado fazer parte da minha comissão de 
acompanhamento, reforçando assim a colaboração já existente com o grupo ao longo dos 
últimos anos e pelo apoio nas várias análises estatísticas. 
À Prof. Doutora Manuela Grazina, por ter aceitado fazer parte da minha comissão de 
acompanhamento, do qual resultou uma colaboração que me permitiu cumprir um dos 
objectivos a que me propus realizar, abrindo-me novas oportunidades de aprendizagem. À 
Maria João Santos e restante equipa do Laboratório de Genética Bioquímica no Centro de 
  
 
 
Neurociências e Biologia Celular (CNC) em Coimbra por toda o apoio durante a realização 
desta parte do projecto.  
À Doutora Teresa Coelho, pela preciosa colaboração e pelo apoio com as amostras de DNA 
indispensáveis para a realização deste projecto, assim como à restante equipa da Unidade 
Corino de Andrade do Centro Hospitalar do Porto. 
Ao Prof. Doutor Pedro Oliveira, pelos excelentes esclarecimentos e precioso apoio em várias 
análises estatísticas. 
Aos doentes, familiares e a todos os que participaram como controlos neste estudo, que sem 
a sua participação nada seria possível. Obrigada por toda a disponibilidade. 
A todos os colegas do grupo UnIGENe, nomeadamente à Conceição Pereira, Sara Morais, 
Marlene Quintas, João Neto, Mariana Santos e Joana Silva e à Patrícia Arinto e Andreia Dias 
do Centro Genética Preditiva e Preventiva (CGPP) por me proporcionarem dia após dia 
momentos de alegria, descontração e convívio. 
Aos restantes colegas do CGPP, como a Filipa Brandão, Susana Sousa, Ana Margarida 
Lopes, Rita Bastos, Milena Paneque, Andreia Perdigão e Víctor Mendes pelo incentivo e força.  
Ao Paulo Silva, pelo apoio bioinformático durante este projecto. 
À Mafalda Bacalhau, por todo o apoio e motivação e pelo abrigo quando mais precisei. 
À Ana Azevedo, pela cumplicidade, amizade, força e motivação. 
À Cheila Ribeiro, pela cumplicidade, amizade, confiança e boa disposição. 
Ao Miguel Castro, por me ter animado em vários momentos e pelos excelentes conselhos.  
À Sofia Félix, pela amizade genuína, por ouvires os meus desabafos, pelos conselhos e apoio 
sempre que precisei. 
À Rita Serrano, pelos conselhos, força e motivação quando mais precisei.  
A todos os meus amigos pelo companheirismo, alegria e palavras de encorajamento.  
A toda a minha familia, que sempre me deu apoio e confiou em mim e aos meus avós 
paternos, que apesar de já não estarem entre nós... tenho a certeza que ficariam muito 
orgulhosos com este passo na minha formação. 
  
 
 
Ao Pedro, que é um pilar na minha vida, obrigada por estares sempre presente, pela 
paciência, amizade, compreensão, apoio incondicional em todos os momentos e por me 
fazeres feliz! OBRIGADA! 
Aos meus queridos pais e irmão, que são os meus alicerces, agradeço todo o apoio, 
confiança, suporte familiar que me proporcionam, carinho e amor. Obrigada por todos os 
conselhos e por me permitirem sempre seguir os meus sonhos. A vocês estou eternamente 
grata! OBRIGADA! 
 
Agradeço ao Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e 
Inovação em Saúde (i3S) por ter proporcionado as condições essenciais ao desenvolvimento 
desta tese. 
 
Agradeço também à Fundação para a Ciência e Tecnologia a atribuição da bolsa de 
doutoramento sem a qual não conseguiria realizar este estudo, assim como à Amyloidosis 
Foundation e a todas as organizações pelo apoio ao longo destes anos.    
 
  
 
 
  
 
 
TABLE OF CONTENTS 
PUBLICATIONS ......................................................................................................................... i 
ABBREVIATIONS.......................................................................................................................ii 
ABSTRACT...............................................................................................................................v 
SUMÁRIO ...............................................................................................................................vii 
1. INTRODUCTION ...........................................................................................................1 
1.1. Major Types of Amyloidoses ........................................................................................3 
1.2. History of Familial Amyloid Polyneuropathy (FAP) .......................................................3 
1.3. The Genetic Cause ......................................................................................................4 
1.3.1. TTR Gene and Molecular Variants .............................................................. 4 
1.4. Structure and Functions of TTR ...................................................................................5 
1.5. Clinical Presentation ....................................................................................................7 
1.6. Genotype-Phenotype Correlation ...............................................................................10 
1.6.1. Clinical Aspects of Late-Onset Patients ..................................................... 11 
1.7. The Origin of Familial Amyloid Polyneuropathy ..........................................................12 
1.7.1. Incidence and Prevalence ......................................................................... 12 
1.8. Age-at-Onset Variability .............................................................................................13 
1.8.1. A Wider Range of Age-at-onset ................................................................. 13 
1.8.2. Recognition of Late-Onset Cases .............................................................. 15 
1.9. Genetic Anticipation ...................................................................................................15 
1.10. Penetrance and Gender-Related Aspects ................................................................16 
1.11. Age-at-onset (AO) Genetic Modifiers .......................................................................18 
1.11.1. Modifier Candidate-Genes ....................................................................... 18 
1.11.1.1. Genes Associated with Regulatory Pathways of TTR ........................... 19 
1.11.1.2. Genes Associated with New Signalling Pathways ................................ 19 
1. Extracellular matrix (ECM) remodelling genes ................................................. 20 
2. Extracellular signal-regulated kinases 1/2 (ERK1/2) and ERK1/2 kinases (MEK1/2)
 .................................................................................................................. 20 
  
 
 
3. Heat Shock Proteins (HSPs) ........................................................................... 20 
4. 14-3-3 proteins ................................................................................................ 21 
1.11.1.3. Repetitive Loci of Genes Related with Neuro-associated Disorders ..... 21 
1.11.1.4. Sex-Linked Genes ................................................................................ 23 
1.11.2. Role of Mitochondrial DNA (mtDNA)........................................................ 24 
1.11.2.1. Structure and Function of Mitochondria ................................................ 24 
1.11.2.2. Mitochondrial Genome and mtDNA Haplogroups ................................. 24 
1.12. Therapies for Familial Amyloid Polyneuropathy........................................................26 
1.12.1. Liver Transplantation ............................................................................... 26 
1.12.2. TTR Tetramer Stabilizers ........................................................................ 27 
1.12.3. Gene Therapy ......................................................................................... 28 
1.12.4. Fibril Disrupters and Amyloid Clearance .................................................. 29 
1.12.5. Anti-oxidant and Anti-apoptotic Treatments ............................................. 29 
1.13. Searching for new answers to old questions regarding AO variability in TTR-FAP 
Val30Met ..........................................................................................................................30 
2. MAJOR GOALS .........................................................................................................32 
2.1. Specific Objectives ....................................................................................... 34 
3. GENERAL PLAN OF INVESTIGATION ...........................................................................36 
4. RESULTS .................................................................................................................40 
4.1. Candidate-genes modulating AO ...............................................................................42 
Article 1. Variants in RBP4 and AR modulate age-at-onset in Familial Amyloid 
Polyneuropathy (FAP ATTRV30M) ............................................................ 44 
Article 2. Familial amyloid polyneuropathy in Portugal: New genes modulating age-at-
onset .......................................................................................................... 59 
Article 3. Large normal alleles of ATXN2 gene associated with a decrease in age-at-
onset in Portuguese patients with TTR-FAP Val30Met ............................... 73 
4.2. Unravelling mtDNA content in TTR-FAP Val30Met ....................................................87 
Article 4. An increase in mtDNA copy number may cause an early age-at-onset in 
Portuguese patients with Familial Amyloid Polyneuropathy ........................ 88 
5. DISCUSSION ........................................................................................................... 101 
  
 
 
5.1. Genetic modifiers in AO modulation ......................................................................... 103 
5.1.1. TTR-FAP Val30Met as a prime model for the identification of genetic modifiers
 .................................................................................................................103 
5.1.2. Strategies to identify genetic modifiers .....................................................105 
Genome-wide association studies (GWAS) ........................................................105 
Linkage analysis ................................................................................................105 
A candidate-gene approach ...............................................................................105 
5.1.3. Beyond case-control studies, the importance of a family-based approach 106 
5.2. Candidate-genes modulating AO ............................................................................. 106 
5.2.1. Importance of re-evaluating previous studies ...........................................106 
Role of APCS and RBP4 as modifier genes .......................................................107 
Role of modifier genes: C1Q complement ..........................................................108 
5.2.2. Uncovering new candidate modifier genes of TTR-FAP Val30Met ...........109 
1. Signal transduction pathways ....................................................................109 
ECM remodelling genes .....................................................................................110 
MEK-ERK MAPK signalling genes .....................................................................110 
HSP gene ..........................................................................................................111 
14-3-3 zeta (YWHAZ) gene ................................................................................112 
2. Sex-linked variants associated with AO variability .....................................112 
3. Repetitive loci as modifiers of AO – the emergent role of ATXN2 gene .....114 
5.2.3. Importance of functional implications in the validation of variants .............116 
5.2.4. Importance of gene-gene interactions ......................................................119 
5.3. Mitochondrial DNA copy number as a potential biomarker of TTR-FAP Val30Met ... 120 
5.4. An integrated perspective of biological mechanisms involved in AO of TTR-FAP 
Val30Met ........................................................................................................................ 122 
TTR aggregates, MEK-ERK MAP kinases pathway genes and other players .....122 
Interaction of AR gene with MEK/ERK and HSPs genes ....................................124 
ATXN2 gene, Ca2+ homeostasis and mitochondrial dysfunction .........................124 
5.5. Strengths of our study .............................................................................................. 125 
1. Sample size ..............................................................................................125 
  
 
 
2. Reliable of definition of AO ........................................................................125 
3. Family-centred approach ..........................................................................126 
4. Using a powerful statistical and in silico analysis .......................................126 
6. CONCLUSIONS ....................................................................................................... 128 
7. FUTURE PERSPECTIVES .......................................................................................... 133 
8. REFERENCES ......................................................................................................... 137 
9. APPENDIX .............................................................................................................. 171 
Appendix 1 .........................................................................................................173 
Appendix 2 .........................................................................................................175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Publications   
i 
 
PUBLICATIONS 
 
Results already published or in preparation were used in this thesis, as described below: 
 
Article 1: Santos D; Coelho T; Alves-Ferreira M; Sequeiros J; Mendonça D; Alonso I; Lemos 
C; Sousa A. Variants in RBP4 and AR genes modulate age-at-onset in Familial Amyloid 
Polyneuropathy (FAP ATTRV30M). Eur J Hum Genet 2016 May;24(5):756-60. doi: 
10.1038/ejhg.2015.180. Epub 2015 Aug 19. 
Article 2: Santos D; Coelho T; Alves-Ferreira M; Sequeiros J; Mendonça D; Alonso I; Lemos 
C; Sousa A. (2016) Familial Amyloid Polyneuropathy in Portugal: New genes modulating age-
at-onset. Ann Clin Transl Neurol. 2016 Dec 20;4(2):98-105. doi: 10.1002/acn3.380. eCollection 
2017. 
Article 3: Santos D; Coelho T; Alves-Ferreira M; Sequeiros J; Mendonça D; Alonso I; Sousa 
A; Lemos C. (2017) Large normal alleles of ATXN2 gene associated with a decrease in age-
at-onset in Portuguese patients with TTR-FAP Val30Met (In preparation) 
Article 4: Santos D; Santos MJ; Alves-Ferreira M; Coelho T; Sequeiros J; Alonso I; Oliveira P; 
Sousa A; Lemos C*; Grazina M*. (2017) An increase in mtDNA copy number may cause an 
early age-at-onset in Portuguese patients with Familial Amyloid Polyneuropathy (Submitted) 
 
 
 
 
 
 
 Abbreviations 
ii 
 
ABBREVIATIONS 
 
AD                       Alzheimer’s disease 
AL                        Light chain 
ALS                  Amyotrophic lateral sclerosis 
AO                       Age-at-onset 
APCS                 Amyloid P component, serum 
Aβ  Amyloid-β  
ApoA  Apolipoprotein A  
APOE              Apolipoprotein E 
AR  Androgen Receptor 
ASOs  Antisense oligonucleotides 
ATN1  Atrophin 1 
ATP  Adenosine triphosphatase 
ATXN1  Ataxin-1 
ATXN2  Ataxin-2 
ATXN3  Ataxin-3 
ATXN7  Ataxin-7 
BGN  Biglycan 
bp                      Base pairs  
C                        Cytosine  
Ca2+  Calcium  
CGPP  Centro de Genética Preditiva e Preventiva 
chr  Chromosome 
C1Q                 Complement, serum 
CNS  Central nervous system 
CSF                 Cerebrospinal fluid  
DHT  5α-dihydrotestosterone 
DM  Myotonic dystrophy 
DM1  Type 1 myotonic dystrophy  
DM2  Type 2 myotonic dystrophy  
DMPK  Dystrophia myotonica protein kinase 
DNA   Deoxyribonucleic acid 
DRPLA  Dentatorubral pallidoluysian atrophy 
ECM  Extracellular matrix 
 Abbreviations 
iii 
 
ER   Endoplasmic reticulum 
ERK1  Extracellular signal-regulated kinases 1 
ERK2  Extracellular signal-regulated kinases 2 
ESR  Estrogen receptor 
E2  17β-estradiol 
FAP   Familial amyloid polyneuropathy  
G  Guanine 
GEE  Generalized estimating equation 
GWAS   Genome-wide association studies  
HD                   Huntington’s disease 
HDL  High-density lipoproteins 
HDL2  Huntington disease Like-2 
HSA  Hospital Santo António 
HSF1               Heat shock transcription factor 1 
HSPs               Heat shock proteins  
HSPA4 or HSP70    Heat shock protein family A member 4 
HSPB1 or HSP27 Heat shock protein family B (small) member 1 
HSPB5     αB-crystallin 
HSPG2            Heparin sulfate proteoglycan 2 
HTT  Huntingtin 
I68L  IIe68Leu 
JPH3  Junctophilin 3 
JNK   c-jun NH2-terminal kinases  
kb                     Kilobases 
kDa  Kilodalton 
KO  Knockout 
L111M  Leu111Met  
LT  Liver transplantation  
MAF   Minor allele frequency 
MEK1  ERK1 kinases 
MEK2  ERK2 kinases 
MJD/SCA3  Machado-Joseph disease/Spinocerebellar ataxia type 3 
MMP-9             Matrix metalloproteinase-9 
mRNA  Messenger RNA  
MS   Multiple sclerosis 
mtDNA  Mitochondrial DNA 
n   Number 
 Abbreviations 
iv 
 
na  Not Applicable 
nDNA  Nuclear genome 
NGAL               Neutrophil gelatinase-associated lipocalin 
NGS   Next generation sequencing  
NPY  Neuropeptide Y 
OXPHOS  Oxidative phosphorylation  
PCR   Polymerase chain reaction 
PD                   Parkinson’s disease 
PNS  Peripheral nervous system 
PST  Presymptomatic testing  
RBP                Retinol binding protein 
ROS  Reactive oxygen species 
SAA                 Serum amyloid A 
SBMA  Spinal and Bulbar Muscular Atrophy 
SCAs   Spinocerebellar ataxias 
SCA1  Spinocerebellar ataxia type 1 
SCA2  Spinocerebellar ataxia type 2 
SCA7  Spinocerebellar ataxia type 7 
SCA17  Spinocerebellar ataxia type 17 
SG  Salivary glands 
siRNA  Small interfering RNA  
SNP                 Single nucleotide polymorphism 
TBP  TATA-box binding protein 
T4  Thyroid hormone thyroxine 
TF  Transcription factor  
TFBSs  Transcription factor binding sites  
T60A  Thr60Ala 
tRNA  Transfer RNA 
TTR                 Transthyretin  
TUDCA  Tauroursodeoxycholic acid 
USA   United States 
UTR    Untranslated regions  
V122I  Val122Ile 
V30M               Val30Met  
WT  Wild-type 
yrs.                  Years  
14-3-3 protein  Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation  
 Abstract 
 
v 
 
ABSTRACT  
 
Familial amyloid polyneuropathy (FAP) Val30Met is an autosomal dominant systemic 
amyloidosis due to point mutations in the transthyretin (TTR) gene (chr18q12.1). The most 
frequent variant, Val30Met (V30M, also known as p.Val50Met) is associated with various 
clusters, being Portugal the largest. Among Portuguese patients, TTR-FAP Val30Met shows a 
remarkable wide variation of age-at-onset (AO) [19-82 years (yrs.)]. In these families, intra- 
and intergenerational AO differences have been found and a large anticipation was uncovered, 
i.e., a decrease in AO over the generations. This variability is also apparent between genders.  
Although this variant is a necessary cause of the disease, other genetic, epigenetic, 
environmental and stochastic factors may also contribute to explain this phenotypic variation. 
Hence, unravelling modifiers that modulate AO variation in TTR-FAP Val30Met can be helpful 
for a deeper understanding of pathological mechanisms and for the development and/or 
validation of novel preclinical biomarkers.  
 Therefore, one of our aims with this project was to assess, in a larger sample of 
Portuguese families (over 300 patients), whether variants in several candidate-genes involved 
in TTR functional and biological signaling pathways could explain AO variation as well as 
gender-related differences in TTR-FAP Val30Met patients.  
Using an innovative method (a family-centred approach, considering that several 
patients belong to the same family), we found variants in several genes significantly associated 
with AO variation. For APCS, RBP4 and C1Q complement (C1QA and C1QC) genes, 
previously analysed in different studies, we confirmed their involvement as genetic modifiers 
of AO and unraveled specific variants associated with early and late AO. These results also 
strengthen the notion that different genetic backgrounds between populations can result in 
different disease pathologic mechanisms. Importantly, we unraveled, for the first time, new 
candidate-genes involved in TTR-FAP Val30Met signal transduction pathways associated with 
AO variability (BGN - in the females group, NGAL, MEK1, MEK2, HSP27 and YWHAZ), 
pinpointing new biological and molecular mechanisms. Additionally, sex-linked genes were 
also studied to explore gender-related differences regarding AO and we found that sex steroid 
hormones and X chromosome genes, as AR and BGN, were associated with AO in both males 
and females, which may help to explain such differences.  
There is currently evidence that unstable oligonucleotide repeats in several genes, 
besides being the cause of various neurodegenerative diseases, may also play a modifier role 
in others. Taking this into account, we analysed the repeat length of ten genes (ATXN1, 
ATXN2, ATXN3, ATXN7, TBP, ATN1, HTT, JPH3, AR and DMPK), where we found that the 
  Abstract 
 
vi 
 
presence of at least one normal allele longer than 22 CAG repeats in the ATXN2 gene may be 
associated with an earlier AO, decreasing its mean in 6 years. 
We also had a special concern with the assessment of functional implications of the 
significant variants found using an intensive in silico analyses through different bioinformatics 
tools. Interesting and unreported results influencing the regulation of the gene expression 
regarding transcription factor binding sites, splicing regulatory factors and miRNA binding sites 
were found, which might have impact in AO and phenotypic variability. Gene-gene interactions 
were also performed and a strong genetic interaction between C1QA and C1QC genes and 
NGAL and MMP-9 were found due to their interaction in biologic pathways. 
To further explore gender-related differences in AO, we studied the role of the mtDNA 
copy number, since mtDNA is exclusively maternally inherited. Thus, we found a significant 
association between mtDNA copy number and V30M TTR mutation carriers, where highest 
mean of mtDNA copy number was observed in early-onset patients. Importantly, early-onset 
offspring showed a significant increase in the mtDNA copy number when compared with their 
late-onset parents. These new findings allow us to suggest that mitochondrial dysfunction is 
associated with earlier TTR-FAP Val30Met events and may potentially function as a biomarker 
of the disease. 
In conclusion, using different approaches, we were able to find new interactions 
between all these different genes and pathways, which may play an important function in the 
TTR-FAP Val30Met pathology, and more importantly, interfere with AO modulation as a 
consequence of their deregulation. These findings may be helpful in follow-up of mutation 
carriers and for the development of novel therapeutic strategies. 
 
Keywords: Familial amyloid polyneuropathy, age-at-onset, modifiers, family-centred 
approach
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SUMÁRIO 
 
A polineuropatia amiloidótica familiar (PAF) Val30Met é uma amiloidose sistémica 
autossómica dominante causada por uma mutação pontual no gene da transtirretina (TTR) 
(chr18q12.1). A variante mais frequente, Val30Met (V30M, também conhecida como 
p.Val50Met) está associada com diversos focos, sendo Portugal o maior. Nos doentes 
portugueses, a PAF-TTR Val30Met apresenta uma grande variação na idade de início [19-82 
anos]. Nessas famílias, têm sido observadas diferenças na idade de início intergerações e 
dentro da mesma geração assim como uma grande antecipação, isto é, uma diminuição da 
idade de início ao longo das gerações. Esta variabilidade também foi observada entre sexos. 
Embora a esta variante seja necessária para causar a doença, outros factores 
genéticos, epigenéticos, ambientais e estocásticos podem também ajudar a explicar esta 
variação fenotípica. Por isso, o estudo de modificadores que interferem na variação da idade 
de início na PAF-TTR Val30Met pode ser útil para uma compreensão mais profunda dos 
mecanismos da doença e para o desenvolvimento e/ou validação de novos biomarcadores 
preclínicos. 
Portanto, um dos objectivos deste nosso projecto foi determinar, numa amostra grande 
de famílias portuguesas (mais de 300 doentes), se variantes em vários genes candidatos 
envolvidos nas vias de sinalização biológicas e funcionais da TTR poderiam explicar a 
variação da idade de início bem como as diferenças relacionadas com o sexo em doentes 
com PAF-TTR Val30Met. 
Utilizando um método inovador (uma abordagem centrada em famílias assumindo que 
vários doentes podem pertencer à mesma família), encontrámos variantes em diversos genes, 
significativamente associadas com a variação da idade de início. Para os genes APCS, RBP4 
e do sistema complemento C1Q (C1QA e C1QC), analisados anteriormente em diferentes 
estudos, confirmámos o seu envolvimento como modificadores genéticos da idade de início e 
identificou-se variantes específicas associadas com uma idade de início precoce e tardia. 
Estes resultados reforçam também a hipótese de que diferentes backgrounds genéticos entre 
as populações podem resultar em mecanismos diferentes da doença. Ainda mais importante, 
desvendámos, pela primeira vez, novos genes candidatos envolvidos em vias de transdução 
de sinais da PAF-TTR Val30Met associados com a variabilidade da idade de início (BGN - no 
grupo das mulheres, NGAL, MEK1, MEK2, HSP27 e YWHAZ), identificando-se assim novos 
mecanismos moleculares e biológicos. Adicionalmente, foram também estudados genes 
ligados ao sexo de forma a investigarmos as diferenças relacionados com o sexo na idade de 
início. Genes que codificam hormonas sexuais e localizados no cromossoma X, tal como o 
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gene AR e BGN, foram associados com a variação da idade de início nos homens e nas 
mulheres, o que pode ajudar a explicar esssas diferenças. 
Actualmente, existem evidências de que repetições oligonucleotídicas instáveis em 
vários genes, para além de serem a causa de várias doenças neurodegenerativas, podem 
desempenhar também um papel modificador em outras. Tendo isto em conta, analisámos o 
tamanho da repetição em dez genes candidatos (ATXN1, ATXN2, ATXN3, ATXN7, TBP, 
ATN1, HTT, JPH3, AR e DMPK), onde verificámos que a presença de pelo menos um alelo 
normal com um tamanho maior do que 22 repetições CAG no gene da ATXN2 pode estar 
associado com uma idade de início mais precoce, diminuindo a média da idade de início em 
6 anos. 
Para além disso, tivemos uma preocupação especial com a determinação das 
implicações funcionais das variantes encontradas, tendo realizado uma intensiva análise in 
silico, utilizando diferentes ferramentas bioinformáticas. Na análise in silico foram encontrados 
alguns resultados interessantes e ainda não descritos, demonstrando que estas variantes 
podem influenciar a regulação da expressão génica quanto à ligação a factores de transcrição, 
factores que regulam o splicing e ligação a miRNAs, o que pode ter um impacto na idade de 
início e variabilidade fenótípica. As interacções entre genes foram também testadas e foi 
encontrada uma forte interação genética entre os genes C1QA e C1QC e entre NGAL e MMP-
9, o que parece ser devido à sua ligação nas vias biológicas. 
De forma a investigar ainda mais as diferenças relacionadas com o sexo na idade de 
início, estudámos o papel do número de cópias do DNA mitocondrial (mtDNA), uma vez que 
o mtDNA é exclusivamente herdado por via materna. Assim, encontrámos uma associação 
significativa entre o número de cópias de mtDNA e os portadores da mutação TTR V30M, 
onde a média maior de número de cópias de mtDNA foi observada nos doentes com idade de 
início precoce. É de realçar que os doentes com idade de início precoce apresentam um 
aumento significativo no número de cópias de mtDNA quando comparado com seus 
progenitores com uma idade de início tardia. Estes resultados permitem sugerir que a 
disfunção mitocrondrial está associada com eventos precoces de PAF-TTR Val30Met, 
podendo potencialmente funcionar como um biomarcador da doença. 
Em conclusão, utilizando diferentes abordagens, fomos capazes de identificar novas 
interacções entre todos estes genes e vias que parecem desempenhar uma importante função 
na patologia da PAF-TTR Val30Met e, mais importante, parecem interferir com a variação da 
idade de início como uma consequência de desregulação de todos esses mecanismos. Estes 
resultados podem ser úteis para o seguimento dos portadores da mutação e para o 
desenvolvimento de novas estratégias terapêuticas. 
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1.1. Major Types of Amyloidoses  
 
Amyloidoses are a large group of diseases characterized by extracellular deposition of 
insoluble misfolded proteins called amyloid that cause the disruption of normal tissue structure 
and function or cytotoxic effects of intermediate forms of protein aggregates [1]. The 
accumulation of amyloid protein may be systemic, involving many organs and/or tissues or 
localized, less common, with amyloid deposition in individual organs.  
Amyloidoses may develop in the context of the underlying conditions usually though 
three major forms:  
1. Primary or idiopathic amyloidosis (AL amyloidosis), the most common type, is 
caused by deposition of light chain (AL) proteins in different disease states, but it may involve 
no underlying disease;  
2. Secondary or acquired amyloidosis (AA amyloidosis), the second most common, is 
due to the accumulation of serum amyloid A protein (or SAA) and it is associated with chronic 
inflammatory diseases; and  
3. Hereditary amyloidosis or familial amyloid polyneuropathy (FAP) is the rarest and is 
caused by deposition of abnormal amyloid protein.  
 
Within this third form, there are three main types FAP defined according to the 
precursor protein of amyloid: (1) transthyretin (TTR), (2) apolipoprotein A-I (apoA-I), and (3) 
gelsolin. Of these three, TTR-related amyloidosis, also known as familial or hereditary 
amyloidosis, is the most common inherited form of autosomal dominant systemic amyloidosis 
and was the first to be identified [2, 3].  
Phenotypically is heterogeneous, although the major clinical feature is sensorimotor 
polyneuropathy, although cardiomyopathy, carpal tunnel syndrome, vitreopathy or 
leptomeningeal involvement may also occur. Moreover, there is also the non-hereditary 
amyloidosis form that is caused by native or wild-type (WT) TTR known, primarily in the heart 
as senile systemic amyloidosis, which is an acquired disorder that mainly affects men after the 
age of 75 years (yrs.) [4]. 
 
1.2. History of Familial Amyloid Polyneuropathy (FAP) 
 
In 1952, Professor Corino de Andrade, a Portuguese neurologist and researcher, first 
described familial amyloid polyneuropathy (FAP or “Andrade disease”) in individuals living in 
Northern Portugal as a disease with insidious onset in the 2nd or 3rd decade of life, essentially 
occurring between 25-35 yrs., with characteristic paresis and impairment of neurological, 
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digestive and gastric function in several families [3]. Following his first observation at Hospital 
Santo António (HSA), Porto, in 1939 of a woman with “a peculiar form of peripheral 
neuropathy”, characterized by “familiar and generalized atypical amyloidosis involving 
specially the peripheral nerves”, Andrade looked for patients with the same clinical picture, 
examined their relatives and thus described the first cluster of the disease, an area in Northern 
Portugal centred and around the districts of Póvoa do Varzim and Vila do Conde, which 
remains the largest concentration of patients worldwide [5]. Furthermore, Andrade reported 64 
patients (from 12 families), 13 of which had no family history of the disease [3]. The “constant, 
repetitive and monomorphic” aspect of their clinical picture was undoubtedly the determinant 
factor to discover this disease. However, it should be highlighted that afterwards it was 
observed that FAP was not a disease only of the North coast and that there was a higher 
variability than initially observed in these patients. In the 60's, Ribeiro de Rosário described 19 
patients observed at Hospital de Santa Maria, Lisbon, of which eight got affected after their 40 
yrs. [6]. Afterwards, Antunes also studied 29 patients, ten of which had the first manifestations 
after the age of 45 yrs. Most of these patients came from Unhais da Serra (Serra da Estrela), 
where until today are concentrated most of the Portuguese families with late-onset [7]. In 1964, 
Becker established the mode of transmission as autosomal dominant [8]. Later, the disease 
was observed in a large group of individuals in Japan (1968) [9], and Sweden (1976) [10] (the 
second and third largest foci of FAP worldwide). The finding of the Swedish cluster [11] had 
implications in the ascertainment of late-onset cases in Portugal. In 1975, Andrade 
acknowledges, for the first time, the existence of late-onset cases in Portugal: “In a small but 
significant number of patients the onset is delayed until they are 35-50 years old, the illness is 
less serious, the effects either atypical or incomplete, and its evolution slower” [12]. This 
prompted the recognition and diagnosis of more late-onset cases (defined as onset at or after 
50 yrs).  
 
1.3. The Genetic Cause 
 
1.3.1. TTR Gene and Molecular Variants 
 
FAP is due to variants in the human TTR gene, which is localized on the long arm of 
chromosome 18, more precisely in the 18q12.1 region (OMIM 176300). This gene has a size 
of approximately 7 kilobases (kb) and is composed by four exons and three introns. The first 
exon, with 95 base pairs (bp) long, encodes a signal peptide of 20 amino acid residues and 
only the first three amino acid residues of the mature protein, while exons 2 (131 bp), 3 (136 
bp) and 4 (253 bp), hold the coding sequences for the residues 4-47, 48-92, 93-127 of the 
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mature protein, respectively [13, 14], encoding a protein with 127 amino acids residues. The 
introns, namely intron 1, intron 2 and intron 3 have length of 923 bp, 2092 bp and 3311 bp, 
respectively (Figure 1) [15]. Regarding evolution, the TTR sequence is highly conserved, since 
there is more than 80% homology among TTR mammalian sequences [16].  
 
 
 
 
Figure 1 – Structure of the human TTR gene showing exons, introns, translated and untranslated 
regions. 
 
 Since the description of the first causal variant - Val30Met (V30M) - associated with 
TTR related FAP (TTR-FAP), in 1984, by Saraiva et al., [17], until today, more than 120 
different disease-causing variants in the TTR gene have been identified, resulting from point 
substitutions in the polypeptide chain (Figure 2) [18, 19].  
 
Figure 2 – Schematic representation showing some of the disease-causing variants described through 
TTR gene (adapted from Alnylam Pharmaceuticals, Inc., 2014). 
 
1.4. Structure and Functions of TTR  
 
Native TTR, also known as prealbumin, is a soluble, relatively abundant 
homotetrameric protein consisting of four identical subunits each of which contains 127 amino-
acid residues, with a molecular mass of ~14 kilodalton (kDa) [15] and composed by eight β-
strands [18]. At the biochemical level, TTR was identified as the major precursor of amyloid 
deposits [20].  
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TTR is mainly synthetized and secreted by liver hepatocytes (approximately 95%) into 
the systemic circulation and only 5% by the choroid plexus into cerebrospinal fluid (CSF) of 
the brain and the retinal pigment epithelium of the eye [18, 20, 21]. TTR circulates in the blood 
predominantly as a 55 kDa tetramer, along with a very small amount of dissociated monomers 
[22].  
The two most acknowledged physiological functions of TTR are the transport of thyroid 
hormone thyroxine (T4) and retinol (vitamin A), in the latter case through binding to retinol-
binding protein (RBP) in plasm and CSF [23, 24]. Other mutant precursor proteins produced 
in the liver, such as apoA-I and apoA-II, lysozyme and fibrinogen Aα may be of etiological 
importance as well [25].  
TTR was found to possess proteolytic activity besides its transport ability. A small 
fraction of TTR is associated with high-density lipoproteins (HDL) through binding to apoA-I 
(the major apolipoprotein constituent of HDL particles) [26] and in vitro studies showed that 
TTR is able to cleave apoA-I in its C-terminal domain [27], which shows that TTR can also act 
as a novel protease. Similarly, TTR is able to cleave others natural substrates, including the 
neuropeptide Y (NPY), a neurotransmitter in the brain and autonomic nervous system, which 
proteolytic activity affects axonal growth [28] and amyloid-β (Aβ), originating smaller and less 
amyloidogenic peptides that might confer protection against Alzheimer´s disease (AD) [29].  
More recently, novel TTR functions, specially related to nervous system physiology 
have also been described, including its involvement in behaviour [30], neuropeptide processing 
[31] and nerve regeneration [32], and were characterized with studies using TTR knockout 
(KO) mice.  Regarding central nervous system (CNS), previous studies using TTR KO mice 
showed that TTR play a role in behaviour, since the absence of TTR is associated to 
behavioural alterations as decreased depressive-like behaviour, increased exploratory activity, 
and impaired spatial learning [30]. Afterwards, more studies using TTR KO mice showed that 
TTR may also be involved in regulation of neuropeptide maturation since increased NPY levels 
were found, with anti-depressant properties among others, reinforcing the previous results [31]. 
Concerning TTR role in the peripheral nervous system (PNS), it may also participate in 
sensorimotor performance, enhances, and accelerates nerve regeneration. Fleming et al., 
2007 showed that TTR WT mouse play a role in nerve regeneration, while TTR KO mice 
present a decreased regenerative capacity after sciatic nerve crush and sensorimotor 
impairment when assessed functionally [32]. The role of TTR in nerve biology and repair, may 
explain the preferential deposition of mutant TTR aggregates in the PNS of TTR-FAP patients 
[32]. Furthermore, TTR may also influences spatial reference memory, where young TTR KO 
mice display impairment compared to old TTR KO mice, suggesting that absence of TTR seem 
accelerate the poorer cognitive performance normally associated with aging [33]. 
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Structurally, TTR is very stable, however, it has been demonstrated that the pathogenic 
variants lead to amino acid substitutions that result in conformational changes in the primary 
structure of TTR protein, making with the tetramer become more unstable and more 
amyloidogenic [34, 35], leading to tetramer dissociation in monomers that are the basis for 
TTR amyloid formation. In agreement with this hypothesis, amyloid fibril formation might be 
triggered by tetramer dissociation, which could result in unfolded monomeric species that lead 
to the formation of non-fibrillary soluble oligomers and protofibrils with high predisposition for 
ordered aggregation into insoluble amyloid fibrils deposits in peripheral and autonomic nerve 
tissues (Figure 3) [36, 37]. 
 
 
 
 
 
 
 
Figure 3 – Hypothetical model for transthyretin amyloid cascade (adapted from Azevedo et al., 2013) 
[38] 
 
1.5. Clinical Presentation 
 
TTR-FAP is a rare autosomal dominant inherited systemic amyloidosis with onset in 
adult life, showing progressive and irreversible sensorimotor and autonomic neuropathy [39] 
and leading to death 10-15 yrs., after disease’ symptoms onset [40-42], if no therapeutic 
intervention is undertaken.  
This disease is characterized by the extracellular deposition of mutant amyloid fibrils 
composed of TTR protein, particularly in PNS, but depending on aetiology, is often also serious 
damage to the heart, kidneys and eyes. It is an axonal, nerve length-dependent neuropathy 
with early involvement of unmyelinated and low diameter myelinated fibres later progressing 
to an extensive degeneration of all nerve fibres. 
These pathological aspects translate into a characteristic clinical presentation: a 
peripheral neuropathy, gastrointestinal dysfunction, cardiac arrhythmia, genitourinary and 
cardiovascular autonomic dysfunction associated with a sensory neuropathy with loss of pain, 
nephropathy and leptomeningeal [43]. Thus, the natural course of TTR-FAP can be classified 
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into three stages: (1) sensory neuropathy, (2) progressive walking disability, and (3) wheelchair 
bound or bedridden [40]. 
 Symptoms of TTR-FAP vary, depending on the TTR genetic variant that is involved 
and the organ (or multiple organs) that demonstrate signs of amyloid deposition. The most 
common sites of amyloid deposits are associated with nerve and/or cardiac involvement 
(called neuropathy and cardiomyopathy, respectively) and the gastrointestinal tract. The 
kidneys, eyes and carpal ligament (also known as carpal tunnel syndrome) can also be 
affected. In table 1 below are described some of the main symptoms of TTR-FAP Val30Met. 
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Table 1 – Neurological and non-neurological symptoms observed in TTR-FAP Val30Met. 
 
Symptoms Manifestations Signs References 
Neurological 
Sensory-motor 
Peripheral 
Neuropathy 
 
 
 Numbness, tingling, pins and needles 
in the feet and hands 
 Weakness and pain in the arms and 
legs 
 Impaired thermal sensitivity in the feet, 
with decreased pinprick sensation 
 Motor deficit – impairment of light 
touch and deep sensations 
 
[44-47] 
Autonomic 
Neuropathy 
 
 Sexual impotence 
 Disturbances of gastrointestinal 
motility – altering diarrhoea and 
constipation, nausea and vomiting 
 Orthostatic hypotension – blood 
pressure drops on standing leading to 
dizziness or fainting 
 Neurogenic bladder 
 
[48, 49] 
Central 
Nervous 
System 
 
 Dementia 
 Seizures 
 Stroke-like episodes 
 Ataxia 
 Brain haemorrhages 
 Focal neurological episodes 
 
[50, 51] 
Extra-
Neurological 
Cardiac 
 
 Cardiomyopathy 
 Episodes of arrhythmias 
 Severe conduction disorders 
 
[52-56] 
Gastrointestinal 
 
 Nausea and early satiety 
 Recurrent vomiting 
 Diarrhoea and severe constipation 
 Weight loss and loss of appetite 
 
[57, 58] 
Ocular 
 
 Vitreous opacity 
 Dry eye 
 Trabecular obstruction 
 Glaucoma 
 Scalloped pupils 
 
[59, 60] 
Renal 
 
 Nephrotic syndrome 
 Progressive renal failure 
 Microalbuminuria 
 
[61, 62] 
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1.6. Genotype-Phenotype Correlation 
 
There is a strong genotype-phenotype correlation, where specific TTR variants may be 
associated with neurological diseases, cardiac diseases or both [63]. From all TTR variants 
described, the majority are amyloidogenic (approximately 40%) and in association with TTR-
related amyloidosis phenotype a neurologic and cardiac involvement have been found, from 
which 23% of TTR variants have been described to be linked to neurologic TTR-related 
amyloidosis and 17% linked only to heart, while fewer than ten were considered non-
pathogenic (data available in http://amyloidosismutations.com/mut-attr.php) [18].  
Most affected individuals are heterozygous for a pathogenic variant and express both 
normal and variant TTR. All are missense point mutations, with the exception of one 
microdeletion (Val122del) [64]. However, V30M disease-causing variant, 
NM_000371.3:c.148G>A (p.(Val50Met)), that results from a guanine (G) to cytosine (C) 
alteration in the exon 2 of the TTR gene, is by far, the commonest, and is the most prevalent 
cause of TTR-FAP Val30Met worldwide, being associated with clusters in Portugal, Japan, 
Sweden, Majorca and Brazil [3, 17, 65].  
By the contrary, more than 30 different TTR variants have been recognized in Japan 
and France [66-68]. On the other hand, Val122Ile (V122I) variant is the most common 
pathogenic variant in the United Sates (USA) and was found in around 4% of the African-
Americans and over 5% of the populations in some areas of West coast of Africa [69]. Some 
variants are associated primarily with neuropathy (e.g. V30M), while others induce 
cardiomyopathy as the predominant feature (e.g. V122I, Ile68Leu (I68L), Thr60Ala (T60A), 
Leu111Met (L111M)), but both manifestations can be present in different proportions (Figure 
4) [70].  
 
 
 
 
 
 
 
 
 
 
Figure 4 – Potential spectrum of genotype-phenotype correlation in TTR-related amyloidosis (Adapted 
from Rapezzi et al., 2013) [70] . 
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Amyloidogenic variants of the TTR gene lead to decrease of stability of the TTR 
tetramer followed of dissociation into monomers and subsequently extracellular deposition of 
amyloid in several tissues like peripheral and autonomic nerves, walls of the gastrointestinal 
tract, heart among others which may be associated with different hereditary amyloidoses [71].  
Furthermore, different non-amyloidogenic TTR variants have also been identified 
(namely Gly6Ser (G6S), Thr119Met (T119M), His90Asn (H90A), etc.). The TTR G6S variant 
was the most frequent [72], followed by TTR T119M and TTR H90A variants in Portuguese 
population [73], which do not seem to have any pathological effects [72, 73]. By the contrary, 
in individuals carriers of compound heterozygous variants of TTR V30M and other non-
pathogenic TTR variants as, for example, TTR V30M with T119M (TTR M30/M119) and TTR 
V30M with R104H (TTR M30/H104), the non-pathogenic TTR variant seems to confer a 
protective role on the clinical evolution of the disease where these individuals present a less 
severe phenotype of TTR-FAP Val30Met with slow progression of the disease, which may 
increase strongly the stability of TTR tetramers against dissociation, protecting V30M carriers 
from disease [74, 75]. However, in other compound heterozygous variants (TTR M30/A90), 
the presence of the non-pathogenic TTR variant (A90) do not seem to affect the pathogenicity 
of TTR-FAP Val30Met [76].  
Moreover, homozygous individuals for TTR V30M variant were described in several 
Swedish and Turkish families and although these contain a double dose of the gene, do not 
present a more severe phenotype than heterozygous individuals [77, 78]. Interestingly, in the 
same population were also discovered homozygous isolated cases, in which none of their 
parents showed symptoms [79], as well as one homozygous individual that was still an 
asymptomatic carrier at 62 yrs. [77]. Furthermore, these homozygous seem to have insufficient 
ability to trigger disease symptoms and additionally an early AO in their offspring was not 
observed [77, 79]. However, it was later reported in Japan, that younger TTR-FAP Val30Met 
homozygous may have a slightly more severe clinical presentation than heterozygotes 
patients, probably due to more TTR protein instability [80].  
 
1.6.1. Clinical Aspects of Late-Onset Patients 
 
Patients with onset of symptoms after 50 yrs. of age have some clinical characteristics 
that significantly delays diagnosis, commonly more than 5 yrs. after the first symptoms 
appeared [61, 81]. This is often due to a lack of previous diagnosis of the disease in their 
families, but also due to a clinical presentation different from Andrade’s classical description 
[3] of a disease with predominant small fiber involvement. The absence of diagnosis in their 
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ancestors may be due either to a misdiagnosis of an affected parent or, more often, because 
their transmitting ancestors remained asymptomatic until advanced ages [82].  A sub-group of 
patients presents predominant severe renal [62] and/or cardiac disease [70] and the 
neuropathy remains silent for several yrs.; even the patients whose first symptoms are due to 
neuropathy show a predominantly sensory and motor neuropathy with few and subtle 
autonomic signs, due to involvement of large fibers [83]. 
 
1.7. The Origin of Familial Amyloid Polyneuropathy 
 
Initially, it was suggested that disease-causing variant originated from one founder in 
Portugal and spread across the world including Europe, Japan, America and Africa, through 
the historical connections of Portugal [84]. After, by comparing TTR haplotype among clusters, 
a common origin of the V30M disease-causing variant could be possible for Portuguese and 
Brazilian, Spanish and Japanese patients, compatible with the time occurrence of important 
migratory flows from Portugal, and it is believed that an independent founder effect may have 
arisen in Swedish patients [85-87].  
Moreover, different mutation events could also have happened in Portugal since it was 
found one individual with a different haplotype [86]. A recent study showed that an independent 
origin for Italian V30M disease-causing variant must have occurred, since V30M haplotype 
differences between the Italian patients and Swedish and Portuguese patients were found. 
Additionally, the authors suggest that the Italian V30M variant may have originated before the 
Portuguese and Swedish V30M variant [88], but it is still an open question. 
 
1.7.1. Incidence and Prevalence 
 
In Europe, the largest cluster of individuals with TTR-FAP Val30Met may be found in 
northern Portugal (Póvoa do Varzim and Vila do Conde), where the incidence is estimated to 
be one in 583 individuals. In contrast, the incidence of TTR-FAP Val30Met in the USA is 
estimated to be one in 100.000 individuals [89]. 
TTR-FAP Val30Met is a disease with a prevalence of 1.1/ 100.000 individuals, although 
there are geographical differences in the distribution of the disease worldwide [89]. Portugal is 
the country with the highest prevalence of the disease followed by Sweden and Japan [5, 90, 
91]. In some Portuguese regions, such as Póvoa de Varzim and Vila do Conde, this disease 
affects approximately one per 1.000 inhabitants. In northern Sweden, 15/1.000 (1.5%) of the 
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population has the mutated gene and in Japan the prevalence has recently been estimated 
around one in 1.000.000 individuals [5, 90, 91]. 
 
1.8. Age-at-Onset Variability 
 
FAP was described by Andrade as a disease of the young adult (“It begins insidiously, 
25-35 yrs.”) [3]. Soon after Andrade’s publication, other descriptions from FAP AO from Brazil 
and Japan arisen.  In these studies, AO was very similar to Portuguese patients described by 
Andrade [92-95]. By the end of the 60’s, Rune Andersson, from Umeå Hospital in Northern 
Sweden, observed two families whose clinical picture resembled the patients described by 
Andrade, although with a much later onset (AO ≥ 50 yrs.). He subsequently looked for other 
FAP patients in the area and described (in 1976) a cluster of 60 patients where mean AO was 
53 yrs. [10]. In the 80´s, Munar-Quès described one focus in the island of Majorca where 
patients had intermediates mean AO between the Portuguese and Swedish patients (third 
European focus of FAP) [96]. 
 
1.8.1. A Wider Range of Age-at-onset 
 
 Remarkable differences in mean AO of the symptoms between clusters associated 
with the V30M disease-causing variant (Portugal: 33.5; Brazil: 34.5; Sweden: 56.7; Balearic 
Islands: 45.7/49.8 and Japan: 33.8/64.5) [5, 90-92, 96-98] were found, however the AO overall 
range is similar (Figure 5).  
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Figure 5 – Distribution worldwide of the differences in mean age-at-onset of symptoms between clusters 
with V30M disease-causing variant (Adapted from IsIs Pharmaceuticals, 2015). 
 
Most importantly, among Portuguese families although the same disease-causing 
variant is present (V30M), TTR-FAP Val30Met shows a remarkably wide variation in AO [19-
82 yrs.] and several aged-asymptomatic gene carriers, up to 95 yrs., have been identified [82, 
99, 100]. 
Although the disease has been characterized by its early-onset (AO <40 yrs.) and is 
assumed to reach full penetrance, in reality this is not that simple. In fact, more and more late-
onset cases have been ascertained, often matched with older asymptomatic parents. 
Moreover, 40% of all probands have no affected parent at the time of diagnosis [82]. 
Another unusual feature is that the V30M disease-causing variant often runs through several 
generations of asymptomatic carriers, before expressing in a proband. However, the protective 
effect may disappear in a single generation, with offspring of late-onset cases unexpectedly 
showing early-onset. Importantly, the reverse was never found, i.e., in more than 75 yrs. of 
patients’ follow-up, that is, no late-onset cases were documented to have an early-onset parent 
[99]. 
Variability in AO of TTR-FAP Val30Met has been a most intriguing feature and the 
object of many studies.  
 
AO: 56.7 yrs.  
[26-84] 
Sousa et al., 1993 
AO: 33.8/64.5 yrs. 
AO: 33.5 yrs. 
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Sousa et al., 1995 
AO: 34.5 years 
 [20-80] 
Saporta et al., 2009 
AO: 45.7/49.8 yrs. 
 [20-84] 
Munar-Quès et al., 2005/ 
Buades Reinés et al., 2014   
 
 
Portugal 
 Japan 
Kato-Motozaki et al., 2008/ 
Koike et al., 2012 
 
Sweden 
 
Majorca, Spain 
 
Brazil 
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1.8.2. Recognition of Late-Onset Cases  
 
Our group has previously shown [82, 101] that late-onset cases and aged-
asymptomatic carriers aggregate in families, and that they often descended from parents who 
had died at old age with no signs of the disease and also that some of these parents, when 
alive and tested for the V30M disease-causing variant, showed to be carriers with no symptoms 
as late as at 95 yrs. of age. In addition, previous studies from our group also confirmed that as 
in Sweden, isolated cases with late-onset often descend from aged-asymptomatic carriers 
[100]. Therefore, the recognition and diagnosis of more late-onset cases have been a focus of 
large interest in TTR-FAP Val30Met, since protective factors associated with late-onset could 
be associated with aging factors and longevity [100]. 
 
1.9. Genetic Anticipation  
 
Genetic anticipation is a phenomenon characterized by the existence of a significantly 
earlier AO in younger generations than their affected parents, with an increased disease 
severity in successive generations within a family (Figure 6) [102]. This occurrence has been 
often observed in diseases caused by repeat instability as spinocerebellar ataxias (SCAs) and 
other neurodegenerative diseases as AD and Parkinson’s disease (PD) [102]. Anticipation of 
AO in TTR-FAP Val30Met families from Portuguese population was recognized for long time 
[40, 103]. Afterwards, further studies have assessed anticipation in TTR-FAP Val30Met 
families in different populations including Portuguese, Swedish and Japanese [5, 90, 104, 105], 
aiming to unravel possible ascertainment biases that could interfere with earlier onset in the 
offspring, such as postulated by Becker, in 1964 [8], using the previous arguments described 
by Penrose, in 1948, in the myotonic dystrophy (DM) [106]. According to Penrose, anticipation 
was an artefact produced by the selection of pedigrees, not having biological significance. The 
biases may be due to (1) preferential selection of parents with late-onset, (2) favoured selection 
of early-onset offspring presenting a more severe phenotype, and (3) preferential inclusion of 
parent-offspring pairs with simultaneous onset [103, 107]. 
However, our group has shown that anticipation of AO in TTR-FAP Val30Met is not due 
to ascertainment biases of the sample [65, 99, 108]. In a recent study with 284 TTR-FAP 
Val30Met Portuguese kindreds, our research group observed that offspring might anticipate 
up to 40 yrs. relatively to their affected parent and that in 926 Portuguese parent-offspring 
pairs, the anticipation was significant even after removal of ascertainment biases. Therefore, 
these findings confirm that anticipation is a true biological phenomenon in TTR-FAP Val30Met, 
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although no biological explanation has been found, so far [99]. The same was found in Japan 
[105].  
Soares et al., 1999 screened, in Portuguese TTR-FAP Val30Met kindreds, nine parent-
offspring pairs with large anticipation and no differences were found in length of ten 
trinucleotide repeats analyzed, concluding that the trinucleotide repeat expansions are not 
associated with large anticipations [109]. Mechanisms involved in anticipation in TTR-FAP 
Val30Met remain elusive [109]. 
Since it is crucial to understand which biological mechanisms are associated with 
phenotypic variability in TTR-FAP Val30Met and that may lead to this pathology, these studies 
provide valuable arguments that (1) allow us to define better strategies for the identification of 
genetic modifiers that can explain AO variability in TTR-FAP Val30Met and (2) stimulate us to 
unravel new clues about molecular mechanisms responsible for AO in this and other related 
neurodegenerative disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Two Portuguese pedigrees showing marked anticipation of AO throughout the generations 
and offspring of late-onset patients shows early-onset. 
 
1.10. Penetrance and Gender-Related Aspects 
 
Gene penetrance among people carrying the same variant varies between countries 
and among families. The penetrance of V30M disease-causing variant in Portugal, Brazil and 
France is high (around 85%), while in Sweden is only 69% in individuals with 80 yrs. of age 
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[41, 92, 110]. However, at intermediate ages, there are large differences in penetrance of 
V30M in the different populations. At 50 yrs. of age, penetrance in Portuguese families is 60%, 
but in French and Swedish families is only 18% and 11%, respectively [41, 110]. The current 
penetrance in Japanese V30M families is unknown, but appears to be high (80%) in early-
onset patients and low in late-onset patients [95, 111]. 
In addition, significant gender-related differences in TTR-FAP Val30Met AO as well as 
obvious differences in penetrance according to gender of the transmitting parent and a parent-
of-origin effect have often been found in some populations. 
In TTR-FAP Val30Met Portuguese families, significant differences in mean AO 
regarding gender were found, where the women (daughters: 33.70 and mothers: 39.57) 
presented a mean AO higher than men (sons: 29.43 and fathers: 35.62) and lower when the 
mother was the transmitting parent comparing with transmitting fathers (30.54 versus 32.21, 
respectively). Likewise, regarding anticipation, a larger mean anticipation (≥10 yrs.) was more 
often found when the disease was inherited from the mothers (70%) than from the fathers 
(30%) and, in addition, mother-son pairs showed a larger mean anticipation (10.43), whereas 
father-daughter pairs showed only a residual anticipation (1.23) [99].  
Similarly, a parent-of-origin effect in Swedish and Japanese families was also observed 
[104, 105]. Moreover, differences in penetrance for TTR-FAP Val30Met according to the 
gender of the transmitting parent was also found in Swedish and French carriers, where the 
penetrance of the disease was higher when the transmitting parent was the mother [110, 112]. 
However, the difference was highly more significant in Portuguese than in Swedish population 
[113] and no significant differences was found for French population [113].  
Plausible hypothesis for these findings might be due to several different mechanisms 
such as (1) genetic imprinting phenomenon to unravel the parent-of-origin effects, since there 
could be a difference in the expression of the mutated allele according to the gender of the 
parent who transmitted the disease-causing variant and (2) mitochondrial DNA (mtDNA) 
related factors as a modifier effect associated with a mtDNA polymorphism on the expression 
of the TTR variant. In the previous study performed by Bonaïti et al., 2010 it was shown that a 
mitochondrial variant may explain the observed difference in penetrance according to gender 
of the transmitting parent in the Portuguese sample, but the same was not observed in the 
Swedish sample, where there are the possibility of several loci involved [112]. 
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1.11. Age-at-onset (AO) Genetic Modifiers 
 
The TTR-FAP Val30Met patients with the same variant, independently of gender, may 
differ dramatically in AO and it is very important to understand what are causing this variation, 
since it might lead to a better understanding of the disease pathogenesis mechanisms.  
Although multiple stochastic and environmental factors cannot be completely ruled out, 
the fact is that AO differences are highly heritable and a large variation may still be found within 
a single geographical area and, above all, within the same family, reinforcing the existence of 
additional, still unknown, genetic and epigenetic factors, involved in AO modulation [99, 114]. 
These AO genetic modifiers may be, for instance, genes affecting the phenotypic expression 
of another gene [115], delaying or anticipating the onset of disease’ symptoms. Moreover, the 
modifier factors may not only be due to the independent main effect of a single-gene, but to 
the combined effect of multiple genetic factors, including interaction between loci, which will 
allow to elucidate biological and biochemical pathway underlying disease such as observed in 
other neurodegenerative diseases [116-118]. 
The increasing interest in the identification of AO modifiers has proved to be a 
successful strategy in several neurological disorders as Huntington’s disease (HD) [119, 120], 
AD [121], PD [122] and, certainly this will occur in TTR-FAP Val30Met [123].  
Factors and mechanisms involved in this phenotypic variation remain largely unknown. 
Still, few studies have been published aiming to disentangle possible genetic modifiers 
involved in AO variability [123, 124].  
 
1.11.1. Modifier Candidate-Genes 
 
A candidate-gene strategy has been used in previous studies linked to several 
disorders, including neurodegenerative diseases like HD in that individual disease 
manifestations are rather determined polygenetically [125, 126] and also in AD [127], and it 
has showed to be a promising approach, since this based on a priori knowledge of the gene’s 
biological functional impact on the trait (severity, AO and other associated phenotypic 
characteristics) or disease in question. 
In TTR-FAP Val30Met, earlier genetic studies have focused on searching for variants 
in several candidate-genes, including within the TTR gene itself, which can modify AO or 
progression of TTR-FAP Val30Met, using a case-control approach. These candidate-genes 
were selected (1) based upon the TTR biological pathways in which they are involved and in 
pathophysiological processes related to TTR-FAP Val30Met pathogenesis or (2) due to their 
biological function [123, 124].  
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1.11.1.1. Genes Associated with Regulatory Pathways of TTR 
 
In a previous study performed by Soares et al., 2005 in a Portuguese sample, common 
and functional variants of six candidate-genes (plasma retinol binding protein 4 (RBP4), 
heparin sulfate proteoglycan 2, (HSPG2), amyloid P component, serum (APCS), 
apolipoprotein E (APOE), serum amyloid A (SAA1 and SAA2)) that are found in all amyloid 
deposits and shown to have potential pathophysiological significance in other disorders [128-
131] were analysed, in order to assess their association with V30M and AO [123]. Noteworthy, 
a classic case-control approach was used either comparing TTR-FAP Val30Met classic (early-
onset) or late-onset patients with controls. Possible interactions between loci seemed to 
contribute more to the observed differences in AO than a single-locus effect. Two different 
genes (APCS and RBP4) associated with AO variation were unravelled and these can act as 
AO genetic modulators in TTR-FAP Val30Met. In early-onset patients (versus controls), the 
APCS gene showed a modifier effect, while in late-onset patients, one variant in APCS and 
two variants in RBP4 seemed to be involved. However, no comparisons were made between 
early- and late-onset patients, although they may coexist within the same family. Therefore, 
these results only explain one small part of AO variability in TTR-FAP Val30Met since familial 
correlations were not taken into account [123].  
Later, a previous study performed by Dardiotis et al., 2009 in a Greek-Cypriot sample, 
other genes (TTR, APCS, C1Q complement and APOE genes) coding for chaperone proteins 
co-localized with TTR deposits in peripheral nerves were selected. Likewise, a significant 
association with AO of one variant in C1QA, C1QC and APOE genes were found, although 
family structure was not taken into account [124].  
 
Although the case-control approach reveals some important information it may not 
prove to be very useful to understand the AO variation both within and among generations in 
TTR-FAP Val30Met patients, since early- and late-onset patients are not separate entities, 
they may coexist within the same family. Thus, focusing in a family-centred approach seem be 
a more promising strategy to unravel new clues about AO variation in TTR-FAP Val30Met.  
 
1.11.1.2. Genes Associated with New Signalling Pathways  
 
In addition to genes aforementioned associated with AO variation in TTR-FAP 
Val30Met, other molecular biomarkers have been described in diverse previous studies as 
having an altered expression or activation in different development stages of the disease 
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compared to controls. Moreover, these markers have helped to better understand the 
molecular mechanisms of TTR deposition in the pathogenesis of TTR-FAP Val30Met as well 
as unveil other functions linked to this disease [132-134]. Therefore, these markers appear to 
be promising candidate-genes to investigate AO variation of TTR-FAP Val30Met, since until 
now any study on AO variability using these genes was performed. 
 
1. Extracellular matrix (ECM) remodelling genes 
 
Several extracellular matrix (ECM) remodelling genes, namely biglycan (BGN), 
neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) 
revealed an increased expression and their proteins were also up-regulated in TTR-FAP 
Val30Met nerve and salivary glands (SG) biopsies of humans and transgenic mouse models. 
BGN showed already an increased expression in the earliest stages of non-fibrillary TTR 
aggregates deposits, whereas NGAL and MMP-9 (which form a complex) were only 
overexpressed at a later stage of disease progression when fibrillary deposits were already 
present [132, 135]. Curiously, MMP-9 has the ability to degrade ECM components and TTR 
aggregates and fibrils in vitro; however, in vivo studies as TTR fibrils are bound to other 
components such as APCS, the ability of MMP-9 to degrade TTR fibrils was decreased, being 
need high levels of this protein for their degradation [132]. 
 
2. Extracellular signal-regulated kinases 1/2 (ERK1/2) and ERK1/2 
kinases (MEK1/2) 
 
Monteiro et al., 2006 previously showed that extracellular signal-regulated kinases 1/2 
(ERK1/2) and another upstream kinase, ERK1/2 kinases (MEK1/2), which belong to MEK-ERK 
MAPK signalling pathway, displayed an increased activation in TTR-FAP Val30Met nerve and 
SG biopsies or only in nerve biopsies of humans and transgenic mouse models both from 
asymptomatic carriers and earlier stage patients relatively to controls; however, in later 
symptomatic stage of the disease progression, the phosphorylation levels of ERK1/2 and 
MEK1/2 and their activation were decreased [133].  
 
3. Heat Shock Proteins (HSPs) 
 
In addition, other studies have described several proteins such as heat shock proteins 
(HSPs), initially designated as molecular chaperones, as being responsible to support the 
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correct refolding of partially denatured proteins, but also to play a critical role in maintaining 
protein homeostasis (proteostasis), preventing protein aggregation associated with disease, 
and interfering with apoptosis, oxidative stress and inflammation [136].  
In TTR-FAP Val30Met it was showed an overexpression of heat shock protein family B 
(small) member 1 (HSPB1 or HSP27) and heat shock protein family A (Hsp70) member 4 
(HSPA4 or HSP70) in the presence of extracellular TTR aggregates in human TTR-FAP 
Val30Met nerve, skin and SG biopsies compared with controls, when a stress response was 
induced [134]. Furthermore, an increased expression of αB-crystallin (HSPB5) in human and 
transgenic mice TTR-FAP Val30Met skin biopsies was also found, as compared to normal skin 
[137]. Therefore, HSPs can protect cells from cell death, preserving cellular integrity and 
viability and functioning as a possible therapeutic target. 
 
4. 14-3-3 proteins 
 
Additionally, it has also been described other proteins, tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation (14-3-3) proteins, which belong to a 
family of highly conserved proteins comprising seven known homologous isoforms in 
mammals (β, γ, ε, η, ζ, σ, and τ/θ), each of them encoded by different genes [138]. 
Recent evidence indicates that the 14-3-3 proteins are important targets in many 
cellular and physiological processes including signal transduction, cell survival, transcription 
control, apoptosis, redox-regulation, protein folding and neuronal development in diverse 
neurodegenerative disorders [139, 140]. Moreover, Vieira et al., 2013 showed that TTR 
regulates 14-3-3 zeta (YWHAZ) protein levels and that in the absence or lower TTR levels, 
YWHAZ levels were decreased in the hippocampus of young/adult TTR null mice when 
compared to WT TTR animals which may have a negative impact in learning and memory and 
in the increase of the autophagy [141].  
 
1.11.1.3. Repetitive Loci of Genes Related with Neuro-associated 
Disorders 
 
In the human genome, repetitive loci are very abundant and may be distributed 
throughout the genome [142]. The main characteristic of such repeats is their genetic instability 
and ability to expand [143, 144]. Instability of these repeat tracts is associated with several 
human diseases. Moreover, expansion of unstable repeat tracts transmitted to subsequent 
generations (intergenerational instability) is a mutational mechanism unique in humans and is 
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the causative factor of more than 40 neurological, neurodegenerative and neuromuscular 
disorders [145]. However, the repetitive tract within the associated gene may differ according 
with the related-disorder, although it is similar for some of them.  
The most common repetitive motif causing inherited neurodegenerative disorders as 
HD and some SCAs (e.g. SCA1, SCA2, SCA3, etc.) is the (CAG)n triplet motif, which can be 
located either in the coding region or in the untranslated regions (UTR) of the respective genes 
[146]. However, there are also other trinucleotide repeat tracts that also cause disease when 
expanded as the (CTG)n, (CGG)n, (GAA)n motifs, which can be located in non-coding regions, 
UTRs and promoter regions [146]. Besides, expansion of tetra and pentanucleotides repeats 
like (CCTG)n and (ATTCT)n may also be associated to certain diseases as myotonic dystrophy 
type 2 (DM2) [147] and SCA10 [148], respectively, in non-coding regions [145].  
 Importantly, in these disorders, the size of pathological/expanded alleles is the most 
relevant factor to understand phenotypic variability since this may be associated with AO 
variation, progression and severity of the disease. Depending on location, expanded repeats 
tracts may either alters expression and/or function of the gene product typically producing a 
faulty protein (if localized in coding regions) or suppresses protein expression, altering its 
splicing or influencing antisense regulation (if localized in non-coding regions) [149, 150].  
Previous studies using a case-control approach have shown that the CAG repeat 
expansion of ataxin-2 (ATXN2) gene, responsible for SCA2, may increase the risk of 
amyotrophic lateral sclerosis (ALS) [151, 152]. However, the observed risk for ATXN2 repeats 
is not only limited to ALS, there are other neurodegenerative diseases in which the genetic 
variation observed may also be associated [153].  
Regarding TTR-FAP Val30Met, although repeat expansion is not a causative factor of 
this disease [109], the hypothesis of the identification of modifier genes associated to unstable 
repeat length variation of loci prone-to expansion cannot be ignored, since the disease-causing 
point variant alone does not fully explain the AO variation. Therefore, the dynamic nature of 
these variants can help us to explain the variable phenotypic expression regarding AO existing 
within and among generations of different TTR-FAP Val30Met families.  
Unlike in trinucleotide neurodegenerative disorders, the phenomenon of genetic 
anticipation observed in TTR-FAP Val30Met was not explained yet. As previously mentioned 
in the genetic anticipation section, no significant trinucleotide repeat size difference was found 
within the parent-offspring pairs analyzed, indicating that the repeat expansions analyzed 
possibly are not responsible mechanism for occurrence of anticipation [109]. Taking into 
account the small sample size, the presence of other tandem repeats in the human genome 
with ability to expand and the evolution of molecular techniques since then, this hypothesis 
cannot still be completely excluded.   
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1.11.1.4. Sex-Linked Genes 
 
As already previously mentioned, in Portuguese TTR-FAP Val30Met population, the 
onset of the disease occur later in women than in men [99] such as in Brazilian population 
[154], whereas no gender-related differences in AO were found in other populations as 
Sweden [90] Cyprus [155]. Although gender-related differences in TTR-FAP Val30Met AO 
have already been described in some populations, the reasons for these differences remained 
largely unanswered.  
In order to better understand what is causing the gender-related differences in the 
aetiology of TTR-FAP Val30Met, some experimental studies have focused on the effect of sex 
steroid hormones (androgens, 5α-dihydrotestosterone (DHT) and estrogens, 17β-estradiol 
(E2)) in TTR expression, in which their mediators (androgen receptor (AR) and estrogen 
receptor (ESR), respectively) also are expressed. Gonçalves et al., 2008 revealed that E2 and 
DHT up-regulate TTR expression in mice liver and that may contribute to amyloid deposition 
[156].  
In addition, Oliveira et al., 2011 showed that in AD increased levels of circulating TTR 
were higher in male mice than in female mice, suggesting that TTR levels are possibly affected 
by hormonal state [157]. Furthermore, these authors discovered, for the first time, the evidence 
for a role of TTR as a potentially important modulator of brain sex steroid hormones levels in 
AD pathogenesis in a gender-dependent manner [157]. Additionally, other previous studies 
using transgenic mouse models showed that sex steroid hormones themselves could positively 
regulate the expression levels of TTR [158-160], in particular, in female mice. 
Although both sex steroid hormones affect the TTR expression levels, DHT appears be 
a strong inducer of TTR synthesis than E2, which may explain the earlier onset of TTR-FAP 
Val30Met in men in some populations [156]. 
AR is a member of the steroid and nuclear receptor superfamily and is a soluble protein 
that function as an intracellular transcription factor (TF) that it is activated by the binding of 
endogenous androgens, including testosterone and DHT [161]. In males, AR is responsible for 
the sexual differentiation in utero and for pubertal changes [161]. In females, AR is also 
fundamental in the maintenance of reproductive function, being expressed in various 
folliculogenesis stages [162]. The ESRs are ligand-activated T receptors that belong to the 
nuclear hormone receptor superfamily and are activated by binding of hormone estrogen (E2). 
Today are known two ESRs, ESRα and ESRβ [163]. 
Numerous experimental studies in neurodegenerative diseases as AD and PD highlight 
that sex steroid hormones may also have a neuroprotective role relevant in their prevention, 
conferring increased neuronal viability against various brain injuries, reduction of Aβ 
accumulation [164], activation of signalling molecules and interaction with growth factors [165]. 
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1.11.2. Role of Mitochondrial DNA (mtDNA) 
 
Since remarkable differences in AO variation have been observed depending on the 
gender of the transmitting parents and of the offspring, mainly when the mother is the 
transmitting parent and, particularly, when the large anticipation was detected in mother-sons 
pairs, to unravel the role of mitochondrial DNA (mtDNA) content may shed some light into the 
AO variation observed in TTR-FAP Val30Met families as mtDNA is considered a lineage 
marker, being transmitted through the maternal lineage [166].  
Furthermore, some factors as oxidative stress and protein misfolding that result of 
cellular processes involving the mitochondria are present in amyloid diseases [167, 168]. 
Therefore, to assess mtDNA copy number may also provide us some clues about the energetic 
performance of the TTR-FAP Val30Met carriers in order to deepen our insight into the 
underlying mechanisms related to TTR-FAP Val30Met pathology. 
As a result, mtDNA could be considered a possible modifier factor for TTR-FAP 
Val30Met as well as for other neurodegenerative diseases [169]. 
 
 1.11.2.1. Structure and Function of Mitochondria 
  
Mitochondria are intracellular organelles, present in most of eukaryotic cells and they 
are composed by a double membrane, surrounded by a protein-rich core, the matrix [170]. 
The main function of mitochondria is to produce energy to the cell under the form of 
adenosine triphosphate (ATP) through the process of oxidative phosphorylation (OXPHOS), 
which involves the respiratory chain of electron transfer (complex I-IV) and the ATP synthase 
(complex V). In addition, mitochondria also play other important roles, including apoptosis, 
calcium (Ca2+) signalling, cellular differentiation, cell senescence, synaptic transmission and 
neuroplasticity in neurons [171]. Mitochondrial dysfunction has been implicated in diverse 
diseases including mitochondrial disorders, diabetes, cancer and neurodegenerative diseases 
such as AD, PD, and HD as well as aging [172-174]. 
 
 1.11.2.2. Mitochondrial Genome and mtDNA Haplogroups 
 
Interestingly, mitochondria contain their own molecular genetic system (mtDNA) and 
protein-synthesizing machinery, distinct of the nuclear genome (nDNA), which is located in the 
mitochondrial matrix. Although the most of mitochondrial polypeptides are encoded in the 
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nuclear genome, synthesized in the cytoplasm and imported into the mitochondria post-
transcriptionally [175]. In addition, there is a large homology of the mitochondrial genome of 
different organism being highly conserved among mammals [176]. Human mtDNA is a small, 
16.6 kb circular double-stranded DNA molecule located within the mitochondria in the 
cytoplasm of the cell [177]. Currently, mtDNA has 37 genes encoding 13 polypeptides 
(mRNAs), all of which are essential subunits for the mitochondrial energy-generating enzymes 
of mitochondrial respiratory chain, as well as 22 transfer RNAs (tRNAs) and 2 ribosomal RNAs 
(12S and 16S) necessary for their synthesis [178]. Additionally, mtDNA present several 
particular features: (1) a haploid genome, since mtDNA is exclusively maternally inherited and 
thus does not undergo recombination [166, 179], (2) unlike nDNA, mammalian mtDNA 
contains no introns, has no protective histones, being exposed to deleterious reactive oxygen 
species (ROS) generated by OXPHOS and (3) it contains a non-coding region that includes a 
unique displacement loop, which is responsible by control of replication and transcription of 
mtDNA. 
Furthermore, each human cell contains hundreds of mitochondria and hundreds to 
several thousands of copies of mtDNA. Each mitochondrion contains between 2 and 10 copies 
of its genome [180]. In addition, mitochondrial content may vary between different cell or 
tissues types in response to metabolic and bioenergetics requirement as consequence or 
cause of aging and/or of a particular pathological disorder [181]. Muscle and neurons cells 
usually contain a high number of mtDNA copies because are high-energy requiring cells, on 
the contrary of spleen and endothelial cells. Therefore, regulation of mtDNA copy number 
biogenesis is an important feature of mitochondrial genetics and biogenesis and is vital for 
normal cellular functioning, maintaining cellular energy requirements and survival of the 
individuals [182]. Deregulation of mtDNA copy number can result in disease [182]. Thus, 
depletion or decrease of mtDNA copy number have been associated with various diseases 
such as multiple sclerosis (MS) [183], cancer [184, 185] and type 2 diabetes [186], while 
increased mtDNA content is less common. 
 Moreover, since mtDNA is transmitted through maternal lineage, it is possible to trace 
the evolutionary history of mtDNA from the original 'ancestor mother' by identifying common 
variants that accumulated over time. However, mtDNA has a very high mutation rate, that is, 
it is highly polymorphic. In the human population, high level of population-specific and unique 
mtDNA variants allowed the reconstruction of human history through creation of several groups 
of specific mtDNA haplotypes and/or groups of related haplotypes (haplogroups) [187-189]. 
Previous studies have shown that several haplogroups may be associated with polymorphic 
biological features in healthy individuals as the haplogroup J being associated with increased 
longevity in Europeans and reduced efficiency of ATP production during OXPHOS [190] and 
haplogroup T with reduced spermatozoa motility [191]. In addition, mtDNA haplogroups can 
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also play an important role in modulating disease expression such as in Leber hereditary optic 
neuropathy [192]. MtDNA haplogroups specific-variants were also previously related to several 
neurodegenerative diseases such as AD, PD, Friedreich ataxia, ALS and MS as well as TTR-
FAP Val30Met [175, 193]. In AD, although has been suggested that inherited haplogroups K 
and U may influence AD risk in Caucasians, this question it is still not completely understood 
[175]. In PD, it was shown that haplogroups J or K decrease the risk of disease, contrarily to 
the most common haplogroup H [194]. In TTR-FAP Val30Met, mtDNA haplogroups were 
studied in Swedish and French patients in order to understand remarkable differences in AO 
in these populations compared to Portuguese and Japanese populations and it was observed 
that mtDNA haplogroups were associated with AO of TTR-FAP Val30Met where haplogroup 
K is associated with an early-onset of the disease [193].  
 
1.12. Therapies for Familial Amyloid Polyneuropathy 
 
  Once the diagnosis of TTR-FAP Val30Met is made, a multidisciplinary team and 
diverse therapeutic approaches are required to relieve symptoms and to prevent complications 
of TTR-FAP Val30Met patients, depending on disease progression stage. 
 
1.12.1. Liver Transplantation 
 
In the early 90s, liver transplantation (LT) was implemented as the first disease-
modifying treatment available to patients with TTR-FAP Val30Met. The aim of LT is to suppress 
the main source of systemic production of variant TTR, slowing or halting progression of clinical 
symptoms, since more than 95% of TTR is produced by the liver [195]. Excellent outcomes 
have been described, including improvement in autonomic and to a lesser extent peripheral 
nerve function coupled with regression of visceral amyloid deposits [196]. However, heart and 
nerve involvement as well as ocular and CNS clinical manifestations might progress even after 
LT due to WT TTR continued deposition on pre-existing amyloid deposits and continued 
deposition in the different organs and tissues of variant TTR synthesized by choroid plexus 
and retinal epithelial cells [43, 50, 197, 198]. 
Asymptomatic disease-causing variant carriers cannot be candidates for LT due to 
incomplete penetrance. Also, and late stage patients (with significant walking impairment) 
cannot be candidates due to a  significant rate of perioperative complications and increased 
risk of progressive neurological and cardiac disease despite LT [199].  
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Domino LT using the TTR-FAP patient's liver for transplantation of another patient 
became a relatively common practice, but symptomatic neuropathy seems to occur after about 
5 yrs. [200]. 
Unfortunately, this treatment encompasses several limitations such as (1) expensive 
medical costs, (2) surgery requirement, (3) lifelong administration of immunosuppressants, (4) 
both carriers of TTR variants who do not show clinical symptoms and patients in advanced 
stage of TTR-FAP cannot undergo LT (5) shortage of liver donors, and (6) lack of 
responsiveness regarding cardiac, ocular and CNS complications [201].  
 
Novel less-invasive therapeutic strategies, some of which are already approved and 
other are still under investigation, have been developed to modify prognosis and management 
of TTR amyloidosis as alternatives to LT. Owing to progress in biochemical and molecular 
genetic studies, the majority of the new proposed strategies for TTR-FAP Val30Met are based 
on the same therapeutic principles investigated for other amyloidosis, such as (1) inhibiting 
TTR aggregation by stabilization of variant TTR (2) gene therapy, (3) disrupting TTR amyloid 
by selective molecules, and (4) immunotherapy [202]. 
 
1.12.2. TTR Tetramer Stabilizers   
 
The first pharmacological therapeutic approach was focused on the stabilization of the 
TTR tetramers. TTR tetramer stabilizers are agents that act in a similar way to the natural 
hormone T4, binding to T4 unoccupied binding sites of TTR tetramer and stabilizing the native 
tetrameric structure, thereby inhibiting TTR amyloid fibril formation by preventing TTR tetramer 
dissociation into monomers and subsequent conformational changes [203]. Although several 
small molecules have exhibited high serum binding selectivity and are potent amyloid fibril 
inhibitors in vitro, validation in vivo is needed to assess toxicity, bioavailability and 
pharmacological properties [21]. Two anti-amyloid drugs, tafamidis and diflunisal, emerged 
into clinical trials.  
Tafamidis, is a pharmacological chaperone and was the first drug approved in Europe 
and Japan for the treatment of adults TTR-FAP patients in stage I (walking unaided) 
symptomatic polyneuropathy to delay peripheral neurological impairment [204]. Data on 
efficacy, safety and tolerability of the tafamidis was evaluated and it was safe and well 
tolerated, showing decreased neurological progression and preserved quality of life in the 
early-onset TTR-FAP Val30Met patients at early stage of neuropathy, which treatment is more 
beneficial [204]. 
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Diflunisal is a nonsteroidal anti-inflammatory drug, which stabilizes TTR tetramers and 
prevents TTR amyloid fibril formation in vitro [205]. A randomized, double-bind, controlled 
study against placebo showed that the use of diflunisal compared with placebo for 2 yrs. 
reduced the rate of neurological impairment progression and preserved quality of life [206]. 
 Moreover, other studies using several natural polyphenols as curcumin and 
nordihydroguaiaretic acid demonstrated that these bind to TTR and also stabilize the TTR 
tetramer [207]. 
 
1.12.3. Gene Therapy  
 
Gene therapy has arisen as a new non-invasive therapeutic strategy for TTR-FAP 
Val30Met by to inhibit hepatic production of both mutant and non-mutant TTR by post-
transcriptional TTR gene silencing with antisense oligonucleotides (ASOs) or small interfering 
RNA (siRNA), thereby reducing plasma TTR levels as well as non-fibrillary TTR species and 
amyloid deposition [208]. 
ASOs are short synthetic single-strand nucleotides designed to prevent the expression 
of a targeted protein by selectively binding to the RNA that encodes the targeted protein, 
thereby preventing translation of the disease associated protein [209]. Ionis-TTRRX is a 
second-generation antisense drug designed to treat TTR amyloidosis, which binds within the 
3’ non-translated portion of the human TTR messenger RNA (mRNA) and results in 
degradation of TTR mRNA, thus preventing production of both WT and mutant TTR protein 
[210]. 
siRNAs are a class of double-stranded RNA molecules that play many functions, 
including in the RNA interference pathway, where they mediate cleavage of target mRNA, 
silencing the post-transcriptional specific-gene expression. ALN-TTR01 and ALN-TTR02 
(Patisiran) are first and second-generation formulations of lipid nanoparticles as agents to 
deliver siRNA. Each formulation encapsulates an identical siRNA that targets a conserved 
sequence in the 3’ untranslated region of mRNA in TTR, thereby affecting both WT and mutant 
forms of TTR. 
Currently, are being evaluated in a Phase 3 randomized, double-blind, placebo-
controlled studies for these two distinct pharmacologic methodologies in patients with TTR-
FAP and showed that these compounds were well tolerated. More studies are ongoing to 
evaluate the efficacy and safety of prolonged treatment in TTR-FAP patients [211]. 
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1.12.4. Fibril Disrupters and Amyloid Clearance 
 
Several other molecules have been described as having the ability of disrupt TTR 
amyloid fibrils.  
4'-iodo-4'-deoxydoxorubicin was described as an agent that could bind to different 
types of amyloid fibrils increasing their solubility and facilitating their clearance into non-toxic 
species [212, 213]. However, as the use this drug is associated with cardiotoxicity, another 
less toxic compound, as doxycycline, was tested in vitro and in vivo studies, where this was 
capable of disrupting TTR amyloid deposits and to decrease standard markers associated with 
fibrillary deposits [214]. 
Moreover, in vitro and in vivo studies showed also that several natural compounds as 
epigallocatechin-3-gallate and curcumin have a potent dual effect as disruptor of TTR amyloid 
fibrils and as inhibitor of fibril formation together with its low toxicity [207, 215, 216]. 
 Another strategy to enhance the clearance of amyloid deposits is the use of monoclonal 
antibodies against APCS, a non-fibrillary normal plasma glycoprotein found in amyloid fibrils. 
A previous study using mice with amyloid deposits showed that anti-human-APCS-antibodies 
remove massive visceral amyloid deposits without adverse effects [217].  
 
1.12.5. Anti-oxidant and Anti-apoptotic Treatments 
 
Since oxidative stress, apoptosis and inflammation are associated with TTR deposition 
in TTR-FAP Val30Met [218], a unique natural compound, tauroursodeoxycholic acid (TUDCA), 
was investigated. TUDCA acts as a potent anti-oxidant and anti-apoptotic agent, reducing 
cytotoxicity in several neurodegenerative diseases. Macedo et al., 2008 showed that TUDCA 
treatment in transgenic mouse models significantly reduced TTR toxic aggregates as well as 
oxidative and apoptotic biomarkers associated with TTR deposition [219]. Afterwards, Cardoso 
et al., 2010 showed a synergistic effect of doxycycline and TUDCA significantly lowering TTR 
amyloid deposition and associated tissue biomarkers compared with the individual compounds 
[220]. Moreover, Obici et al., 2012 showed that the combination of these compounds stabilizes 
the disease for at least 1 yrs. in the majority of patients [221]. 
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1.13. Searching for new answers to old questions regarding AO 
variability in TTR-FAP Val30Met 
 
Despite interesting results have already been found regarding AO variability in TTR-
FAP Val30Met, there are still many open scientific hypotheses for which there is still no 
response. Until today, it is not yet understood (1) what causes differences in AO among or 
within some generations, but not others and (2) why are some gene carriers still asymptomatic 
at such old age (95 yrs.), while their offspring may early and severely affected and the reverse 
never observed. Therefore, in order to fill these research gaps we will focus in the genetic 
modifiers strategy, exploring several candidate-genes and assessing the role of mtDNA copy 
number, using a family-centred approach. 
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This doctoral dissertation essentially focused on genetic modifiers and their impact on 
AO variation of TTR-FAP Val30Met, a debilitating neurodegenerative disorder leading to death 
after 10-15 yrs. after disease’ symptoms onset. The two major goals were:  
1. To identify factors that may explain AO variation in TTR-FAP Val30Met by 
searching for intra- and intergenerational differences between and among these 
families that might explain why AO further varies in some families and not in others; 
 
2.  To explore these factors comparing old-age asymptomatic carriers with early-onset 
patients and severely affected offspring. 
 
 
To achieve these purposes, new approaches centred on the study of AO variability 
within families were used. 
 
2.1. Specific Objectives 
 
1. To investigate the role of several candidate-genes associated with TTR regulatory 
pathways as possible genetic modifiers of AO in TTR-FAP Val30Met.  
 
2. To analyse some sex-linked candidate-genes as sex-steroid hormones and/or X-linked 
genes in order to understand gender-related differences associated with AO in TTR-FAP 
Val30Met.  
 
3. To evaluate if the normal repetitive length of loci prone-to-expansion associated with 
diverse neurological, neurodegenerative and neuromuscular disorders may function as 
genetic modifiers of AO in TTR-FAP Val30Met. 
 
4. To explore, in silico, the potential functional impact of variants of candidate-genes with 
significant results associated with AO and to analyse the strong synergistic interaction 
between genes involved in analysed pathways. 
 
5. To assess whether the mtDNA copy number have a modifier effect in AO in TTR-FAP 
Val30Met families and between genders. 
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In this section, we present a schematic flowchart, in order to summarize the different 
studies design, the methodologies and strategies used during this thesis, and that are 
described in detail in the Results section (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Flow chart describing the used sample and the entire workflow.  
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4.1. Candidate-genes modulating AO 
 
A wide variation in AO in TTR-FAP Val30Met between clusters, families and, 
particularly, among generations has been observed. For the search of genetic modifiers of AO 
in TTR-FAP Val30Met, we studied several candidate-genes using the largest collection of TTR-
FAP Val30Met samples of Portuguese origin.  
Firstly, we focused in re-evaluating candidate-genes implicated in known TTR 
regulatory pathways with previous positive findings in Portuguese population, but now using a 
family-centred approach, in order to assess the potential role of variants these genes with AO 
variation and evaluate possible interactions between genes. We found that APCS and RBP4 
genes were associated with late AO and one variant of the RBP4 was associated with early 
AO. These results strengthen and confirm the role of APCS and RBP4 in TTR-FAP Val30Met 
pathology [Article 1].  
Afterwards, we also assessed the involvement of variants of the C1Q complement 
genes with AO, which are co-localized with TTR deposits, as found for Greek-Cypriot 
population, in order to confirm if the same happens in our population, but using a family-centred 
approach. Regarding C1QA and C1QC complement genes, we found some variants 
associated with an earlier and later AO. Later, an intensive in silico analysis, in order to predict 
differences in regulation of gene expression, and an analysis of putative gene-gene 
interactions were performed using various software. In silico analysis showed some unreported 
modifications in transcription factors binding sites (TFBSs) and in the mechanism of splicing 
for the C1Q complement genes. In addition, a strong interaction between C1QA and C1QC 
was found [Appendix 1].  
Additionally, we wanted to further explore other candidate-genes already described as 
being implicated in TTR signalling pathway and assess, for the first time, the possible functional 
impact of these significant variants associated with AO as well as interactions between genes. 
Our results showed, for the first time, that variants from six genes (NGAL, BGN - in the female 
group, MEK1, MEK2, HSP27 and YWHAZ) might significantly modulate AO in TTR-FAP 
Val30Met. Importantly, we found interesting results in the in silico analysis for some variants 
in linkage disequilibrium (LD) with variants of MEK1 gene which may alter binding sites of the 
transcription factors (TFs), microRNA and splicing regulatory factors. Furthermore, we 
confirmed a strong synergistic interaction between NGAL and MMP-9, showing that these 
genes may act together as genetic modifiers [Article 2].  
Besides, other candidate-genes that modify AO of other neurodegenerative disorders 
may also to be considered. Although it is well known that expanded repetitive motif in different 
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genes are responsible by several neurological, neurodegenerative and neuromuscular 
disorders and that the length of these repeat tracts are strongly correlated with the onset of 
symptoms of these diseases, it is still unknown if variation within the normal repeat length of 
these genes can modulate phenotypic variability, in particular, AO in TTR-FAP Val30Met, 
being also one of our aims. Thus, the normal CAG/CTG repeat length of ten candidate-genes 
(ATXN1, ATXN2, ATXN3, ATXN7, TBP, ATN1, HTT, JPH3, AR and DMPK) were analysed, in 
order to assess whether the repeat length could influence AO variability of TTR-FAP Val30Met. 
Our data uncovered that ATXN2 gene have a modifier effect in AO variation, when at least one 
normal allele longer than (CAG)22 in the ATXN2 was associated with an earlier onset, 
decreasing mean AO by 6 yrs. [Article 3]. 
Furthermore, remarkable AO differences between genders have also been found in 
TTR-FAP Val30Met patients where women were found to have a later onset when compared 
to men. To unravel these differences, we investigated, for the first time, the involvement of sex-
linked genetic modifiers, as sex-steroid hormones genes: AR and HSD17B1. In this study, we 
found that in AR gene, in the male group three variants were associated with an early-onset, 
whereas in the female group four variants were associated with an early- and late-onset, 
showing that AR may contribute as an AO modifier in both males and females. Regarding 
HSD17B1 gene, no significant result was found associated with AO variation. Moreover, in 
silico analysis predicted that one variant in LD with rs5919393 may alter TFBSs in the AR gene 
[Article 1]. 
Our findings disentangled the interplay of these different genes and pathways, which 
seem to modulate AO in TTR-FAP Val30Met and revealed additional mechanisms of 
deregulation in this pathology. 
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ABSTRACT 
 
Familial amyloid polyneuropathy (FAP) ATTRV30M is a neurodegenerative disorder, due to 
point mutations in the transthyretin gene, V30M being the commonest. FAP ATTRV30M shows 
a wide variation in age-at-onset (AO) between clusters, families and generations.  Portuguese 
patients also show remarkable AO differences between genders.  
Genes found to be associated with FAP ATTRV30M pathways may act as AO modifiers. Our 
aim was to further explore the role of APCS and RBP4 genes and to study for the first time the 
involvement of sex-linked genetic modifiers - AR and HSD17B1 genes – in AO variation, in 
Portuguese families. 
We collected DNA from a sample of 318 patients, currently under follow-up. Eighteen tagging 
SNPs from APCS, RBP4, AR and HSD17B1 and five additional SNPs from APCS and RBP4, 
previously studied were genotyped. To account for non-independency of AO between 
members of the same family, we used generalized estimating equations (GEE). 
We found that the APCS and RBP4 were associated with late AO. In addition, rs11187545 of 
the RBP4 was associated with an early AO. For the AR, in the male group, three SNPs were 
associated with an early AO while, in the female group, four were associated with both an early 
and later AO. 
These results strengthened the role of APCS and RBP4 genes and revealed for the first time 
the contribution of AR genes as an AO modifier both in males and females. These findings 
may have important implications in genetic counselling and for new therapeutic strategies. 
 
 
Keywords: FAP ATTRV30M; candidate-genes; genetic modifiers; age-at-onset variation. 
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INTRODUCTION 
 
Familial amyloid polyneuropathy (FAP) ATTRV30M is an autosomal dominant systemic 
amyloidosis, characterized by amyloid deposition of mutated fibrillary transthyretin (TTR) 
protein. The main clinical expression of this disease is a progressive peripheral sensori-motor 
and autonomic neuropathy due to a point mutation in the TTR gene (chr18q12.1) (OMIM 
176300). Although more than 100 mutations have been found in the TTR gene [222], V30M, 
NM_000371.3:c.148G>A (p.(Val50Met)) is the commonest. 
Andrade first described FAP in Northern Portugal as a disease occurring between 25-
35 years [3]. Variation in age-at-onset (AO) between clusters and within the same focus has 
been described [5, 90, 99, 223]. Among Portuguese families, a remarkable wide variation in 
AO [19-82 years] has been observed, and an increasing number of late-onset cases (≥ 50 
years) are being ascertained, including asymptomatic carriers aged 95 [5].  
Variation in AO between generations has also been observed: late-onset parents often 
have early-onset offspring (<40 years) – an evidence for anticipation – while the reverse has 
never been observed. Recently, our group has shown that anticipation is a true biological 
phenomenon in FAP ATTRV30M [99].  
In order to clarify why there is such a striking AO variation in FAP ATTRV30M, an 
attractive strategy is to focus on modifier genes, which can affect transcription through 
immediate gene transcript expression, or translate into phenotypical alterations at multiple 
organizational levels [224]. Some modifier genes such as amyloid P component, serum 
(APCS), complement C1QA and C1QC and plasma retinol-binding protein 4 (RBP4) have 
been unravelled so far but they only explain a small part of the AO variability in FAP 
ATTRV30M [123, 124]. In a previous study, Soares et al., 2005 compared Portuguese patients 
in a classic case-control approach; these authors found that the variants studied in the APCS 
gene had a combined modifier effect when analysing early-onset group versus controls, while 
the combination of one variant from APCS (rs6689429) and two variants from RBP4 
(rs7091052 and rs28383574) seemed to be involved with late-onset [123]. No comparisons 
were made between early and late-onset cases. 
The APCS gene encodes a highly conserved plasma glycoprotein, which is associated 
with amyloid deposition independently of protein origin. Apart from the plasma, APCS can also 
exist in amyloid deposits [225] and has the ability to bind to several ligands such as amyloid 
fibrils through a specific calcium-dependent mechanism [225]. In humans, the biological role 
of this protein has yet to be clarified. However, recently, it was found that the APCS has 
become an attractive therapeutic target in amyloid diseases [226].  
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RBP4 gene encodes the specific carrier of retinol in the human plasma. RBP4 is 
synthesized in the liver and when binding to all-trans-retinol circulates as a complex with TTR, 
forming a ternary RBP4-retinol-TTR complex. In the blood, the formation of the RBP4-retinol-
TTR complex causes the apparent increase of molecular mass and thus prevents its loss 
through glomerular filtration by the kidneys, stabilizing the quaternary structure of TTR [227].  
In several studies with Portuguese FAP ATTRV30M patients, women were found to 
have later-onset than men [5, 228]. Our group recently reiterated this finding [99]. Moreover, 
mother-son pairs showed larger anticipation while the father-daughter pairs showed only 
residual anticipation [99]. Therefore, to clarify gender-related differences associated with AO 
variation we will focus on sex-steroid hormones as androgen receptor (AR) and hydroxysteroid 
(17-beta) dehydrogenase 1 (HSD17B1). Both affect TTR expression levels, however AR 
seems to have a stronger inducer effect in the TTR expression than HSD17B1 [156]. The AR 
gene is located in the X chromosome and its nuclear transcription factor is activated to mediate 
binding of the androgenic hormones testosterone and 5α-dihydrotestosterone whereas the 
HSD17B1 gene may play an important role in regulating the local cellular levels of estradiol 
[229]. 
Therefore, the aim of this study was to investigate whether variants of these candidate-
genes have a modifier effect in AO within FAP ATTRV30M families, what was not taken into 
account in previous studies.   
We reassessed the role of APCS and RBP4 genes and for the first time analysed sex-
linked genes (AR and HSD17B1) as possible modifiers for AO.  
 
MATERIAL AND METHODS 
 
Subjects 
 
Unidade Corino de Andrade (UCA-CHP, Porto) has the largest FAP ATTRV30M 
registry worldwide: over 2000 patients, belonging to more than 500 families, collected over 75 
years and clinically well characterized. We concentrated on families with at least 2 generations 
affected and currently under follow-up at CHP. We achieved a sample of 318 patients from 
106 families, coming from different geographical areas of the country. 
For each individual, AO had been established by the same team of neurologists 
specialized in FAP ATTRV30M, when the first sensori-motor symptoms were observed. The 
DNA samples of these patients were collected and stored at the Centro de Genética Preditiva 
e Preventiva (CGPP, Porto) biobank, authorized by CNPD (National Commission for Data 
Protection). 
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All patients gave written informed consent and the study was approved by the Ethics 
Committee of CHP. 
 
DNA extraction 
 
Genomic DNA was extracted from peripheral blood leukocytes, using the standard 
salting out method [230] or from saliva, using ORAGENE kits according to the manufacturer’s 
instructions (DNA Genotek, Inc.).  
 
Selection of SNPs and genotyping 
 
We selected a total of 18 tagging single-nucleotide polymorphisms (SNPs) 
(Supplementary Table 1) through the degree of linkage disequilibrium (LD) existing between 
them, using Haploview v.4.1 [231], at an r2 threshold of 0.80 (with a minor allele frequency of 
0.10%). Also, we included 5 SNPs previously studied in order to replicate the results found by 
Soares et al., 2005 [123].  
The SNPs frequencies in the European population were obtained resorting to the 
HapMap Project and to dbSNP. All variants were submitted to the Leiden Open Variation 
Database shared installation (URL: 
http://databases.lovd.nl/shared/screenings?search_owned_by_=="Carolina%20Lemos"), with 
the following submission IDs: APCS: http://www.lovd.nl/APCS; AR: http://www.lovd.nl/AR; 
HSD17B1: http://www.lovd.nl/HSD17B1; RBP4: http://www.lovd.nl/RBP4 [patient IDs 38827-
39346]. 
Primers were designed using Primer3Plus software. Afterwards, the AutoDimer 
software was used to assess the formation of hairpins and primer–dimer secondary structures. 
Single base extension (SBE) primers were designed as described in the literature [232]. 
A multiplex reaction for eighteen tagging SNPs was carried out, using the QIAGEN 
Multiplex PCR Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. 
Amplified products were purified with ExoSAP-IT (Amersham Biosciences, Uppsala, Sweden). 
Genotyping was performed by a SNaPshot reaction using the SNaPshot Multiplex kit (Applied 
Biosystems). Final products were purified with SAP (Amersham Biosciences).  
To genotype rs6689429, rs3758539, rs28383574 and rs7091052, PCR products were 
digested using BsaJI, MnlI, BsrI, HinP1I restriction enzymes and loaded in QIAxcel 
multicapillary electrophoresis system (Qiagen). For rs28383573 genotyping was performed by 
sequencing. Also, uncertain genotypes were sequenced. Automatic sequencing was 
performed using the Big Dye Terminator Cycle Sequencing v1.1, Ready Reaction (Applied 
Biosystems), according to the manufacturer’s instructions. Samples resulting from the 
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SNaPshot reaction and sequencing were loaded in an ABI-PRISM 3130 XL Genetic Analyzer 
(Applied Biosystems). SNaPshot results were analysed with the GeneMapper™ v4.0 software.  
 
Design and Statistical Analysis 
 
Our family-centred approach means that we included in the analysis several members 
of the same family therefore each patient was “nested” in his/her family.  To account for non-
independency of AO between members of the same family, we used generalised estimating 
equations (GEE) [233].  
Therefore, we assessed any simultaneous association of the different variants with AO 
in FAP ATTRV30M (as the dependent variable), using the most common genotype as the 
reference category. 
 The unstandardized coefficient (B) corresponds to the mean AO variation observed in 
the individuals carrying a specific genotype when compared with the reference category. To 
correct for multiple testing, we applied a Bonferroni correction. All statistical analyses were 
performed using IBM SPSS Statistics software (v.20).  
Haplotypes estimation was performed using SNPator software [234]. To estimate 
haplotype frequencies, the Haploview v.4.1 software was also used. Parental transmission 
was assessed using a Fisher exact test. 
To detect gene-gene interactions, we used Multifactor Dimensionality Reduction (MDR) 
software (v.2.0) [235]. Significant results were corrected for multiple testing, based on a 1000-
fold permutation test, using the MDR Permutation Testing Module (v.1.0). 
SNP Function Prediction (FuncPred), a bioinformatic tool was used to predict putative 
SNPs functional effects [236].  
 
RESULTS 
 
Our patient sample shows a mean AO of around 39 years, but mean AO in males 
(37.28) is lower than in females (40.52) as already described in the literature4 [99] (Table 1).   
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Table 1.  Mean AO of male and female patients 
 
Using a candidate-gene approach with 318 Portuguese FAP ATTRV30M patients we 
unravelled some variants for the first time associated with AO variation in FAP ATTRV30M, as 
presented in Table 2. 
 
The role of APCS gene 
 
Regarding the genotype GT for the rs28383573, we did not find a significant result. 
However, it is worth noting that the one individual with the TT genotype presented a later-onset 
and the difference corresponds to an increase of twenty-six years in mean AO (Table 2). For 
the other SNPs assessed no significant results were found. 
 
RBP4 gene and AO  
 
We found that the CC genotype (p=0.012) and the CT genotype (p=0.011) of 
rs7094671 were associated with a later-onset (increasing AO in nineteen and ten years, 
respectively). The CT genotype (p=0.035) of rs11187545 was associated with an earlier-onset, 
when compared with the TT genotype, with a decrease of nine years in AO (although it is the 
only result that does not stand after multiple testing correction). Noteworthy, the individual with 
the CC genotype also presented an earlier-onset. 
Using MDR, we analysed a possible interaction between APCS-RBP4 genes but we 
did not find any strong interaction (data not shown). 
 
The involvement of sex-hormone genes 
 
Taking into account that AR gene is located in the X chromosome the analyses were 
stratified by gender and the genotypic analyses were only performed in the female group. We 
found a total of five SNPs significantly associated with AO variation in the AR gene, three in 
the male group and four in the female group including two in common for both genders. 
 Gender N  Range  Minimum Maximum Mean AO 
Standard 
Deviation 
AO        
 
Male 152 51 21 72 37.28 13.96 
Female 
TOTAL 
166 
318 
53 
53 
21 
21 
74 
74 
40.52 
38.97 
12.30 
13.19 
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Regarding the allelic analyses performed in the male patients group, significant results 
were found associated with a decrease in AO for the A allele (p<0.001) of rs17217069 and the 
G allele (p=0.002) of rs2361634, and this variation correspond to ten and nine years, 
respectively (Table 2). 
Additionally, in the female group, the CT genotype (p<0.001) of rs5919392, the GA 
genotype (p=0.001) of rs2361634 and the AT genotype (p=0.033) of rs5965433 were 
significantly associated with an earlier AO, and this variation correspond to nine and seven 
years for these variants. On the other hand the CT genotype (p<0.001) of rs5919393 was 
significantly associated with a later AO (Table 2).  
For rs5919393, in the male group, the C allele (p=0.015) was associated with a 
decrease of eleven years while in the female group, this SNP was associated to an increase 
in AO and the differences in mean AO correspond to seven years for the CT genotype (Table 
2). 
 
Concerning the HSD17B1 gene none of the SNPs were found to be significantly 
associated with AO variation. Also, we did not find any significant interaction between AR and 
HSD17B1 genes. 
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Table 2. Significant results of the analysis of APCS, RBP4 and AR SNPs and AO variation taking into 
account intrafamilial non-independency 
Gene SNP  Genotypes B      95% CI p-value 
APCS 
  GG (reference) - - - 
rs28383573  TT(*) 26.17 [23.08; 29.25]  p<0.001 
RBP4 
  CC (reference) - - - 
rs7094671 
TT 18.95 [4.10; 33.80] 0.012 
CT 10.42 [2.38; 18.46]  0.011 
rs11187545 
TT 
(reference) 
- - - 
CC(*) -28.49 [-44.56; -12.42] 0.001 
CT -8.98 [-17.06; 16.67]  0.035 
AR (male 
group) 
  
T 
(reference) 
- - - 
rs5919393 C -10.59  [-19.14; -2.04]  0.015 
 
G 
(reference) 
- - - 
rs17217069 A -10.38 [-14.22; -6.54]  p<0.001 
 
A 
(reference) 
- - - 
rs2361634 G -8.88  [-14.45; -3.31]  0.002  
AR (female 
group) 
  
CC 
(reference) 
   
rs5919392 CT -8.53  [-12.76; -4.30]  p<0.001 
 
TT 
(reference) 
- - - 
 
rs5919393 CT 6.63 [3.38; 9.87]  p<0.001 
 
AA 
(reference) 
- - - 
rs2361634 GA -6.96 [-11.00; -2.92]  0.001  
 
AA 
(reference) 
   
rs5965433 AT -6.76 [-12.97; -0.56]  0.033 
B – unstandardized coefficient (estimated quantitative effect of each genotype on AO variation 
compared with the reference genotype); C.I. – confidence interval; p-value – significance level was set 
to 0.05; (*) – based in only one individual with this genotype. 
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No haplotypic effect was found for any of the genes studied (data not shown).  
Regarding parental transmission of the SNPs to the affected children, we found a 
differential transmission for allele T of rs28383573 in the APCS gene. We found that non-
affected fathers transmitted more often than expected this allele that is involved in a later-
onset. 
Regarding AR gene, for rs5919392, we found that the affected mothers transmitted 
more often than expected the T allele, which is associated with an early-onset. For the other 
SNPs we did not find any significant differences in parental transmission. 
A bioinformatic’s analysis using FuncPred was also performed to assess the functional 
impact of the SNPs associated with AO variation of FAP ATTRV30M. This analysis predicted 
that one SNP in LD with rs5919393 (rs2473881) may alter transcription factors’ binding (TFB) 
sites in the AR gene with a higher number of TFB sites when the A allele was present.  
 
DISCUSSION  
 
Mechanisms responsible for AO variation in FAP ATTRV30M are still elusive. Similarly 
to several other neurodegenerative disorders, the TTR gene point mutation alone does not 
fully determine the AO variation or the course of the disease. Therefore, we have applied, for 
the first time, a family-centred approach also used in studies of other diseases [233, 237] and 
focused on modifier genes related with (1) TTR functional pathways involved in 
pathophysiological processes related to FAP ATTRV30M pathogenesis and also (2) sex-linked 
genes due to observed differences between genders and parent-of-origin effects associated 
with AO variation.  
In a previous study, Soares et al. [123] analysed five SNPs (also studied by us) in a 
Portuguese sample of 92 patients and 85 controls using a classic case-control approach. Thus, 
for APCS gene the authors obtained significant results for the combination of rs6689429 and 
the rs2808661 genotypes associated with early-onset when the early-onset group versus 
controls was compared; additionally, a joint effect of one SNP of the APCS gene (rs6689429) 
and two of the RBP4 gene (rs7091052 and rs28383574) was associated with a later-onset 
when the late-onset group versus controls was compared. Additionally, in the study performed 
by Dardiotis et al. [124], which analysed only one SNP (rs2808661) of the APCS gene, also 
studied by us, the results were quite different as no significant modifier effect was found.  We 
did not find any significant results for these SNPs showing that different approaches can lead 
to different results. Also, different genetic risk factors can be involved in different populations 
as in the case of the Cypriot sample. Furthermore, the samples’ size was quite small when 
 Results – Article 1   
 
54 
 
compared with ours showing that a larger sample, increasing the statistical power, is needed 
to draw some conclusion.  
 
The role of rs28383573 in the APCS gene 
 
Unlike other studies, we found in our sample a putative evidence of an association with 
a later-onset for the APCS gene. However, it should be noted that the TT genotype (rare 
homozygous) of the rs28383573 only appears once in our sample. This is in accordance with 
the observed genotype frequencies in the European population (TT=0.013) and, therefore we 
think that this result is worth mentioning. Although one may question if the effect found in this 
one individual is sufficient to associate this gene with AO, we look to this result as a hypothesis 
to be further explored, due to the differential parent transmission effect found and to the role 
of rare variants as genetic modifiers.  
APCS has been associated with several amyloid deposits and it has been suggested 
that it stabilizes amyloid fibrils protecting them from proteolytic degradation [226]. A study 
performed in vitro using Drosophila model showed that APCS binds to early TTR aggregates 
that are toxic to neuronal cells, therefore acting as a protective factor in inhibition of TTR-
induced toxicity [238]. Therefore, this protective role of APCS could be increased by the 
presence of this variant, increasing the inhibition of TTR toxicity and preventing an earlier AO. 
 
RBP4 gene variants associated with different AO patterns 
 
One SNP (rs7094671) of the RBP4 gene was associated with a late AO. In addition, 
rs11187545 was associated with an early AO. 
As with rs28383573 of APCS gene, the CC genotype of the RBP4 rs11187545 also 
appeared only once in our families but the CC genotype frequency of this SNP is also low 
(CC=0.003) in the European population. As we found a significant result for the CT genotype 
we consider that we cannot exclude the result for the CC genotype since it strengthens the 
involvement of the C allele of the rs11187545 in AO variability. RBP4 and TTR variants cause 
either RNA or protein instability and result in abnormally low retinol levels [239]. Therefore, the 
lack of RBP4 or TTR alters the retinol levels and increases urinary excretion of RBP4-retinol 
complex [240, 241]. The presence of these variants could therefore alter RBP4-TTR binding, 
preventing or increasing their binding to retinol, allowing us to hypothesize that the protective 
role of RBP4 could be decreased due to damaged TTR stability increasing aggregates 
formation, leading to an earlier AO.  
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AR gene and AO variability 
 
The anticipation effect in FAP ATTRV30M as a mechanism associated to patients’ 
gender was already previously described [99] and reinforced the hypothesis that sex steroid 
hormones genes may also have a modifier role in the disease onset with the differences in AO 
between males and females.  
Importantly, we found that the rs5919393 was associated with an earlier-onset in males 
and a later-onset in females leading us to suggest that this variant can have a possible 
protector effect in females. AR acts as a DNA-binding transcription factor that regulates 
positively or negatively gene expression [242]. From the in silico analysis we found that the A 
allele of the rs2473881 which is in LD with rs5919393 may alter TFB sites promoting up-
regulation of this gene in the female late-onset group. Furthermore, the rs2361634 is 
associated with an earlier-onset both in males and females and we hypothesize that this variant 
could be a genetic risk factor to both genders. Interestingly, we found a differential parental 
transmission regarding rs5919392, showing that affected mothers add a risk genetic effect to 
AO variation. These differences in AO variation could also be partially explained by different 
androgen levels in circulation in males and females since males have higher androgen levels 
than females [243], and this can induce TTR expression. Thus, as men have higher 
testosterone levels, increased levels of TTR will be produced possibly leading to early TTR 
amyloid deposits. Importantly, and confirming these observations, lower levels of TTR were 
found in women [244]. In a study using a mouse model with Alzheimer’s disease it was shown 
that a decrease or absence of TTR influences the levels of sex hormones with a gender effect 
[157]. A positive association between sex hormones and TTR levels were found in other 
studies [159, 160]. In addition, testosterone showed to have a neuroprotective role in animal 
studies [245, 246], and some studies have shown protective actions of sex hormones in several 
neurodegenerative diseases[164]. 
Regarding the HSD17B1 gene, although we did not found an effect in AO variation, this 
does not exclude other variants in other estradiol-linked genes as possible modifier candidate-
genes in FAP ATTRV30M. 
All the results found seem to be due the main effects of each gene, since no interaction 
between genes was observed. 
 
Our study has several strengths: a large sample size for a rare disease and a family- 
centred approach which prevents population stratification, unlike a case-control study [242]. 
GEE analysis is also appropriate, since it corrects for familial correlations of AO and it tends 
to have a greater power to detect a statistically significant effect than other similar methods 
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[247]. We also paid a special attention to statistical analysis by including multiple testing 
corrections. 
However, further investigation around AO variability in FAP ATTRV30M is necessary 
to deepen our results and provide more insight about the underlying mechanisms involved. 
Also, functional studies will also be required in a near future to confirm these results. The 
present study included only Portuguese patients, thus replication of this approach in other 
populations would be very interesting.  
 Our findings confirmed the involvement of APCS and RBP4 genes in the AO variation 
in FAP and this is the first study that unravels a new modifier gene – AR gene – as a potential 
modulator of AO variation in FAP ATTRV30M, particularly, sex-linked. In conclusion, these 
findings may have important implications in genetic counselling of offspring and in the follow-
up of mutation carriers.  
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Supplementary Table 1. The eighteen tagging SNPs and the 5 SNPs analysed by Soares et al., 2005, selected for each gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Candidate-genes 
APCS NC_000001.11   AR NC_000023.11:  RBP4 NC_000010.11 
rs6689429* chr1:g.159587731A>G 
 
rs2207040 chrX:g.67548107G>A  rs17484721 chr10:g.93593555A>G 
rs2808661 chr1:g.159588468A>G 
 
rs9282610 chrX:g.67566112A>G  rs7091052* chr10:g.93595641G>A 
rs28383573* chr1:g.159588882G>T 
 
rs5919392 chrX:g.67581463C>T  rs7094671 chr10:g.93595860G>A 
  
 
rs5919393 chrX:g.67605515C>T  rs11187545 chr10:g.93597348A>G 
 
 
rs12009820 chrX:g.67609772A>G  rs28383574* chr10:g.93598696T>C 
HSD17B1 NC_000017.11  
 
rs17217069 chrX:g.67616907G>A  rs3758539* chr10:g.93601831C>T 
rs2676531 chr17:g.42552167C>T 
 
rs2361634 chrX:g.67643001A>G  
  
rs2676530 chr17:g.42553937C>T 
 
rs5965433 chrX:g.67690762T>A  
  
rs676387 chr17:g.42554255C>A 
 
rs12011793 chrX:g.67698249T>C  
  
   
rs11497352 chrX:g.67707333T>C  
 
 
   rs5031002 chrX:g.67722783G>A    
Genomic location according to hg19 
* SNPs analysed by Soares et al., 2005 [123] 
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ABSTRACT  
Objectives:  Familial amyloid polyneuropathy (FAP ATTRV30M) shows a wide variation in 
age-at-onset (AO) between clusters, families and among generations. We will now explore 
some candidate-genes involved in altered disease pathways in order to assess their role as 
genetic modifiers of AO, using a family-centred approach. 
 
Methods: We analysed 62 tagging SNPs from 9 genes  NGAL, MMP-9, BGN, MEK1, MEK2, 
ERK1, ERK2, HSP27 and YWHAZ - in a sample of 318 V30M Portuguese patients (106 
families), currently under follow-up. A generalized estimating equation analysis was used to 
take into account non-independency of AO between relatives. Also, an in silico analysis was 
performed in order to assess the functional impact of significant variants associated with AO.  
 
Results: We found for the first time variants from 6 genes (NGAL, BGN (in the female group), 
MEK1, MEK2, HSP27 and YWHAZ) that were significantly associated with early- and/or late-
onset. Then, we confirmed a strong synergistic interaction between NGAL and MMP-9 genes. 
Additionally, by an in silico analysis we found some variants for MEK1 gene that may alter 
binding of the transcription factors and that influence the regulation of gene expression 
regarding microRNA binding sites and splicing regulatory factors. 
 
Interpretation: These findings showed that different genetic factors can modulate differently 
the onset of disease’s symptoms and revealed new mechanisms with clinical implications in 
the genetic counselling and follow-up of mutation carriers and could contribute for development 
of potential therapeutical targets. 
 
 
Keywords: FAP ATTRV30M signalling pathways; candidate-genes; genetic modifiers; age-at-
onset variation. 
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INTRODUCTION 
 
Familial amyloid polyneuropathy (FAP) ATTRV30M is an autosomal dominantly (AD) 
systemic amyloidosis with variable clinical presentation, age-at-onset (AO) and phenotype 
severity [248]. It is characterized by extracellular amyloid deposits of fibrillary transthyretin 
(TTR) that results in degeneration of the peripheral nerves and it is caused by a point mutation 
in the TTR gene (chr18q12.1) (OMIM 176300). More than 100 different mutations have been 
identified [222], but the Val30Met (V30M) missense mutation is the commonest worldwide. 
Typically a disease of adult-onset [3], FAP ATTRV30M has shown a wide variation in 
AO between clusters, but also within the same focus [5, 90, 92, 96, 223]. In Portugal, where it 
was first described [3], it was characterized as having onset between 25-35 yrs. Nowadays, 
AO in Portuguese patients varies from [19-82 years] [99]. However, given the large anticipation 
detected in Portuguese patients [99], AO variability observed between generations is our 
target.  
Earlier genetic studies focused on some candidate-genes that can modify AO of FAP 
ATTRV30M, using a case-control approach [123, 124], but they did not take into account that 
early and late-onset are not separate entities, since they may coexist within the same family. 
In our recent study, we used for the first time a family-centred approach concluding that 
APCS and RBP4 genes have an important role in AO variation and revealed for the first time 
the androgen receptor (AR) gene as an AO modifier both in males and females [249].  
Now, additional candidate-genes related with other FAP ATTRV30M signalling 
pathways were selected. We used the same sample derived from the large Portuguese registry 
[249]. 
A study using nerve and salivary glands biopsies found that biglycan (BGN), neutrophil 
gelatinase-associated lipocalin (NGAL), and matrix metalloproteinase-9 (MMP-9) proteins 
were up-regulated in FAP ATTRV30M when compared to controls. BGN seems to be 
increased in the earliest stages of TTR deposition in the form of nonfibrillar aggregates, 
whereas NGAL and MMP-9 were only overexpressed at a later stage of disease progression 
when fibrillary deposits were formed [132]. 
Monteiro et al., 2006 previously showed that extracellular signal-regulated kinases 1/2 
(ERK1/2) showed increased activation in FAP ATTRV30M salivary gland and nerve biopsies. 
ERK1/2 kinases (MEK1/2) activation was also up-regulated in peripheral nerves, with 
phosphorylation of ERK1/2. Therefore, this may represent an early signalling cascade leading 
to cytotoxic effects of TTR aggregates [133].   
Furthermore, heat shock proteins (HSPs) have been involved in several 
neurodegenerative diseases including FAP ATTRV30M and an increased expression of heat 
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shock 27kDa protein 1 (HSP27) related to the presence of extracellular TTR deposition in 
human FAP nerve, skin and salivary gland biopsies was found, as compared to controls [134]. 
Moreover, it has been described that tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta (14-3-3zeta or YWHAZ) expression levels decreased 
with aging [250]. Also, Vieira et al., 2013 showed that TTR regulates YWHAZ protein levels 
and so the absence of TTR correlated with decreased levels of YWHAZ in the hippocampus 
in young/adult TTR null mice when compared to WT TTR animals, although no changes in 
gene expression were found [141].   
The aim of our study was to assess for the first time whether variants in these 
candidate-genes have a modifier role in AO variation between generations in FAP ATTRV30M 
families and to look for a possible interaction between them. 
 
SUBJECTS AND METHODS 
 
Subjects 
 
From the largest FAP ATTRV30M registry worldwide (at UCA-CHP, Porto), we 
collected DNA samples and clinical data concerning 318 patients (106 families). Details are 
described at length at Santos et al., 2016 [249]. 
The study was approved by the Ethics Committee of CHP and all patients gave written 
informed consent. 
 
DNA extraction 
 
Genomic DNA was extracted from peripheral blood leukocytes, using the standard 
salting out method [230] or from saliva, using ORAGENE kits according to the manufacturer’s 
instructions (DNA Genotek, Inc.).  
 
Selection of SNPs and genotyping 
 
A total of 62 tagging single-nucleotide polymorphisms (SNPs) were selected (Table 1) 
with Haploview v.4.1 [231], using an r2 threshold of 0.80 (as measure of linkage disequilibrium)  
and with a minor allele frequency of 0.10%.  
A multiplex polymerase chain reaction (PCR) amplification for 56 tagging SNPs was 
performed and genotyping was carried out by a SNaPshot reaction. To genotype rs350911, 
rs7698, rs983583 and rs1451637, PCR products were digested using TfiI, HinP1I, PsiI and 
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BfaI restriction enzymes, respectively, and loaded in QIAxcel multicapillary electrophoresis 
system (Qiagen). The rs12906411 and rs2289858 genotyping was performed by sequencing. 
Primers’ design and genotyping techniques are described in more detail elsewhere [249]. 
 
Table 1. Tagging SNPs selected for each gene 
Candidate-genes 
NGAL MMP-9 BGN MEK1 MEK2 ERK1 ERK2 HSP27 YWHAZ 
 
   
rs2289860 
    
 
   
rs350916 
  
 
 
 
   
rs1979013 
  
 
 
 
  
rs1549854 rs350911  rs2276008  rs17365305 
 
 
rs2266862 rs745796 rs10250  rs13515  rs4734497 
 rs1805088 rs7062216 rs9672789 rs2289858  rs1063311  rs1376672 
 rs3918249 rs1126499 rs1432442 rs350903 rs7698 rs2298432  rs17365661 
rs12006030 rs3918256 rs2073479 rs12906411 rs10412325 rs1143695 rs7286558 rs11769502 rs7835096 
rs3780836 rs3787268 rs2269404 rs16949939 rs350897 rs11865086 rs3827303  rs3134354 
 rs2250889 rs1042103 rs11630608 rs350895  rs8141815  rs35083016 
 rs17577 rs743642 rs7181936 rs7258366  rs9610417  rs983583 
   rs8039880 rs350894  rs5755694  rs1451637 
    rs1823059     
    rs12609676     
    rs12459484     
        rs350887         
 
Design and Statistical Analysis 
 
Our family-centred approach meant that several members of the same family were 
included in the analysis; therefore, each patient was “nested” in his/her family.  We used 
generalized estimating equations (GEE) [233], since AO is non-independent between 
members of the same family.  The design and statistical analysis were described in detail 
elsewhere [249]. 
 
RESULTS 
 
We present a family-centred study f of variants in 9 candidate-genes involved in FAP 
ATTRV30M signalling pathway.  
In this study with 318 Portuguese FAP ATTRV30M patients (106 families) with a mean 
AO of ∼39 years we unravelled for the first time some polymorphisms associated with AO 
variation in FAP ATTRV30M, as presented in Table 2. No significant results were found to be 
associated with AO variation regarding MMP-9, ERK1 and ERK2 genes (data not shown). 
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The role of NGAL and BGN genes  
 
In NGAL gene, the CT genotype (p=0.019) of rs3780836 was significantly associated 
with an earlier onset corresponding to a decrease of 6 years in mean AO (Table 2). For the 
other SNPs assessed and for the haplotypic analyses no significant results were found.  
Since BGN gene is located in the X chromosome, the analyses were stratified by 
gender and the genotypic analyses were only performed in the female group.  
 Regarding the allelic analyses performed in the male patients group, no significant 
result was found associated with AO (data not shown). 
Importantly, in the female group, the TT genotype (p=0.030) of rs2269404 was 
significantly associated with a later AO, an increase of 10 years in disease onset (Table 2). In 
the haplotypic analyses performed for the female group we found a significant result when the 
C-G-T-C-C-A-G haplotype is present (p=0.036) associated with a later onset. 
Regarding parental transmission for these genes, no significant differences were found. 
 
MEK1 and MEK2 genes and AO  
 
For MEK1 gene, we found four SNPs significantly associated with AO: the CC genotype 
(p=0.002) and the CT genotype (p<0.001) of rs11630608 and the CC genotype (p=0.023) of 
rs745796 were associated with an earlier onset and this variation corresponds from 9 to 13 
years in disease onset for these polymorphisms (Table 2). On the other hand, the CT genotype 
(p<0.001) of rs16949939 was associated with a mean increase of 26 years in AO (Table 2).  
Regarding the MEK2 gene, we found that the TT genotype (p=0.010) of rs1823059 was 
associated with a later AO, an increase of 17 years (Table 2).  
In the haplotypic analyses, no significant results were found (data not shown). 
Concerning parental transmission of the SNPs to the affected children, we found a 
differential transmission for allele C of rs11630608 and allele C of rs745796 in the MEK1 gene. 
Non-affected fathers transmitted more often than expected these alleles that are involved in 
an earlier onset. In addition, for the rs11630608 sons of non-affected fathers received more 
often than expected the C allele (p=0.012), while for the rs745796 daughters of non-affected 
fathers received more often than expected the C allele (p=0.013) (data not shown). 
Regarding MEK2 gene, for the rs1823059, we found that non-affected fathers 
transmitted more often than expected the T allele that is associated with a later onset 
(p=0.015). For the other SNPs we did not find any significant differences in parental 
transmission (data not shown). 
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HSP27 and YWHAZ genes and AO variation 
 
We found that the CT genotype (p=0.005) of rs11769502 for HSP27 gene and the GA 
genotype (p=0.033) of rs17365305 for YWHAZ gene, were significantly associated with earlier-
onset and the difference corresponds to a decrease of 7 years in mean AO (Table 2). For these 
genes, we also performed haplotype-based analysis, but no differences were found (data not 
shown). 
For these genes, no significant differences were found in parental transmission. 
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Table 2. Significant results of the analysis of NGAL, BGN, MEK1, MEK2, HSP27 and YWHAZ SNPs 
and AO variation taking into account intrafamilial non-independency 
Gene SNP  Genotypes B 95% CI p-value 
NGAL 
  
CC 
(reference) 
- - - 
rs3780836  CT -6.07 [-11.15; -0.98] 0.019 
BGN (female 
group) 
  
CC 
(reference) 
- - - 
rs2269404 TT 10.48 [1.03; 19.93] 0.030 
MEK1 
  
AA 
(reference) 
- - - 
rs8039880 GG -7.02  [-14.03; 0.00]  0.050 
 
TT 
(reference) 
- - - 
rs11630608 
CC -12.75 [-20.98; -4.53]  0.002 
CT -9.38 [-14.21; -4.55]  p<0.001 
 
CC 
(reference) 
- - - 
rs16949939 CT 26.15 [14.34; 37.96]  p<0.001 
 
TT 
(reference) 
- - - 
rs745796 CC -10.49 [-19.50; -1.47]  0.023 
MEK2 
  
CC 
(reference) 
- - - 
rs1823059 TT 17.08 [4.13; 30.03]  0.010 
HSP27 
  
CC 
(reference) 
- - - 
rs11769502 CT -6.664 [-11.30; -2.02]  0.005 
YWHAZ 
  
GG 
(reference) 
- - - 
rs17365305 GA -6.759 [-12.97; -0.55]  0.033 
B, unstandardized coefficient (estimated quantitative effect of each genotype on AO variation compared 
with the reference genotype); CI, confidence interval; p-value, significance level was set to 0.05. 
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Functional impact and gene-gene Interactions 
 
To explore the functional impact of the SNPs associated with AO variation, we 
performed an in silico analysis using FuncPred and is-rSNP. Particular attention was paid to 
rs745796 of MEK1 gene since some SNPs in LD (rs10851759, rs11071895, rs12914079, 
rs4776791, rs7403574, and rs8043062) may alter transcription factors’ binding (TFB) sites. In 
addition, the is-rSNP algorithm highlighted that this SNP may also significantly affect the ability 
of one transcription factor to bind to DNA (LM120, p=0.001) (Figure 1). This analysis also 
predicts that rs537 (which is in LD with rs745796) may affect microRNA binding sites. 
 
 
 
 
 
 
 
 
 
Figure 1. The sequence logo of the one Transcription factor (TF) binding site potentially disrupted by 
MEK1 rs745796 
 
Additionally, we found that rs11071896 and rs17851970 (which are in LD with 
rs11630608 of MEK1), rs1030986 and rs16953566 (which are in LD with rs16949939 of MEK1) 
may alter the recognition sites for splicing regulatory factors. 
A strong synergistic interaction was found with the MDR analysis, as shown in the 
dendogram (Figure 2) for the best model, between the rs17577 of the MMP-9 gene and 
rs12006030 of the NGAL gene, with a testing balanced accuracy (TBA) of 0.59 and a cross-
validation consistency (CVC) of 10/10. After permutation testing, this model was still significant 
(p=0.037).  
 
 
 
 
 
 
Figure 2. Dendogram showing a strong synergistic interaction among NGAL-MMP-9 genes (darker lines 
suggest a synergistic relationship – shorter the lines, stronger the interaction 
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DISCUSSION  
 
Research on age-at-onset (AO) variation has been central in several dominant 
diseases including FAP ATTRV30M, since it might lead to a better understanding of the 
disease pathogenesis mechanisms. Thus, this study addresses the identification of variants of 
possible candidate-genes as AO genetic modifiers in FAP ATTRV30M. To our knowledge, this 
is the first study that examines the association of these six potential candidate-genes (NGAL, 
BGN, MEK1, MEK2, HSP27 and YWHAZ) linked to several FAP ATTRV30M signalling 
pathways with AO, using a family-centred approach. 
 
NGAL and BGN variants associated with AO variation 
 
We examined variants in genes linked to remodelling of the extracellular-matrix (ECM)-
related components as NGAL, MMP-9 and BGN due to its overexpression in FAP ATTRV30M. 
In our sample, we found that the CT genotype of rs3780836 in the NGAL gene was associated 
with an earlier onset and we hypothesize that this variant could be a genetic risk factor for the 
FAP ATTRV30M patients. On the other hand, we found that in the female group the rare 
genotype (TT) of rs2269404 of the BGN gene was associated with a later onset, leading us to 
suggest that this variant can have a possible protective effect in females. We also performed 
a MDR analysis for detection of gene-gene interaction, which is a powerful statistical tool of 
multilocus data reduction to improve the detection of genotypic combinations that predict 
disease risk [251]. We found a strong synergistic interaction between NGAL and MMP-9 
genes, confirmed by a 1000-fold permutation test. In addition, this study confirm the data 
already described in a previous study, using FAP ATTRV30M nerve and salivary glands 
biopsies, which showed that NGAL forms a complex with MMP-9 and where expression of 
these genes seems to overlap [132]. Therefore, this was the first study that explored the 
possible involvement of the variants of these genes associated with AO variation, using a 
family-centred approach. Furthermore, NGAL and MMP-9 were only overexpressed at a later 
stage when amyloid fibrils were already present, while BGN was up-regulated in the earliest 
stages of TTR deposition, when nonfibrillar TTR aggregates were already present, but could 
coexist with TTR fibrils [132]. Similarly, Cardoso et al., 2008 corroborated the observations 
reported for human tissues [132], but using an FAP ATTRV30M transgenic mice model [135]. 
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 Role of MEK1 and MEK2 variants in AO variability 
 
Although molecular signalling mechanisms in FAP ATTRV30M are not fully understood, 
a previous study provides evidence for the involvement of the MEK-ERK MAPK signalling 
pathway in disease pathogenesis [133]. Therefore, we selected MEK1/2 and ERK1/2 as 
candidate-genes due to their role as mediators of the cytotoxic effects of TTR aggregates in 
different stages of disease progression. 
In a study using human FAP ATTRV30M nerve biopsies, MEK1/2 activation was found 
upregulated in both asymptomatic carriers and patients when compared to controls. 
Furthermore, phosphorylation levels of MEK1/2 were decreased in later symptomatic stages 
[133]. MEK1/2 is activated after phosphorylation and may lead to ERK1/2 activation in 
response to a variety of hormones, growth factors and oxidative stress, which can regulate 
transcription and translation [252, 253]. When ERK signalling cascade is early activated it can 
lead to increased cell proliferation and TTR aggregates expression levels. This will lead to 
cytotoxic effects by TTR aggregates and to an earlier AO [133]. Likewise, it was shown in 
peripheral nerves of a FAP transgenic mouse model an increased ERK1/2 activation when 
TTR deposits occurs when compared to control animals, where older animals (17 months) had 
twice the activation of younger ones (2 months) [133]. Additionally, it was shown a sequential 
activation of MEK1/2 and ERK1/2 in brains with early stage of neurofibrillary degeneration 
[252]. 
We found that four variants in MEK1 were associated with an earlier AO and one variant 
associated with a later disease onset. Interestingly, we found a differential parental 
transmission regarding rs11630608 and rs745796 in the MEK1 gene where the non-affected 
fathers added a genetic risk effect to AO variation. Moreover, sons of non-affected fathers in 
the case of rs11630608 and daughters of non-affected fathers in the case of rs745796 have 
an increased susceptibility for earlier AO when they receive the rare allele (C). Additionally, we 
found that the rs1823059 TT genotype of MEK2 was associated with a later AO. Furthermore, 
for the rs1823059 in the MEK2 non-affected fathers added a protector genetic effect to AO 
variation leading to a later AO.  
The adverse or protective effects associated to early and late-onset of MEK1/2 variants 
point to an effect of these genes in our sample. We also found a possible modulatory effect on 
AO associated with the non-carrier chromosome (a trans-acting effect).  
In silico analysis revealed some variants in LD with rs745796 of MEK1 gene that may 
alter binding of the transcription factors LM120 promoting upregulation of this gene. 
Furthermore, LM120 was predicted to have more affinity when the C allele is present, 
reinforcing our genotype analysis where the CC genotype was found to be associated with 
individuals with an earlier AO. As in other studies this could lead to an early activation of this 
 Results – Article 2   
 
70 
 
pathway [252]. Additionally, we also found other alterations that could influence the regulation 
of gene expression regarding microRNA binding sites and splicing regulatory factors. 
Therefore, the inhibition or activation of the factors involved in the MEK1/2 signalling cascade 
can be good targets for the development of novel therapeutic approaches.  
 
HSP27 and YWHAZ variants and AO  
 
Several studies have reported the essential role of the heat shock proteins (HSPs) in 
various neurodegenerative disorders associated to protein aggregation since these are 
considered important for cellular defence mechanisms. Thus, it was already demonstrated that 
in the presence of protein misfolding and aggregation a neuroprotective stress response 
mediated by HSPs can be induced in Alzheimer’s disease (AD) [254], Parkinson’s disease 
[255] and Huntington’s disease [256]. However, activation of heat shock transcription factor 1 
(HSF) is required to occur upregulation of the HSP synthesis. In a previous study, it was shown 
that in FAP ATTRV30M human nerve, skin and salivary gland biopsies with extracellular TTR 
deposits there is induction of intracellular activation of HSF1 and consequently the an increase 
of expression of HSP27 and HSP70 [134]. 
In present study, we selected the HSP27 gene in order to investigate if it influences AO 
variation, since HSP27 upregulation was only observed in tissues with extracellular TTR 
deposition [134]. We found that rs11769502 of HSP27 was associated with an earlier onset, 
reinforcing the important role of HSP27 in FAP ATTRV30M. Therefore, the effect of this variant 
could induce an early neuroprotective intracellular stress response by increasing of  HSP27 
expression, activating the cell defence mechanism to prevent neurodegeneration in FAP 
ATTRV30M. 
As with HSPs, YWHAZ protein might act as a neuroprotection mechanism against 
toxicity in a variety of neurodegenerative diseases with common cellular and molecular 
mechanisms including protein aggregation since this may function as a sweeper of misfolded 
proteins [257]. In a previous study in AD, the authors found that YWHAZ stimulates tau 
phosphorylation [258] and is upregulated in the patients’ brains [259]. In other study, it was 
shown the specificity of TTR to regulate YWHAZ levels and decreased YWHAZ protein 
expression in the hippocampus of young/adult TTR null mice when compared to WT TTR 
animals [141]. Also, it was shown that YWHAZ expression levels decrease with aging [250]. 
We found that rs17365305 of YWHAZ gene was associated with an earlier onset, 
leading us to suggest that in the presence of this variant the potential risk effect may be 
increased and the YWHAZ-related defence mechanisms blocked. Therefore, the modulation 
of this variant will be important in order to protect early-onset patients.  
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In conclusion, the results of our study provide evidence for an association of DNA non-
coding variants of genes in FAP ATTRV30M pathways that may have phenotypic implications, 
particularly, in AO variation. However, our study does not preclude the possibility that other 
genes involved in these or other pathways may act as genetic modifiers of AO. Although an in 
silico analysis has been performed to predict functional impact of significant variants, functional 
studies will be important to deepen our knowledge.  Moreover, in the future, it would also be 
interesting to replicate our study in other FAP ATTRV30M populations. 
Therefore, with this study we reveal for the first time, using a family-centred approach, 
that variants of NGAL, BGN, MEK1, MEK2, HSP27 and YWHAZ may act as potential genetic 
modulators of AO in FAP ATTRV30M, which could be useful for the development of novel 
therapeutic approaches, improve patient care, and aid in the genetic counselling of mutation 
carriers. 
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ABSTRACT 
 
Introduction: Transthyretin (TTR) related familial amyloid polyneuropathy (TTR-FAP) is a 
dominant neurological disease, caused most frequently by a Val30Met (V30M) substitution in 
TTR. Age-at-onset (AO) ranges between 19-82 years and variability exists mostly between 
generations. Unstable oligonucleotide repeats in various genes are the mechanism behind 
several neurological diseases, found also to act as modifiers for other disorders.  In this study, 
our aim was to investigate whether large normal repeat alleles of ten candidate-genes, had a 
possible modifier effect in AO in Portuguese TTR-FAP Val30Met families.  
 
Materials and Methods: We analysed 329 patients (128 families). Repeat length (at ATXN1, 
ATXN2, ATXN3, ATXN7, TBP, ATN1, HTT, JPH3, AR and DMPK) was assessed by single 
and multiplex PCR, using fluorescently-labelled primers, followed by capillary electrophoresis. 
Results were analysed with GeneMapper™ v.4.0 software. We used a family-centred 
approach and generalized estimating equations (GEE) were used to account for AO correlation 
between family members. 
 
Results: For ATXN2, the presence of at least one allele longer than 22 CAG repeats was 
significantly associated with an earlier onset in TTR-FAP Val30Met, decreasing mean AO by 
6 years (p=0.001). No association was found for the remaining repeat loci. 
 
Conclusions: Length of normal repeats at ATXN2 may modify AO in TTR-FAP Val30Met and 
may function as a risk factor. This can be due to ATXN2 role in RNA metabolism and as a 
modulator of various cellular processes, including mitochondrial stress. This may have relevant 
implications for prognosis and the follow-up of presymptomatic carriers.  
 
 
Keywords: Familial amyloid polyneuropathy (FAP); TTR gene, repeats; genetic modifiers; 
age-at-onset. 
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INTRODUCTION 
 
Transthyretin (TTR) related familial amyloid polyneuropathy (TTR-FAP) is an 
autosomal dominant systemic amyloidosis characterized by extracellular amyloid deposits of 
mutated fibrillary TTR that result in degeneration of the peripheral nerves and it is caused by 
a point mutation in the TTR gene (chr18q12.1) (OMIM 176300). Although more than 100 
different variants have already been identified, Val30Met (V30M, also known as c.148G>A; 
p.Val50Met - NM_000371.3) is the more frequently described disease-causing variant in this 
gene, associated with large clusters [222]. 
In Portugal, FAP was initially characterized by Andrade as a disease with onset mostly 
between 25-35 years (yrs.) [12]. Nowadays, in Portuguese families, TTR-FAP Val30Met shows 
a wide variation in AO [19-82 yrs.] and early- (AO <40 yrs.) and late-onset (AO ≥50 yrs.) cases, 
and even asymptomatic carriers aged 95, may coexist in the same family [99].  
Interestingly, it was observed that offspring of late-onset parents quite often show early-
onset (anticipation) [99] and was described as early as 1964 by Becker, who dismissed it as a 
statistical artefact [8]. Later, Sousa et al., 1990 analysed 147 parent-offspring pairs and 
hypothesized that anticipation should be due to some modifier mechanism [103]. 
 As from 1991, a new molecular mechanism responsible for several neurogenetic 
disorders was found (the expansion of triplets from normal to disease range, becoming 
unstable) legitimizing anticipation in myotonic dystrophy type 1 (DM1), fragile X syndrome and 
other diseases such as Huntington’s disease (HD) [260]. 
Expanded repetitive tracts are located in different genes, being very abundant in the 
human genome and they are also known to be associated with other neurological disorders. 
Some of these genes share similar characteristics as (1) the repetitive motif is a CAG/CTG 
and cause disease when expanded; (2) the repeat length and AO are inversely correlated and 
(3) the phenotype is variable in patients with the same genotype [146, 261]. 
More recently, their role as genetic modifiers of other Mendelian diseases has been 
evidenced. Previous studies showed that an intermediate-length (CAG)n expansion in the 
coding region of the ataxin-2 (ATXN2) gene, responsible, when expanded, for spinocerebellar 
ataxia type 2 (SCA2), was a major genetic contributor to amyotrophic lateral sclerosis (ALS) 
[151, 152, 262].  
 Additionally, other authors found that AO of some spinocerebellar ataxias (SCAs) was 
also modulated by the normal repeat length in other SCA genes [263]. For instance, in 
SCA3/MJD subjects, CAG repeat length in the ATXN2, atrophin 1 (ATN1) and huntingtin HTT 
interacting with ataxin-3 (ATXN3) may differently modulate AO: longer intermediate ATXN2 
alleles and larger ATN1 alleles may decrease AO in SCA3/MJD patients, while shorter HTT 
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alleles may increase AO [263]. However, these results were not replicated, for example, in an 
Azorean cohort [264]. 
Genes like HTT, TATA-box binding protein (TBP) and ataxin-7 (ATXN7) are directly 
involved in transcription and transcriptional regulation [265-270], and others like ataxin-1 
(ATXN1) and ATXN2 may interfere with the RNA metabolism [271, 272]. In DM1, repeat 
expansions may affect the splicing of the same target RNAs [273]. Importantly, androgen 
receptor (AR) gene is located on the X chromosome and in a previous study we found, for the 
first time, SNPs in this gene associated with AO variability both in men and women [249]. 
Recently, some studies have focused on possible modifier genes of AO in TTR-FAP 
V30M, using 2 different approaches: case-control [123, 124] and family-centred [249, 274]. 
However, the role of repetitive loci in TTR-FAP Val30Met associated with AO variability have 
not been explored yet. 
To the best of our knowledge, there was only one study that aimed to correlate repeat 
expansions with TTR-FAP, analysing a small sample of 9 Portuguese affected parent-offspring 
pairs with large anticipation (>12 yrs.) and 19 non-carriers individuals, looking for 10 triplet 
repeat expansions as a possible explanation for TTR-FAP anticipation [109]. Despite no major 
differences were found, the study was focused only in a possible explanation for TTR-FAP 
anticipation and not in AO variability [109] Therefore, the role of the repeat length in the 
molecular mechanism underlying AO variation in TTR-FAP Val30Met patients is still 
unexplored. 
In the present study, we focused on AO variation and the length of the normal repeats 
of ten candidate genes that, when expanded, cause several inherited neurodegenerative 
disorders, using a family-centred approach.  
 
MATERIAL AND METHODS 
 
Subjects 
 
Patients and relatives 
 
From the largest TTR-FAP Val30Met patient’s registry worldwide, collected and 
clinically characterized over 75 years, at Unidade Corino de Andrade – Centro Hospitalar do 
Porto (UCA-CHP, Porto), we retrieved a total of 329 patients with known AO, 120 
asymptomatic carriers aged at least 50 yrs. and 70 healthy individuals (spouses and unaffected 
siblings from the same families, molecularly confirmed as non-carriers of the V30M variant). 
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These patients and relatives belonged to 128 different families with at least 2 generations 
affected, coming from different geographical areas of the country. 
For each patient in the registry, AO was established by the same team of neurologists 
specialized in TTR-FAP, usually when first sensori-motor symptoms were observed and 
coincide with abnormal neurological or neurophysiological exam. All DNA samples were 
collected and stored at the Centro de Genética Preditiva e Preventiva – Institute for Molecular 
and Cell Biology and Instituto de Investigação e Inovação em Saúde (CGPP-IBMC and i3S, 
Porto), a biobank authorized by CNPD (National Commission for Data Protection) for collection 
and storage of diagnostic and research samples and associated data. Written informed 
consent was obtained for all participants and the study was approved by CHP’s Ethics 
Committee. 
 
Control population 
 
In order to assess the distribution of normal repeat length for each candidate-gene, our 
first step was to establish a control population. Our group of TTR-FAP Val30Met patients and 
their relatives could be seen as a control population, since individuals were enrolled due solely 
to the presence of TTR-FAP Val30Met (without any other disease), but unselected and 
unbiased towards any of the candidate-genes to be assessed.  
However, we chose to be more stringent in the inclusion criteria for the control sample, 
so that only one affected individual per family was included, in order to avoid biasing the 
sample with TTR-FAP Val30Met patients. 
Each family was therefore represented by 1) a noncarrier spouse plus his/her affected 
spouse or 2) a noncarrier relative plus one randomly selected patient or carrier of the same 
family or 3) in families without proven noncarrier individuals, only one randomly selected 
patient or V30M carrier was included. 
Using this approach, we achieved a control sample of 181 individuals (362 
chromosomes). Table 1 describes, for each gene, the range of normal alleles as established 
in the literature and also the range found in our control sample. Moreover, Figure 1 shows the 
distribution of each repeat length in our sample.   
If we consider the acceptable ±2 CAGs error margin, in terms of range and the more 
frequent alleles, our control population is very much alike the ones described in studies from 
other countries [263, 275], as well as in previous studies in the Portuguese population for HD 
[264, 276], MJD/SCA3 [264, 277, 278], and SCA1, SCA2, SCA7, DRPLA  [264, 278] and 
SCA17 [278]. 
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DNA analyses 
 
Genomic DNA was extracted from peripheral blood leukocytes, using the standard 
salting out method [230]; or from saliva, using ORAGENE® kits, according to the 
manufacturer’s instructions (DNA Genotek, Inc., Kanata, ON, Canada). DNA samples were 
quantified in a NanoDrop spectrophotometer and possible degradation or contamination was 
checked on QIAxcel, a capillary electrophoresis system (Qiagen). 
 
Repeat selection and Genotyping 
 
A set of ten candidate-genes that show CAG/CTG trinucleotide repeat expansions 
associated to different neurological disorders were selected in order to explore the impact of 
repeat size at these loci on AO of TTR-FAP Val30Met (Table 2).  
 
Table 2. Characteristics of all repeat loci selected and associated diseases  
Gene 
Chromosome 
location 
Repetitive motif Disease 
ATXN1 6p22.3 (CAG)n (CAT) n (CAG)n SCA1 (Spinocerebellar ataxia type 1) 
ATXN2 12q24.1 [(CAG)n CAA (CAG)n]n SCA2 (Spinocerebellar ataxia type 2) 
ATXN3 14q21 
(CAG)2 CAA AAG CAG CAA 
(CAG)n 
MJD/SCA3 (Machado-Joseph disease) 
ATXN7 3p21.1-p12 (CAG)n SCA7 (Spinocerebellar ataxia type 7) 
TBP 6q27 (CAG)n (CAA)n (CAG)n SCA17 (Spinocerebellar ataxia type 17) 
ATN1 12p13.31 (CAG)n DRPLA (Dentatorubral pallidoluysian atrophy) 
HTT 4p16.3 (CAG)n HD (Huntington’s disease) 
JPH3 16q24.3 (CTG)n HDL2 (Huntington’s disease-like 2) 
AR Xq12 (CAG)n SBMA (Spinal and bulbar muscular atrophy) 
DMPK 19q13.3 (CTG)n DM1 (Myotonic dystrophy type 1) 
 
Repeat length was determined by a polymerase chain reaction (PCR) amplification 
assay, using fluorescently labelled forward primers. PCR primers sequences were designed 
with the software Primer3Plus and the presence of hairpins and secondary structures were 
ascertained with AutoDimer v1.0 (primer sequence are available upon request).  
Five singleplex PCR amplifications for the ATXN2, ATXN7, TBP, HTT and dystrophia 
myotonica protein kinase (DMPK) genes were performed in a final volume of 12.50μL, with 
exception of HTT gene that was in a final volume of 10.94μL containing 6.25μL of HotStar Taq 
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Master Mix Kit (Qiagen). In each PCR reaction, primer concentration was 10μM. All reactions 
used 1.25μL of DMSO (10%) except TBP gene (0 μL). The cycling conditions are available 
upon request. 
Two multiplex PCR reactions were carried out (one for ATXN1, ATN1 and junctophilin 
3 (JPH3) genes and the other for ATXN3 and AR genes), in a final volume of 12.50μL, using 
6.25μL of Multiplex PCR Master Mix Kit (Qiagen), 10μM of all primers and 10ng of DNA. The 
PCR products were mixed with the Liz-500 size standard (Applied Biosystems, Foster City, 
CA, USA). The size of the fragments was determined by capillary electrophoresis using the 
ABI-PRISM 3130 XL Genetic Analyzer (Applied Biosystems) and analysed with the 
GeneMapperTM v4.0 software (Applied Biosystems). Automated DNA sequencing of 
representative alleles from each locus in the reverse direction using Big Dye Terminator Cycle 
Sequencing v1.1, Ready Reaction (Applied Biosystems), according to the manufacturer’s 
instructions was performed to determine the exact correspondence between fragment size and 
repetitive tract length. 
 
Classification of allele size according to the number of CAG/CTG repeats 
 
For candidate-genes ATXN1, ATXN2, ATXN3, ATXN7, HTT and DMPK, normal alleles 
were classified as short, medium, intermediate short and intermediate large according to the 
classification of Tezenas Du Montcel et al., 2014 or the criteria of Gene Reviews (Table 3). 
In what concerns TBP, ATN1, JPH3 and AR loci, either there are no description of 
intermediate alleles (as for TBP, JPH3 and AR) or there were none in our population (for 
ATN1). Therefore, we considered a different approach for their analysis (see in Design and 
Statistical Analysis section): alleles were classified as short if their size was equal or smaller 
than the median and large if they were larger than the median.  
 
Design and statistical analysis 
 
For ATXN1, ATXN2, ATXN3, ATXN7, HTT and DMPK, genotypes were divided into 
two categories: (1) both alleles were of short or medium length; (2) there was at least one 
intermediate allele. In what concerns TBP, JPH3, ATN1 and AR, we divided genotypes into 
three categories: (1) both alleles were equal or smaller than the median; (2) at least one was 
larger than the median and (3) both alleles were larger than the median.  
For each locus, genotypes where both alleles were short/medium length or equal or 
smaller than the median were considered as the reference category and were compared to all 
genotypes including at least one intermediate allele. 
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Our family-centred approach means that we included in the analysis several members 
of the same family, where each patient was “nested” in his/her family.  To account for non-
independency of AO between members of the same family, we used generalized estimating 
equations (GEE), by performing a weighted analysis adjusted for gender [233]. 
Therefore, we assessed if there was association of the different repeats length with AO 
(as the dependent variable). The unstandardized coefficient (B) corresponds to the mean AO 
variation observed in the individuals carrying a specific genotype when compared with the 
reference category. To correct for multiple testing, we applied a Bonferroni correction (α was 
set at 0.005 in the GEE analysis, since we tested ten different genes). 
We also analysed parent-offspring transmissions, assessing whether larger alleles 
were more often transmitted by the father or the mother, using a Fisher exact test. All statistical 
analyses were performed with IBM SPSS Statistics v.23 and confirmed by SuperMix software. 
A P-values < 0.05 was considered statistically significant. 
 
RESULTS  
 
We assessed in a sample of 519 Portuguese individuals the length of repetitive alleles 
of a set of ten candidate-genes (ATXN1, ATXN2, ATXN3, ATXN7, TBP, ATN1, HTT, JPH3, 
AR and DMPK) that cause disease when expanded. In order to search for potential modifier 
effects of the repetitive motif size in AO variation of this disease, we analysed a sample of 329 
TTR-FAP Val30Met patients. We tested the hypothesis that larger normal alleles in these 
genes are more prone to be associated with an earlier onset of TTR-FAP Val30Met than 
smaller normal alleles.  
No significant differences in the CAG/CTG repeat length in ATXN1, ATXN3, ATXN7, 
TBP, ATN1, HTT, JPH3, AR and DMPK genes examined were detected in the TTR-FAP 
Val30Met patients associated with AO (data not shown).   
 
ATXN2 (CAG)>22 alleles are associated with an earlier onset in TTR-FAP Val30Met 
patients  
 
Normal CAG repeat alleles in the ATXN2 gene ranged from 14-31 repeats (Table 1). 
However, in our sample, the normal ATXN2 (CAG)n alleles showed to be less polymorphic, 
displaying only seven different sizes, ranging 22-28 repeats (Table 1). Size distribution of the 
ATXN2 CAG repeats in TTR-FAP Val30Met patients was similar to our control population and 
to distributions in other populations. The (CAG)22 allele was the most frequent (88%), followed 
by (CAG)23 (9%) (Figure 1), as seen in other populations.  
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The homozygous genotypes for 22 CAG repeats (n=261 patients) was considered the 
reference category and compared to all genotypes (n=68 patients) where at least one allele > 
22 CAG repeats was present.  
Using a family-centred approach, we found that patients carrying at least one ATXN2  
allele with length higher than 22 CAG repeats was associated with an earlier onset (a decrease 
of almost 6 years) (p=0.001), adjusted for gender (Table 4). This result remained significant 
even after adjustment for multiple comparisons using the conservative Bonferroni correction 
(p=0.005, adjusted for multiple comparisons). There was no parent-of-origin effect in the 
transmission of large normal alleles. 
 
Table 4. Analysis of ATXN2 repeat length and AO variation taking into account intrafamilial non-
independency 
Gene  Repeat length range B 
95% CI P-value 
ATXN2 
At least 1 Allele > 22 CAG repeats -5.49 [-8.81; -2.18] 0.001 
Alleles ≤ 22 CAG repeats 
(reference) 
- - - 
B, unstandardized coefficient (estimated quantitative effect of each repeat length on AO variation compared with 
the reference length); CI, confidence interval; P-value, significance level was set to 0.05. 
 
DISCUSSION 
 
Variability of age-at-onset (AO) in TTR-FAP Val30Met presents a challenge for the 
identification of genetic modifiers that could explain the early- or late-onset observed in some 
TTR-FAP Val30Met families. Different genetic modifier factors have been identified in TTR-
FAP Val30Met, but large normal alleles in genes containing repeats motifs were never 
considered and deserve particular attention. With this in mind, our strategy was to assess if 
the normal CAG/CTG repeat length in ten candidate-genes (ATXN1, ATXN2, ATXN3, ATXN7, 
TBP, ATN1, HTT, JPH3, AR and DMPK) could act as genetic modifiers influencing AO of TTR-
FAP Val30Met patients. We hypothesized that variation within the normal range of CAG/CTG 
alleles influences the AO in TTR-FAP Val30Met patients. We found that CAG repeat length in 
one of our candidate-genes studied, ATXN2, is significantly associated with an earlier-onset. 
Although a previous study from Soares et al. in 1999, aimed to assess if some repeats 
motifs were associated with TTR-FAP anticipation, the results were not conclusive, in particular 
due to the small sample size studied [109]. Furthermore, our aim now was to focus in AO 
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variability with a family-centred approach and applying more recent technologies for the 
accurate and reproducible determination of repeat length. 
In our Portuguese cohort and among the 10 genes tested we have found that patients 
carrying at least one allele with a length higher than 22 CAG repeats in the ATXN2 gene was 
associated with an earlier onset, showing a strong association with AO variability in TTR-FAP 
Val30Met.  
Previous studies have shown that the normal CAG repeat length in the ATXN2 is quite 
variable [14-31 CAG repeats], depending on the population, with 22 and 23 CAG repeats has 
the most common alleles, similarly to what was found in our sample [279, 280]. The CAG 
repeat length in ATXN2 is responsible by SCA2 when (CAG)n length is higher than 32-34 
repeats, with an impact on AO and severity [281, 282]. Importantly, some SCA2 patients 
presenting 32-33 CAG repeats show a late-onset of the disease [283-285]. Moreover, previous 
studies have suggested that intermediate-length CAG repeats in ATXN2 (27-33 CAG repeats) 
are associated with an increased risk for some pathologies and to function as a modulator of 
AO in ALS [151, 152, 286] and Parkinson’s disease [287]; although in other studies the 
opposite has been found, in which intermediate-length CAG repeats do not seem to be a risk 
factor as, for example, in the hereditary spastic paraplegias (HSP) [288]. Thus, in our study 
and using a family-centred approach we have found, for the first time, a statistically significant 
result associating an earlier onset in TTR-FAP Val30Met patients that present at least one 
allele with a length higher than 22 CAG repeats in the ATXN2 gene. Therefore, the presence 
of alleles with this length leads us to suggest a possible risk effect for TTR-FAP Val30Met 
patients.  
Ataxin-2 is one of the polyglutamine proteins, highly expressed in various neuronal and 
non-neuronal tissues, including the brain [289] and has been involved in the regulation of 
several biological processes such as RNA-mediated metabolism, translation regulation, 
cytoskeleton reorganization, Ca2+ homeostasis, and mitochondrial stress [290]. As the 
hallmark of TTR-FAP Val30Met is the presence of extracellular deposits of TTR aggregates 
and amyloid fibrils in several tissues, particularly, in peripheral nerves , diverse molecular 
pathways associated to degeneration have been confirmed, using in vivo samples and cell 
culture studies, including activation of nuclear factor kB, pro-inflammatory cytokines, oxidative 
stress and endoplasmic reticulum (ER) stress [291]. Oxidative stress may be further increased 
by the presence of (CAG)23-28 alleles at the ATXN2 locus and contribute to the processing of 
misfolded proteins, which, in turn, cause ER stress with enhanced reactive oxygen species 
(ROS) production, creating thereby a feedback loop [292]. 
 Another interesting feature is that when ATXN2 interacts with ALS pathogenic 
pathways, an altered localization of ATXN2 was observed [151]. These altered mechanisms 
can lead to an early AO because ATXN2 intermediate-length repeats can alter protein stability 
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or degradation affecting ataxin-2 levels, which may promote interaction with other proteins 
[151]. This can also be true for TTR-FAP Val30Met although further studies are required. 
Importantly, Tezenas du Montcel et al., 2014, also found in a large cohort that the repeat-
encoding genes can be modulators of AO for other SCAs, within the normal repeat length, 
confirming that these interactions may occur in different populations and disorders [263].  
 
In conclusion, our findings support the hypothesis that large normal CAG alleles, 
specifically in ATXN2, may modulate the AO variation in TTR-FAP Val30Met. Despite no 
significant association was found for the other genes, we cannot exclude a role for other 
dynamic mutations besides the ones that were studied. In the present work, we had a special 
concern with the statistical power, taking into account multiple testing corrections. The results 
obtained also reinforce the importance of replication studies in other populations to confirm 
these results. Unravelling the factors that contribute for AO modulation is important for the 
complete understanding of the disease pathogenesis, improvement of genetic counselling and 
follow-up of presymptomatic carriers.  
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Figure 1 – Normal repeat length distribution of the ten candidate-genes studied (ATXN1, ATXN2, ATXN3, ATXN7, TBP, ATN1, HTT, JPH3, AR and DMPK) 
for our Portuguese control sample.   
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Table 1 – Range of normal alleles for each gene analysed (ATXN1, ATXN2, ATXN3, ATXN7, TBP, HTT, JPH3, ATN1, AR and DMPK) such as described in 
the literature and also the range found in our control sample. 
 
    Genes 
 Alleles   ATXN1 ATXN2 ATXN3 ATXN7 TBP HTT JPH3 ATN1 AR DMPK 
Normal 
Literature 
6-38; 39-44 CAT 
interrupted 
14-31 12-44 4-19 25-42 ≤26-35 6-28 6-35 9-36 5-37 
Our sample 24-39 22-28 14-37 7-15 29-42 9-35 8-24 5-26 14-30 5-44 
 
 
Table 3 – Classification of short, medium, intermediate short and intermediate large alleles for all candidate-genes studied based on Tezenas du Montcel et 
al., 2014 and Gene Reviews.  
 
  Genes 
Normal Alleles ATXN1 ATXN2 ATXN3 ATXN7 TBP HTT JPH3 ATN1 AR DMPK 
Normal 
Short <36 <22 <16 <10 - ≤26 - <37 - ≤37 
Medium - 22 16-24 10-11 - - - - - - 
Intermediate 
Intermediate short - 23-26 - - - - - - - - 
Intermediate large 
36-38 (pure 
repeat) 
27-29 25-37 12-15 - 27-35 - 37-48 - 38-50 
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4.2. Unravelling mtDNA content in TTR-FAP Val30Met   
 
To further explore the question of gender-related differences associated with AO 
variation in TTR-FAP Val30Met, particularly, the gender differences of the transmitting parent, 
since a larger anticipation (>10 yrs.) was detected in our Portuguese series when the mother 
was the transmitting parent and when mother-son pairs were analysed, we decided to quantify 
mtDNA content. We devoted special attention to mtDNA, since it is exclusively maternally 
inherited to both males and females, which may help to explain some these differences. 
Moreover, as mitochondrion is considered the main site of energy production, we aimed to 
assess the energetic performance through the analysis of mtDNA copy number and to explore 
further underlying mechanisms related to TTR-FAP Val30Met pathology.  
We analysed different groups of individuals with and without TTR-FAP Val30Met and 
from of comparison of different groups our results showed, for the first time, that the patients 
and asymptomatic carriers have a higher mean mtDNA content than controls. Importantly, the 
highest mean of mtDNA copy number was observed in early-onset patients. Regarding parent-
offspring pairs analysis, we found a significant increase in the mtDNA copy number in the early-
onset offspring, when compared with their late AO parents. [Article 4]. 
Therefore, mtDNA copy number seems to have a significant effect in AO variability 
observed in parent-offspring transmission and mitochondrial gene expression is possibly 
associated with TTR-FAP Val30Met mechanisms. 
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ABSTRACT 
 
Purpose: Familial amyloid polyneuropathy (FAP ATTRV30M) shows a wide variation in age-
at-onset (AO) between generations and genders, as in Portuguese families, where women 
display a later-onset and a larger anticipation (>10 years), the mitochondrial DNA (mtDNA) 
copy number we assessed to clarify whether it has a modifier effect in AO variability in 
Portuguese patients. 
 
Method: The mtDNA copy number of 262 samples (175 Val30Met (V30M) TTR carriers and 
87 controls (proven Val30Val) was quantified by quantitative real-time polymerase chain 
reaction. Statistical analysis was performed using IBM SPSS v.23 software. 
 
Results: This study shows that V30M TTR carriers have a significantly higher (p<0.001) mean 
mtDNA copy number than controls. Furthermore, the highest mtDNA copy number mean was 
observed in early-onset patients (AO<40 yrs.). Importantly, early-onset offspring showed a 
significant increase (p=0.002) in the mtDNA copy number, when compared with their late AO 
parents.  
 
Conclusions: The present findings suggest, for the first time, that mtDNA copy number is 
associated with earlier FAP ATTRV30M events and may therefore be further explored as a 
potential biomarker for the development and/or validation of novel therapeutic targets. 
 
 
Keywords: Familial Amyloid Polyneuropathy (FAP); TTR gene; mtDNA copy number; age-at-
onset. 
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INTRODUCTION 
 
Familial amyloid polyneuropathy (FAP) ATTRV30M is an autosomal dominant systemic 
amyloidosis due to a point mutation in the transthyretin (TTR) gene (chr18q12.1) (OMIM 
176300), resulting in a misfolded protein. Although more than 100 amyloidogenic mutations 
have been found in the TTR gene [222], Val30Met (V30M) NM_000371.3:c.148G>A 
(p.(Val50Met)) is the most common. 
 FAP was classified by Andrade C. as a peculiar form of neuropathy [12]. It is 
characterized by extracellular amyloid deposits of mutated fibrillary TTR protein throughout 
connective tissue and degeneration of peripheral nerves [293]. Moreover, it was first described 
in Northern Portugal as a disease occurring between 25-35 years (yrs.) [12]. However, 
differences in mean age-at-onset (AO) between clusters have been described, as well as 
differences within the Portuguese population [5, 90, 99, 223]. In FAP ATTRV30M Portuguese 
families, a wide variability in AO [19-82 yrs.] and differences in AO between generations and 
genders have been observed [5]. 
Recently, our group showed that anticipation (a decrease in AO over the generations) 
is a true biological phenomenon in FAP ATTRV30M [99]. Additionally, significant differences 
in AO regarding gender were confirmed, namely women present a later-onset than men and 
larger anticipation (>10 yrs.) was more frequent when the disease was inherited from the 
mothers (70%) than from the fathers (30%). In addition, the mother-son pairs showed a larger 
anticipation, while father-daughter pairs showed only a residual anticipation [99]. To clarify 
gender-related differences associated with AO variation we reported a candidate-genes’ 
approach that included sex-steroid hormones and we revealed, for the first time, the 
contribution of the AR gene as an AO modifier both in men and women [249]. 
The mitochondrial DNA (mtDNA) is inherited exclusively from the mother and has a 
lower DNA repair capacity, when compared to nuclear genome [175, 294, 295]. In contrast to 
this fixed diploid genome, mitochondria are polyploids, i.e., have hundreds to several thousand 
copies of mtDNA for each cell, depending on the energy demands of the tissue or the 
developmental stage [181]. It codes for 13 polypeptides of the oxidative phosphorylation 
pathway and rRNAs (2) plus tRNAs (22) for their translation inside mitochondria. The mtDNA 
replication and transcription are regulated by a complex and not completely understood 
interaction with nuclear genome [296].  
To further explore the clear evidence in the remarkable AO variation between genders 
and especially due to the evident anticipation when the mother is the transmitting parent, our 
strategy focused now on mtDNA content quantification in FAP ATTRV30M carriers 
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(asymptomatic carriers and patients with early-onset (<40 yrs.) or late-onset (≥40 yrs.)) and 
non-carriers. 
The regulation of mtDNA copy number is an important aspect of mitochondrial genetics 
and biogenesis, essential for normal cellular function and crucial for maintaining cellular energy 
requirements. Thus, depletion, variation, decrease or excess of mtDNA copy number may be 
associated with several diseases, including multiple sclerosis and many other 
neurodegenerative disorders, or cancer [183, 185, 297, 298]. 
A previous study in FAP Portuguese and Swedish families showed that a variant in 
mtDNA may explain the observed differences in penetrance for FAP ATTRV30M according to 
the gender of the transmitting parent in Portuguese families [112]. In addition, another previous 
study with FAP Swedish and French patients, showed that mtDNA haplogroups may be 
associated with AO variation; haplogroup K, relatively rare in Europe, was associated with an 
earlier-onset of the disease [193]. However, the analysis of mtDNA copy number was never 
performed in FAP ATTRV30M before; therefore, we believe that this is a ground-breaking 
approach. 
Based upon these observations, the aim of the present study was to evaluate, for the 
first time, whether the mtDNA copy number has a modifier effect in AO in FAP ATTRV30M 
families, including gender influence, to infer the mtDNA-related bioenergetics’ performance in 
FAP ATTRV30M patients. 
 
MATERIALS AND METHODS 
 
Subjects 
 
DNA samples were ascertained from Unidade Corino de Andrade - Centro Hospitalar 
do Porto (UCA - CHP, Porto), which has the largest database of FAP ATTRV30M worldwide, 
with a registry collected and clinically well characterized over 75 yrs. The Ethics Committee of 
Hospital de Santo António (HAS - CHP, Porto), approved the study and all participants signed 
a written informed consent. All carriers have the V30M mutation and AO of each patient has 
been established by the same team of neurologists, specialized in FAP ATTRV30M, when the 
first sensori-motor symptoms emerged. 
 We have analysed a total of 262 blood-derived DNA samples from 56 early-onset (<40 
yrs.) and 52 late-onset (≥40 yrs.) patients, 67 asymptomatic carriers (aged ≥40 yrs.) and 30 
noncarriers (proven Val30Val (V30V) relatives belonging to same familial background). Control 
subjects (proven V30V) included blood donors and patient’s spouses (n=57; 29 males and 28 
females), without any FAP ATTRV30M familial history, were also enrolled in this study (Table 
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1). DNA was isolated by the same method for all selected subjects. Additionally, all samples 
were genotyped for ATTRV30M mutation and matched for the same ethnic and geographic 
origin of Portugal. All DNA samples were collected and stored at the Centro de Genética 
Preditiva e Preventiva (CGPP, Porto) biobank, authorized by CNPD (National Commission for 
Data Protection, Portugal). 
 
Table 1- Description of the sample for V30M TTR carriers and noncarriers used to quantification of 
mtDNA copy number 
na - Not Applicable 
 
DNA extraction  
 
Genomic DNA was extracted from peripheral blood leukocytes, using a standard salting 
out method [230], according to the manufacturer’s instructions. The concentration and purity 
of the DNA was assessed using a Nanodrop 2000 spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA). 
 
mtDNA copy number relative quantification 
 
The relative mtDNA copy number was measured in all samples using quantitative real-
time polymerase chain reaction (qRT-PCR). This method for determining mtDNA copy number 
was detailed in a previously publication by Venegas et al., 2012 [299], and was shown to have 
high inter-assay reliability. 
DNA samples were initially diluted to 2ng/μL from the stock DNA using DNA Tris-EDTA 
buffer solution. The DNA samples were further diluted for 0.4ng/μL. For each sample, two 
primer pairs were used to amplify the tRNALeu(UUR) gene - mtDNA  and ß-2-microglobulin (ß2M) 
Status V30M TTR carriers (n=175) Noncarriers (n=87)   
Characteristics 
Early-
onset  
Late-
onset  
Asymptomatic Relatives Controls TOTAL 
n 56 52 67 30 57 262 
Age-at-onset (AO), 
yrs. 
[24-39] [40-71] na na na na 
Age-at-observation, 
yrs. 
na na [19-81] [18-76] [21-89] na 
Gender       
               Male 27 21 27 15 29 119 
               Female 29 31 40 15 28 143 
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gene - nuclear DNA, in separate wells. The primers sequence and qRT-PCR amplification 
procedure were described previously [299]. A qRT-PCR amplification for each sample was 
performed in a final volume of 10 μL, using the 2× SYBR SuperMix (iTaq SYBR Green 
Supermix with ROX, BioRad). Primer concentration used in qRT-PCR was 5 μM. All samples 
were run in triplicate for both mitochondrial and nuclear genes on a 96-well plate with a 7500 
Fast Real-time PCR system (qRTPCR; PE7500 real-time PCR instrument; Applied 
Biosystems, Foster City, CA, USA). A negative and a positive control were also included in 
each run, to control possible contaminations and to act as internal calibration. Standard 
deviations for the threshold cycle value were accepted at 0.50. Otherwise, the analysis was 
repeated. The results were analysed with the 7500® v2.0.4 software (Applied Biosystems).  
 
Statistical analysis 
 
The statistical power and effect size of sample were estimated using the power analysis 
for ANOVA designs software (http://www.math.yorku.ca/SCS/Online/power/) (setting α=0.05, 
N≥50, with 5 levels of factor for power, ∆=1.0) and the sample size was in accordance with the 
expected power. 
Normal distribution was assessed using the Kolmogorov-Smirnov test. A power 
transformation was performed to normalize mtDNA copy number values and to satisfy the 
homogeneity of variances’ assumption for the errors. We performed power transformations 
and the only transformation that confirmed the homogeneity of variance between groups, as 
assessed by Levene’s test for equality of variances (p=0.519), was the (1-1/x) transformation 
[300], which allowed us to perform parametric tests. Multiple comparisons among groups were 
analysed by one-way analysis of variance (one-way ANOVA) followed by post Hoc corrections 
with Tukey HSD method.  
In order to investigate the effect of mtDNA copy number in AO variation, a generalized 
estimating equations’ (GEE) analysis, to account for non-independency of AO between 
members of the same family, was performed, adjusted for gender [233]. Evaluation of the 
parent-offspring transmissions was achieved using the t-test for paired samples. All statistical 
procedures were performed using the transformed variable for mtDNA copy number except for 
the initial descriptive analysis. The level of significance for all statistical tests was set at p<0.05. 
All statistical analyses were performed using IBM SPSS Statistics software (v.23). 
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RESULTS 
 
Quantification of mtDNA copy number for 262 individuals of Portuguese origin, 
comprising 175 V30M and 87 noncarriers (Table 2), was performed to search for a modifier 
effect in age-at-onset (AO).  
 
mtDNA copy number of peripheral blood leukocytes is associated with V30M TTR 
mutation  
 
In table 2, we can find the descriptive analysis for mean mtDNA copy number for all 
groups studied. It is important to note that the non-transformed mean mtDNA copy number of 
noncarriers (155.21±85.23) was lower than that of V30M TTR carriers (460.11±478.91).  
Normality of our sample was tested and the Kolmogorov-Smirnov test showed that the 
data were not normally distributed (p<0.05).  
 
Table 2- Descriptive analysis of mtDNA copy number for all the groups studied 
 
 
 
 
 
 
 
 
 
 
We investigated differences in mean mtDNA copy number (using the transformed 
variable) and we found a statistically significant difference between groups as shown by the 
one-way ANOVA test (F (4, 257) = 6.611; p<0.001). A Tukey post hoc test revealed that the 
mtDNA copy number in controls was significantly lower, compared to 1) asymptomatic carriers 
(p<0.001), 2) late-onset patients (p=0.001) and 3) early-onset patients (p<0.001). There were 
no statistically significant differences between the controls and noncarrier-relatives (p>0.05), 
neither between noncarrier-relatives and V30M carriers (p>0.05) (Figure 1).  
Concerning gender differences, no significant differences associated to mtDNA copy 
number were found in all groups studied (p>0.05; results not shown). 
 
Status Groups n 
Mean mtDNA 
 copy number/cell 
Standard 
Deviation 
Noncarriers 
Controls 57 140.19 63.11 
Relatives 30 183.75 112.09 
All 87 155.21 85.23 
V30M TTR 
carriers 
Asymptomatic 67 406.58 382.37 
Late-onset 52 479.74 527.21 
Early-onset 56 505.92 535.17 
All 175 460.11 478.91 
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Figure 1 – Analysis of differences in mtDNA copy number for various groups in study (noncarriers: 
controls and relatives and V30M TTR carriers: asymptomatic carriers, late-onset patients and early-
onset patients). Asterisks (**) indicate statistical significance - p<0.05. 
 
mtDNA copy number is not associated with AO variation 
 
The role of the mtDNA copy number on AO variation between the late-onset and early-
onset patients, using GEE, did not show a significant effect (p>0.05; results not shown). 
 
Variation of mtDNA content in the parent-offspring transmissions  
 
Regarding parent-offspring pairs analysis, no significant difference was found between 
asymptomatic carriers with their affected parents (p>0.05), even when stratified by AO of the 
affected parents. Importantly, early-onset offspring showed a statistically significant increase 
in the mtDNA copy number, when compared with their late AO parents (p=0.002) (Table 3).  
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Table 3- Analysis of mtDNA copy number, using the transformed variable, for parent-offspring 
transmissions stratified by AO of the affected parents 
aStd. Dev. - Standard Deviation; bCI- Confidence Interval; cp-value, significance level was set to 0.05 
 
DISCUSSION  
 
Mitochondria are the major organelles in providing of the energy needed for the vital 
function of human cells. As these organelles contain hundreds to thousands of mtDNA copies 
in each cell, the evaluation of mtDNA content could be considered an important candidate as 
a modifier factor for unravelling the biological mechanisms underlying the phenotype of several 
neurodegenerative diseases. 
Diverse neurological disorders, including FAP ATTRV30M, show a wide phenotypic 
variability within and among families. However, in FAP ATTRV30M, the issue of age-at-onset 
(AO) variation, particularly associated to gender and specially the role of the transmitting 
parent need to be more deepened. In the present study, mtDNA copy number was quantified 
in FAP ATTRV30M carriers and non-carriers to better explore the AO variation and its effect 
on gender of the transmitting parent and offspring, since to date a minor attention has been 
dedicated to mtDNA content in this disease. To our knowledge, this is the first study that 
demonstrates a positive association between the peripheral blood mtDNA content and the FAP 
ATTRV30M, with implications in the underlying biological mechanisms. 
 
Increased mtDNA copy number in carriers of the V30M mutation  
 
Comparing the different groups with or without the V30M mutation, we have found that 
the highest mean mtDNA copy number per cell was observed in early-onset patients. 
Moreover, subjects harbouring the V30M mutation (patients and asymptomatic carriers) have 
higher mean mtDNA content than controls. Our results contrast with studies in other diseases, 
such as in Huntington’s [301] and Parkinson’s diseases [302], in which the mtDNA copy 
number per cell declined in mutation carriers compared to controls, possibly revealing a 
compensatory effect. 
A previous study showed that increased cellular mtDNA copy number and mtDNA 
mutations accumulated during aging may be caused by oxidative stress [303]. It is plausible 
Affected Parent Offspring n Mean Std. Dev.a 95% CIb p-valuec 
Late-onset Asymptomatic 26 -162.41 508.82 [-367.93; 43.10] 0.116 
Early-onset Asymptomatic 18 -149.25 462.48 [-379.23; 80.73] 0.189 
Late-onset Early-onset 14 -307.11 293.63 [-476.64; -137.57] 0.002 
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that the increase in mitochondrial content in V30M carriers, particularly, in early-onset patients 
may be due to a compensatory response to maintain mitochondrial function possibly owing to 
decreased cytochrome c-oxidase (complex IV) function, as observed in blood cells from 
amyotrophic lateral sclerosis patients [304]. Also, previous reports lead us to suggest that 
increased levels of mtDNA content, mainly in V30M carriers, may be related with higher 
production of ROS, possibly due to the unpaired cellular processes, such as oxidative stress 
and the presence of misfolded proteins, occurring in FAP ATTRV30M progression [37, 167]. It 
is well known that the function of mitochondria and endoplasmic reticulum (ER) are closely 
linked, since both produce ROS, generated by products of oxidative phosphorylation [305] and 
by unfolded-protein response [292, 306]. Indeed, several studies have described that high 
levels of ROS may disrupt protein folding processes and increased production of misfolded 
proteins result in extra ER stress due to the accumulation of misfolded proteins possibly 
leading to additional ROS production [292]. For that reason, we hypothesized that an 
adaptation of the energetic metabolism, to improve mitochondrial function and cell growth 
[307], must have occurred in these patients through a compensatory mechanism, involving an 
increased ROS production and, consequently, energy failure. Therefore, to our knowledge, the 
present findings revealed, for the first time, that mtDNA copy number is associated with earlier 
FAP ATTRV30M events. 
Moreover, we found significant differences between controls and V30M carriers 
(asymptomatic carriers, late-onset and early-onset patients), suggesting that the mtDNA 
content is associated with the etiopathogenic mechanisms of the disease. Interestingly, the 
mtDNA content is not significantly different neither between controls and noncarrier-relatives 
nor between noncarrier-relatives and V30M carriers, which can be due to a common genetic 
background between relatives of the same families besides the V30M mutation, showing that 
the genetic background is an important issue in studying the genetic modifiers of patients’ 
phenotype. 
 
mtDNA content was not associated with a gender-linked effect  
 
Regarding gender analysis, these results show that gender differences observed in 
FAP ATTRV30M patients are not associated with mtDNA content, suggesting that the mtDNA 
content does not have a specific gender-linked effect similar to what was observed in other 
diseases [308, 309], or that it is under the control of nuclear genes, inherited from either the 
mother or the father. 
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Early-onset offspring have higher mtDNA copy number than their affected parents 
 
The comparison of mtDNA content of late-onset offspring with their affected or non-
affected parents could not be performed due to the small sample size of the parents group. 
Importantly, a higher mean mtDNA copy number was found in the early-onset offspring when 
compared with their late-onset parents. This result suggests that early-onset offspring possibly 
receive from their affected mother a mitochondrial risk effect, modulating AO.  
 
In conclusion, this study suggests that mtDNA copy number seems to have a significant 
effect in AO variability observed in parent-offspring transmission. Also, we found that 
mitochondrial gene expression is possibly associated with FAP ATTRV30M mechanisms. 
However, the mtDNA content is specific for tissue and developmental stage/age and varies 
according to the population. Therefore, it will be important to replicate this study in other 
tissues, such as liver (main organ of TTR synthesis), and in different populations, to unravel 
new clues about the biological mechanisms that explain the role of mitochondria energetic 
performance in processing of misfolded proteins. 
Our results, although preliminary, derive from the largest FAP ATTRV30M cohort 
available worldwide. In addition, we had a special concern with the power of the statistical 
analyses, to obtain accurate and reliable results. 
Further studies are required to elucidate the pathophysiological significance of the 
observed changes in mitochondrial content in FAP ATTRV30M patients, but the present study 
is a step forward and opens a new possibility for elucidating the mechanisms underlying FAP 
ATTRV30M. 
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5.1. Genetic modifiers in AO modulation 
 
Although it is known that a large amount of the phenotypic variability in the Mendelian 
disorders is associated with the nature of the variant in the disease-causing gene and with 
their underlying protein product [310], this gene abnormality cannot explain alone the observed 
variation as, for example, in AO. Different mechanisms might help to explain this variability and 
it has been widely recognized that other genetic, epigenetic (e.g. DNA methylation and histone 
modification), environmental and stochastic factors, with or without interaction, contribute to 
phenotypic variation, and might significantly be involved in AO modulation, which shows that 
AO may function as a complex trait.  
Furthermore, it has become increasingly evident that the identification of AO genetic 
modifiers in Mendelian diseases are a unique challenge, since these modifiers may have a 
fundamental role in the knowledge of the functional consequences of the genetic variation, 
thereby altering the course of disease. In addition, protective genetic modifiers associated with 
a later onset and reduced penetrance may constitute targets to modify disease presentation 
and progression. Variants in the APOE gene are known to play a role as genetic modifiers of 
AO in several neurodegenerative diseases, including AD [128, 311, 312], PD [313], HD [314], 
SCA3/MJD [237], ALS [315] and Wilson’s disease [316]. In AD, for example, the APOE ε4 
allele is the major known genetic risk factor, decreasing AO and increasing the risk of cognitive 
impairment [317-320], whereas APOE ε2 allele was associated with a later AO (acting as a 
protective factor) [319]. Besides this gene, many other genetic modifiers may contribute to AO 
variation in several disorders as for example, variants or dynamic mutations in other genes, 
for example, in PD [321] and MJD [275], and also epigenetic modifiers as DNA methylation in 
the promotor region of genes [322].  
Therefore, in this project, we aimed to unravel such modifiers to clarify AO variation in 
TTR-FAP Val30Met, since these could contribute to a deeper understanding of pathological 
and molecular mechanisms of this disease and, consequently, to the identification of novel 
preclinical biomarkers for validation of therapeutic interventions. 
 
5.1.1. TTR-FAP Val30Met as a prime model for the identification of 
genetic modifiers 
 
TTR-FAP Val30Met is a progressive and eventually fatal Mendelian disease that 
displays wide variability in clinical features, primarily characterized by sensorimotor peripheral 
polyneuropathy and autonomic dysfunction [3]. It is an autosomal dominant inherited disease 
in which a single variant at a specific single gene (TTR) is deemed sufficient to cause 
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conformational changes in the structure of TTR protein, becoming more unstable and more 
amyloidogenic [323, 324]. 
In Portugal as well as in other disease clusters as Sweden, Japan, Brazil and Spain, 
although patients have the same disease-causing variant (V30M), AO of symptoms can 
strikingly differ between families, particularly, between generations of the same family [5, 87, 
89, 93, 251]. Moreover, significant differences in AO regarding gender were also found in 
different populations, including in Portugal [5] and Brazil [154], but not in Sweden [90] and 
Cyprus [155].  
The study of AO variability in the TTR-FAP Val30Met besides being an interesting 
subject of research may have important clinical implications for offspring genetic counselling 
and follow-up of disease-causing variant carriers. 
In TTR-FAP Val30Met, a large AO anticipation has also been observed with possible 
samples’ ascertainment biases removed and, therefore it was confirmed as a true biological 
phenomenon [94, 100]. The genetic basis for anticipation in several neurological diseases as 
HD and type 1 myotonic dystrophy (DM1) has been shown to be attributable to inter-
generational expansions of the unstable repeats responsible for the clinical phenotype [146, 
150]. Telomere shortening and subsequent genomic instability has also been described as 
another mechanism of anticipation in hereditary breast cancer [325]. However, Soares et al., 
1999 previously hypothesized that the mechanism of repeat expansions probably do not 
explain the anticipation occurrence in TTR-FAP Val30Met [109]. Thus, given the huge 
phenotypic variability observed among the carriers of the same variant, it is crucial to identify 
what is causing this variation and, then to elucidate their associated mechanisms to identify 
targets for therapeutic intervention.  
There are already different therapies under study such as TTR tetramer stabilization, 
gene therapy, fibril disruption, amyloid clearance and anti-oxidant and anti-apoptotic 
treatments to prevent TTR amyloidosis. However, the only treatments currently available are 
LT, that is limited by organs availability and this not sufficient for all patients [202] and 
Tafamidis, a tetramer stabilizer, that can only be applied to a fraction of the patients that are 
eligible taking into account the inclusion criteria and, among these there are patients that do 
not respond to this treatment [204, 326]. Consequently, with this study we can provide new 
mechanisms that may act as early preclinical biomarkers for the development and/or validation 
of novel effective therapeutic targets.  
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5.1.2. Strategies to identify genetic modifiers 
 
Several different approaches were already developed in order to identify genetic 
modifiers that can be based either in a systematic approach, where a blind search of the whole 
genome is systematically scanned, or in a more focused approach, biologically hypothesis-
driven, where specific candidate-genes and candidate-pathways are selected [327, 328]. 
Moreover, the strategy used to assess the role of these modifiers depends on the type of the 
data available as, for example, genome-wide association studies and linkage analyses. 
 
Genome-wide association studies (GWAS) 
 
GWAS are a hypothesis-free, unbiased with respect to genomic structure and previous 
knowledge of the investigated trait [329]. We have chosen not to apply this approach, since 
these studies are applied more to common diseases in which their frequency in the population 
justifies the high costs and resources. Moreover, as a large battery of markers is required to 
assess the genotype-phenotype association, false positive results can easily occur due to 
multiple comparisons. Thus, a very large sample size (of cases and controls) is needed in 
order to achieve a high statistical power and to decrease spurious associations; moreover, 
replication of the significant loci in independent populations is mandatory [330]. 
 
Linkage analysis 
 
Linkage analysis, an unbiased scan of chromosomal regions that are transmitted within 
families, have been extremely useful to decipher the genetic basis of diseases with Mendelian 
inheritance such as cystic fibrosis [331] and HD [332]. Although this analysis may be a more 
successful approach [333], since various members of families affected by the disorder are 
analysed simultaneously, we did not considered this approach to search  for genetic modifiers 
in TTR-FAP Val30Met, because linkage is a more powerful method to detect rare variants with 
major effects associated with Mendelian traits with high penetrance than common variants with 
small effects [334].   
 
A candidate-gene approach  
 
We have decided to apply a candidate-gene approach and dedicated a special 
attention to the selection of putative candidates based on prior knowledge about gene function 
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and its relevance in the disease mechanism of the trait of interest (AO behaves as a complex 
trait), that is, genes encoding proteins that act in various TTR regulatory or altered signalling 
pathways. While this approach has the disadvantage of unravelling only a fraction of genetic 
modifiers, it has proven to be an extremely powerful method to identify genetic risk factors 
associated with clinical traits and to study genetic mechanisms of complex traits, being an 
effective, fast and cost-effective method [335].  
 
5.1.3. Beyond case-control studies, the importance of a family-based 
approach  
 
Although case-control studies are the most commonly used designs due to a simple 
sample ascertainment and already revealed important data in the study of AO variation in TTR-
FAP Val30Met [123, 124], the main problem is population stratification [336], which can 
decrease statistical power and introduce potential bias in the results, leading to false positives 
[337]. Thus, a family-centred approach seemed to be more useful to understand AO variation 
both within and among generations in TTR-FAP Val30Met patients, since early- and late-onset 
patients are not separate entities, they may coexist within the same family, with offspring often 
showing anticipation. This approach has been described as an advantageous complementary 
strategy [338], offering a better genotype quality control, increased robustness against 
admixture and population stratification, due to the presence of a common genetic background 
among the family members and allowing a variety of genetic analysis to be performed, 
including the analysis of parent-of-origin effects and de novo variants [338, 339]. 
Therefore, we focused our analysis in the study of genetic variants in several candidate-
genes belonging to mechanisms that may affect TTR function and related biological signalling 
pathways, which are essential to fundamental biochemical processes in the course of this 
disease and that, may explain gender-related differences in AO in TTR-FAP Val30Met carriers.  
 
5.2. Candidate-genes modulating AO 
 
5.2.1. Importance of re-evaluating previous studies 
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Role of APCS and RBP4 as modifier genes 
 
As mentioned before, previous genetic studies have used the candidate-gene approach 
to investigate the association between certain variants in genes involved in TTR functional 
pathways with AO variability, using a case-control study. Soares et al., 2005 in a Portuguese 
sample of 92 TTR-FAP Val30Met patients and 85 controls found variants in the APCS and 
RBP4 genes associated with earlier and later AO, when early and late group were compared 
with controls [123]. Additionally, Dardiotis et al., 2009 using a Greek-Cypriot sample of 71 TTR-
FAP Val30Met patients and 59 controls found also variants in the C1QC, C1QA and APOE 
genes associated with AO variation [124].  
In the first section of the results, we showed the modifier role of APCS and RBP4 genes, 
suggested to affect TTR regulatory pathways, and showed a significant modifying effect on the 
AO. Contrary to other studies, our results pointed to the existence of two variants associated 
with a later AO (rs28383573 in the APCS and rs7094671 in the RBP4), whereas one variant 
was associated with an earlier AO (rs11187545 in the RBP4) [Article 1].  
In addition, it should be noted that the TT genotype found in APCS rs28383573 and 
CC genotype found in RBP4 rs11187545 only appear once in our sample, arising the question 
whether the effect found in these two individuals is sufficient to associate them with AO. 
Although our study was addressed to analyse common genetic variants in the population (MAF 
> 5%) with significant functional impact on AO variability, we do not preclude the possibility of 
other variants, in particular, rare variants (MAF < 1%) may act as genetic modifiers of AO, 
since these variants play an important role in human diseases and can help to explain 
additional disease risk and AO variability. Moreover, previous studies have showed that highly 
penetrant rare variants are genetic modifiers of many Mendelian and the cause of some 
common disorders [340]. 
Furthermore, APCS is always present in all types of amyloid deposits independently of 
the protein origin [341] and recognizes and binds not only to mature amyloid fibrils, but also to 
early toxic TTR aggregates [238]. Hence, this binding suggests its possible role as a 
chaperone, since it prevents proteolysis of the amyloid fibrils in vitro and contributes to 
deposition of the amyloid fibril in various types of amyloidosis, including AD [226]. Additionally, 
studies performed in vivo using mice as animal model, demonstrated that inhibition of APCS 
binding to amyloid fibrils may prove to be an attractive therapeutic target [342]. Based on these 
assumptions, we hypothesized that the presence of this variant appears to have a protective 
effect against toxicity (amyloid deposits) and an earlier AO.  
Interestingly in RBP4 gene, a specific carrier of retinol (vitamin A) [343], our findings 
suggest that the variants found were differently associated with later and earlier AO and might 
function as protective factors or as risk factors, respectively, in TTR-FAP Val30Met patients in 
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our Portuguese sample. RBP4 forms a tight complex with retinol, which interact with tetrameric 
TTR. The formation of this RBP4-retinol-TTR complex besides preventing loss of TTR by 
filtration through the kidney glomeruli, also prevents protein misfolding and amyloid fibril 
formation in amyloid disorders by stabilizing TTR tetramer, suggesting a relationship between 
structure and function [343]. Thus, a slight alteration in RBP4 may be sufficient to change the 
normal conformation of the protein and, consequently, disturb the binding of this complex. 
Thereby, destabilizing TTR tetramer and increasing amyloid fibril formation. Although we did 
not find any relevant functional impact for the associated SNPs in the RBP4 gene through in 
silico analysis, we believe that the presence of these genetic variants could affect positively or 
negatively this binding, allowing us to hypothesize that functional properties of RBP4 might be 
affected, contributing to a later or earlier AO as it is observed for APOE in AD [319]. Further 
functional studies are needed to address this hypothesis. 
 
Role of modifier genes: C1Q complement 
 
Then, we decided to analyse the modifier effect of the C1Q complement genes (C1QA 
and C1QC genes), in order to reassess the results found in the Greek-Cypriot population. 
Similarly, C1QA and C1QC genes showed also a significant association with AO 
variability in our sample, but none of the statistically significant variants found match the results 
observed in the Greek-Cypriot population [Appendix 1] [344]. These findings may indicate that 
different genetic background between populations can result in different disease modifiers. 
The differences may be possibly explained by geographic differences. Moreover, previous 
studies have demonstrated that human inter-population diversity may be due to genetically 
determined gene expression as, for example, in TTR gene [345]. Another important fact are 
the non-coding regions, which are affected by population diversity and potentially have 
consequences on gene expression [346, 347]. Moreover, the variants found in the C1QA seem 
act more as protective factors, whereas the variants found in the C1QC seem to have a dual 
role functioning as protective and risk factors. C1q complement system function as an immune 
defence mechanism that has been involved in the pathogenesis of neuronal damage in various 
disorders [348]. In AD, it has been reported that complement protein C1q prevents toxicity 
induced by Aβ oligomeric forms [349]. The inflammatory reaction seems to play an essential 
role in AD [350] as well as in other neurodegenerative diseases such as PD [351], HD [352] 
and prion disease [353], and deposition of Aβ and other aggregated proteins is able to activate 
complement cascade. Thus, complement activation by C1q may cause neurodegeneration and 
neuroinflammation [354]. This way, the complement system may be helpful in eliminating 
aggregated and toxic proteins associated with several neurological disorders and have a 
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protective role, which may be reinforced by the presence of the variants found in C1QA gene. 
Nevertheless, the activation of microglia, secretion of various pro-inflammatory cytokines, 
mitochondrial dysfunction, generation of oxidative products and possibly the presence of the 
significant variants found in the C1QC gene may lead to a deregulation in the activation of the 
complement system resulting in risk effects. Therefore, as C1Q is involved in several biological 
functions, including neuroprotection, it may be an excellent therapeutical target to prevent 
neurodegeneration via direct inhibition [355].   
 
Hence, our study showed that different approaches in a revaluation of previous studies 
can lead to different results, and most of the differences found may be related to the sample 
size and with different biological backgrounds. 
As part of the population diversity, in other studies described above, sample size was 
quite small when compared with ours, showing that a large sample is required to increase the 
statistical power and to achieve robust results. Furthermore, those previous studies did not 
have a special concern in obtaining a high case: control ratio (1:2), being a fundamental criteria 
in this type of approach [356, 357], and used a sample with fewer controls than cases, which 
may contribute to decrease the power to detect an effect. 
 
5.2.2. Uncovering new candidate modifier genes of TTR-FAP Val30Met  
 
1. Signal transduction pathways  
 
As the previous genes studied solely do not explain all AO variation, in the second 
section of the results, using the same family-centred approach, we studied other potential 
candidate-genes (BGN, NGAL, MMP-9, MEK1, MEK2, ERK1, ERK2, HSP27 and YWHAZ). 
Despite they are involved in several signalling pathways, rather than a particular pathway, 
these genes have never been studied before as modifiers of AO in TTR-FAP Val30Met [Article 
2].  
Although there is no previous study that associates directly these genes with AO 
variation in human TTR-FAP Val30Met patients, there is large evidence in the literature that 
shows that these genes may be considered good candidate-genes to contribute to AO variation 
in this disorder. Previous studies using different type of biopsies (as salivary gland, nerve 
and/or skin) have shown up-regulated and/or increased activation in the levels of the proteins 
encoded by these genes in the presence of TTR amyloid deposits [132-134, 141, 250]. Indeed, 
we found, for the first time, variants of six of these genes (BGN - in the females group, NGAL, 
MEK1, MEK2, HSP27 and YWHAZ) significantly associated with AO variation. 
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ECM remodelling genes 
  
In TTR-FAP Val30Met, amyloid deposits are constituted mainly by TTR, but also by 
other molecules as extracellular matrix (ECM)-related components, including BGN, NGAL and 
MMP-9 [132], which may contribute to disease pathogenesis by accelerating the formation of 
amyloid fibrils through preventing proteolytic degradation, such as occur in AD [358]. In 
addition, as the ECM remodelling components are closely related with inflammation, a higher 
expression of these factors in TTR-FAP Val30Met may possibly contribute to 
neurodegeneration [132]. ECM remodelling is controlled continuously and is a mechanism 
essential for normal organ development, tissue homeostasis [359], and may be important in 
peripheral axonal nerve regeneration [360]. However, it may be affected by endogenous 
stimulus as pro-inflammatory cytokines [361]. In this sense, previous studies have shown that 
BGN was found overexpressed in the earliest stages of TTR deposition, when non-fibrillary 
TTR aggregates were already present, but also in the later stages where already exist TTR 
fibrils, whereas NGAL only appears in later stages [132]. Consequently, lead us to hypothesize 
that variants in the BGN associated to late AO may function as protective factors, since it may 
prevent the organizing and binding to TTR aggregates, inhibiting the progression to TTR fibrils. 
Regarding NGAL, which forms a complex with MMP-9 [362], it may avoid degradation of ECM 
components, and so variants in this gene associated with an earlier AO may function as risk 
factors, since they may further increase fibrils binding contributing to disease pathogenesis.  
 
MEK-ERK MAPK signalling genes 
 
The MEK-ERK pathway is a signalling cascade responsible for the communication 
between the outside to the inside of the cell. The cascade begins when an extracellular 
molecule (as TTR aggregates) binds to the receptor on the cell surface and starts a signalling 
chain of proteins to the nucleus, where results in different protein expressions that alter the 
nature of the cell. As TTR-FAP Val30Met is characterized by extracellular deposition of TTR 
aggregates and amyloid fibrils, mainly in PNS [293, 363], we hypothesize that genes involved 
in early intracellular signalling events as MEK1/2 and ERK1/2 could be one of the pathways 
involved in the variation of AO. Previous studies have shown that signal transduction pathways 
may be implicated in the pathogenesis of many human diseases, including neurodegenerative 
diseases as AD [252], PD [364] and ALS [365, 366]. In AD, the abnormal hyperphosphorylation 
of tau have been suggested to be involved with MEK-ERK MAPK signalling cascade, where 
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their activation after phosphorylation of ERK contribute to progression of neurofibrillary 
degeneration [252]. Hence, inhibitors of MEK, ERK1/2 as well as of c-jun NH2-terminal kinases 
(JNK) and p38 have been explored as possible therapeutics targets [367-369]. Similarly, a 
previous study performed in TTR-FAP Val30Met provide evidence that abnormal activation of 
MEK-ERK MAPK signalling cascade may lead to neurodegeneration [133]. It was shown that 
TTR aggregates bind to the receptor of advanced glycation end-products (RAGE) and this 
interaction induces activation of MEK-ERK MAPK signalling cascade, which produces 
cytotoxic effects leading to activation of the nuclear transcription factor kB (NFkB) [370]. 
ERK1/2 are serine-threonine kinases and are activated by MEK1/2 through the 
phosphorylation of their regulatory threonine and tyrosine residues. Thus, ERK1/2 activation 
in response to a variety of hormones and growth factors is thought to promote neuronal 
survival. However, in TTR-FAP Val30Met, abnormal activation of ERK1/2 may represent an 
early intracellular signalling cascade leading to increased cell proliferation or differentiation and 
cytotoxic effects induced by TTR aggregates and neurodegeneration [133]. Consequently, it 
may promote an increased expression of pro-inflammatory cytokines and oxidative stress 
related molecules, contributing to fibril formation [37, 218]. Therefore, variants found in the 
MEK1 gene associated with an earlier AO may function as risk factors further contributing to 
the pathogenesis in TTR-FAP Val30Met. Thus, inhibitors of the MEK-ERK signalling pathways 
related to significant variants found in the MEK1 associated with earlier AO may be good 
candidates to the development of new drugs for TTR-FAP Val30Met. Furthermore, as we also 
found variants associated to later AO in the MEK1/2 genes, we hypothesize that these may 
act as protective factors, inhibiting cell responses induced by activated MAPK signalling 
pathways as well as the cytotoxic effects induced by TTR aggregates. Besides, it has also 
been described that the ERK signalling induces expression of matrix metalloproteinases (as 
MMP-9), which promote degradation of extracellular matrix proteins, and the use of MMP 
inhibitors may also have interesting implications as therapeutic agents [371]. 
 
HSP gene 
 
In addition, ERK1 may also modulate the heat shock response. This discovery is 
interesting since HSPs have shown to have an important neuroprotective role in several 
diseases characterized by the aggregation of misfolded proteins [372], including TTR-FAP 
Val30Met [134, 137]. In particular, it has been reported that high levels of these HSPs may be 
helpful in neuronal damage protection in response to stress [373-375]. These can function as 
molecular chaperones preventing interactions of the misfolded protein aggregates with other 
cellular proteins and reducing the risk of formation of toxic non-fibrillary aggregates and 
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oligomers in the cell [372]. Moreover, these also play a crucial role in the intracellular correct 
folding during stress and protect cells from denaturation and aggregation that can lead to 
cellular death [376]. Therefore, we studied HSP27 gene since a previous study in TTR-FAP 
Val30Met showed upregulation of this HSP in different tissues with extracellular TTR deposits 
[134]. This gene is regulated by HSF1, which is activated by stress [377] mediated by ERK 
pathway. ERK1 binds stably to HSF1 and regulate the expression of specific genes with anti-
apoptotic and cytoprotective activity. Subsequently, for this binding, 14-3-3 protein may also 
regulate the transcription of molecular chaperones [378, 379]. We have found one variant in 
the HSP27 gene significantly associated with an earlier AO and we considered the hypothesis 
that an increased selective expression of HSP27 gene may be induced by an early 
neuroprotective stress response, to help the correct folding of proteins and directing misfolded 
proteins to degradation. 
 
14-3-3 zeta (YWHAZ) gene 
 
Proteins involved in neuroprotection have being implicated in the pathogenesis of many 
neurodegenerative diseases, as 14-3-3 proteins (encoded by the YWHAZ gene). These 
proteins have many brain functions as neural signalling, neuronal development and 
neuroprotection against toxicity [140, 380]. In AD, 14-3-3 zeta is associated with tau in the 
brain and stimulates tau phosphorylation and synergistic effects between both genes 
contribute to a decrease in AD risk [381]. In addition, it was described that 14-3-3 zeta 
expression levels decrease with aging [250]. Therefore, we assessed the role of YWHAZ gene 
in AO variation since this may act as a sweeper of misfolded proteins by facilitating the 
formation of aberrant protein aggregates such as the observed in AD [382], PD [383] and SCA1 
[384]. Thus, in our sample, we found a variant in the YWHAZ associated with an earlier AO, 
leading us to suggest that this risk variant affects the protective role of 14-3-3 proteins 
regarding the cytotoxic effects caused by the TTR aggregates, thus preventing a 
neuroprotective response by YWHAZ. 
 
2. Sex-linked variants associated with AO variability 
 
Another pertinent issue is a mean AO difference observed between gender in TTR-
FAP Val30Met patients and the pathophysiology mechanisms underlying that difference. There 
is evidence in the literature showing that that women were found to have a significantly later 
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onset than men [5, 40, 154], and that the anticipation effect differs depending on the gender of 
transmitting parent [99]. 
Also, in AD [385], PD [386] and ALS [387], gender-related differences were found. In 
these group of neurological diseases, the differences were mainly due to action of gonadal 
steroid hormones, but also to variation found in sex-chromosome genes (as a direct genetic 
effect) [388]. In TTR-FAP Val30Met, studies in vivo using mice model have described that sex 
hormones may increase TTR synthesis and, consequently, amyloid deposition, and may help 
to explain differences in AO in males and females [156]. For these reasons, these genetic 
factors may be considered excellent modifiers to disentangle differences in AO regarding 
gender in human patients. 
Regarding this, to unravel these gender-related differences in AO, we assessed, for the 
first time, the role of three candidate-genes (AR, HSD17B1 and BGN) linked to sex-steroid 
hormones and/or X-chromosome as genetic modifiers of AO variation in our Portuguese 
families. In this study, significant results were found for AR gene in both genders and for BGN 
gene in females as AO modifiers. However, no significant result was found regarding 
HSD17B1 gene [Article 1 and Appendix 2].  
AR is a ligand-activated and sequence-specific DNA-binding transcription factor 
regulating gene transcription, and it has also been shown to mediate rapid activation of 
signalling pathways independent of their transcriptional activity, as activation of TTR pathways 
[389]. Previous experiments in vivo and in vitro in AD and TTR-FAP Val30Met showed a 
positive correlation between sex hormones and TTR levels [158-160].  
As most of significant variants found for this AR gene were associated with earlier onset 
in both genders, we may hypothesize that the presence of these variants might likely induce 
increased TTR expression, resulting in an increase in amyloid deposition and earlier AO, which 
may act as genetic risk factors in males and females. Moreover, evidences in the literature 
have demonstrated that high concentration of hormones are slightly toxic to neurons, 
decreasing thereby the neuroprotective status [390]. As males have higher androgens levels 
than females [243], it might induce earlier increased levels of circulating TTR, misfolding and 
aggregation, which may help to explain earlier AO in males than females in various 
populations. We found one variant associated with late-onset in females group, which can 
result in a decrease of the AR levels and, consequently, in a reduction in TTR levels. The 
protective effect of this variant can be through various mechanisms as (1) interaction with 
HSPs via increased hsp70 expression during stress events, (2) inhibition of apoptotic and rapid 
cell signalling pathways and (3) activation of signal transduction pathways as MEK-ERK MAPK 
signalling cascade, which may be relevant to cell viability [391].  
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However, future studies relating TTR induction by androgens and neuroprotection in 
TTR-FAP Val30Met should be performed, in order to validate functionally these results and to 
unravel new factors. 
 Regarding BGN gene, it is also located in the X-chromosome and there is emerging 
research showing that X-linked genes play a direct role in gender differences [392]. This fact 
may impact variation in their expression among females as result of X-chromosome 
inactivation [393]. Indeed, a previous study provide evidences that BGN is subject to X-
inactivation and that there is no homolog on the Y-chromosome [394]. BGN plays a role in 
connective tissue metabolism participating in assembly of collagen fibrils and muscle 
regeneration [395], and has already been associated with TTR amyloid deposits [132]. Hence, 
if this gene is deregulated, it may increase the risk effect in females by promoting genetic 
instability, which is important in amyloidogenic diseases. On the contrary, in our TTR-FAP 
Val30Met female group, we found one variant significantly associated with later AO, leading 
us to suggest a scenario of protection in basement membrane metabolism through organizing 
and binding collagen fibrils, likewise has already been suggested in other amyloid-related 
disorders [396]. 
 
3. Repetitive loci as modifiers of AO – the emergent role of ATXN2 
gene  
 
There is currently large evidence in the literature that expansions of unstable 
oligonucleotide repeats are the mechanism associated with a wide variety of human genetic 
neurological diseases, including HD, SCAs disorders, among others [261]. A common factor 
between all these diseases is a significant negative correlation between repeat length and AO, 
although a large variability of AO exists within each repeat length [397, 398]. Furthermore, 
previous studies have shown that repeat length in the causative gene of many of these 
disorders may act as possible genetic modifiers and have been associated with risk, AO and/or 
severity in other diseases, such as SCA2, MJD/SCA3 [237, 275, 399-401].   
Intermediate-length CAG repeats, ((CAG)24-33), in ATXN2 gene, responsible, when 
expanded, by SCA2, were associated with increased genetic risk for ALS, with a cut-off set at 
≥27 repeats [151]. This association has been further established in a larger European cohort, 
in which this association is stronger when the cut-off set is ≥29 repeats [152, 402]. Therefore, 
the cut-off for ATXN2 repeat length and risk for ALS may vary among different human 
populations, and may also be linked to an increased frequency in other neurodegenerative 
diseases, as progressive supranuclear palsy [153]. However, no association was found 
between ATXN2 and AD, PD, frontotemporal dementia and hereditary spastic paraplegia in 
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Caucasian populations [153, 288]. But, it should be noted that intermediate repeat expansions 
in ATXN2 were found to be associated with PD in Asian populations [403, 404], indicating that 
ethnic or geographic differences can induce different genetic background, possibly due to 
founder effects. In addition, normal repeat length of polyglutamine genes interacting with other 
SCA diseases may modify AO [263]. For instance, in MJD/SCA3 individuals of European 
ancestry, CAG repeat length in ATXN2, ATN1 and HTT interacting with ATXN3 may differently 
modulate AO: longer intermediate ATXN2 alleles and larger ATN1 alleles may decrease AO 
in MJD/SCA3 patients, while shorter HTT alleles may increase AO [263]. Interestingly, in the 
Chinese population with MJD/SCA3, long normal CAG repeats in ATXN2, but not ATN1 and 
HTT, were associated with an earlier AO [275]. However, these results were not replicated, for 
example, in an Azorean cohort [264]. Furthermore, SNPs in the repeat loci may also impact in 
AO modulation of several SCAs such as was found for an ATXN2 variant influencing AO in 
MJD/SCA3 patients of Chinese origin, which shows that these genes are interesting candidate-
gene modifiers [405].   
In this study, our findings suggested that the presence of, at least, one allele with length 
higher than 22 CAG repeats in ATXN2 was associated with an earlier AO in TTR-FAP 
Val30Met patients (a decrease of 6 yrs. in the disease onset), showing a strong association 
with AO variability.  
As the hallmark of TTR-FAP Val30Met is the presence of extracellular deposits of TTR 
aggregates and amyloid fibrils in several tissues, particularly, in peripheral nerves, diverse 
molecular pathways associated to degeneration have been confirmed, including activation of 
nuclear factor kB, pro-inflammatory cytokines, oxidative stress and ER stress, using in vivo 
samples and cell culture studies [291]. Ataxin-2 is one of the polyglutamine proteins, highly 
expressed in various neuronal and non-neuronal tissues, including the brain [289] and is 
involved in the regulation of several biological processes such as RNA-related metabolism, 
translation regulation, cytoskeleton reorganization, Ca2+ homeostasis, and mitochondrial 
stress [290]. ER plays a major role in regulating synthesis, folding and orderly transport of 
proteins, being also involved in various cellular signalling processes such as Ca2+ signalling. 
On the other hand, Ca2+ signalling is also linked to mitochondrial function, and thereby 
increased Ca2+ influx into neurons and other types of tissues by mitochondria may lead to 
production of reactive oxygen species (ROS), which are responsible by oxidative stress in cells 
[306]. Oxidative stress may be further increased by the presence of (CAG)23-28 alleles at the 
ATXN2 locus and contribute to the processing of misfolded proteins, which, in turn, cause ER 
stress with enhanced ROS production, creating thereby a feedback loop [292]. Furthermore, it 
is tempting to speculate that the presence of (CAG)23-28 alleles at the ATXN2 locus may also 
implicate changes in post-translational modifications (known to affect protein structure and 
function) or altered proteolytic processing, leading to the formation of a more unstable protein 
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and more aggregation prone resulting in an earlier AO of symptoms [406]. Additionally, similar 
to observed in ALS through in vivo studies, ATXN2 may have an altered localization and lead 
to earlier AO in TTR-FAP Val30Met patients, since intermediate repeat length may increase 
the ATXN2 stability and prevent its degradation by increase of their concentration [151]. In 
ALS, it was also found that ATXN2 intermediate alleles modulates disease pathways via its 
RNA-dependent interaction with other ALS-related proteins, such as FUS and TDP-43 [406].  
Therefore, it would be interesting to assess ataxin-2 interaction with other TTR-FAP Val30Met-
associated proteins. Another study found that co-expression of ATXN2 intermediate allele, 
combined with C9orf72 depletion, increases ataxin-2 aggregation, leading to neuronal toxicity 
[407].  
However, to confirm these hypotheses future studies focused on at the level of protein 
expression derived from (CAG)23-28 alleles are needed. These results lead to the hypothesis 
that (CAG)23-28 alleles at the in ATXN2 locus might influence the TTR aggregation and amyloid 
fibril formation in these patients contributing as a risk factor to neurodegeneration. 
Furthermore, these findings may also indicate that this population-specific genetic profile at an 
ATXN2 locus influences the ability to confirm/discard the potential modifier effect in AO 
variation and, for this reason, replication studies should be performed in different populations 
[264]. 
 
5.2.3. Importance of functional implications in the validation of variants 
 
Once unveiled the significant variants associated with AO variation for different 
candidate-genes studied, our next strategy was to decipher the potential functional impact of 
these variants through an intensive in silico analysis. Using several computational biology 
tools, we were able to shed light on molecular or biochemical mechanisms associated with AO 
variation of TTR-FAP Val30Met. Depending on the location of the variants in each gene, they 
may have different effects on protein function, transcriptional regulation, RNA splicing or 
miRNA binding. Since there is no single bioinformatics tool that can be used to obtain a 
complete report of the functional impact of allelic variants, we used diverse complementary 
bioinformatics tools [408]. Therefore, in our studies, we used a software diversity in order to 
predict the possible regulatory effects of variants found, such as Alamut Mutation Interpretation 
Software (Interactive Biosoftware, Roune, France), Polyphen-2 [409] and Functional 
Prediction (FuncPred) [236]. The in silico-regulatory SNP detection (is-rSNP) [247] and rSNP-
MAPPER [410] software were used to predict the TFBSs in the SNPs. The ESE finder and 
Human Splicing Finder (HSF) algorithms were used to predict changes in splicing sites and 
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miRNA target sites in the 3’ UTR were predicted by miRWalk [411, 412] and mirDIP [413] 
algorithms.   
In recent years, bioinformatics tools have been extensively used in various studies. 
Polimanti et al., 2014 investigated coding and non-coding regions and interactive network in 
the TTR using diverse in silico approaches and identified non-coding variants in cis-regulatory 
elements on the TTR and CpG sites that may affect TTR expression [347]. In addition, a study 
of our group, aiming at the identification of possible genetic modifiers within the TTR gene, 
assessed the putative association of the SNPs found with AO. For this purpose, it was used 
an intensive in silico analysis to understand possible regulation of TTR gene expression, where 
we found interesting results regarding mechanisms of TFB, splicing and miRNA binding [414]. 
Also, Kalia et al., 2016 through an in silico analysis of non-synonymous and regulatory SNPs 
in the human MBL2 gene, which play an essential role in innate immunity, identified that these 
SNPs are functionally important and deleterious to their structure and expression [408].  
Furthermore, missense variants are particularly important to human diseases, since 
they may affect the protein function [415]. For C1QA and C1QC, we explored variants located 
in the coding regions, using Polyphen-2, in order to assess whether these variants may have 
a high probability to affect protein structure and function. We found that all variants were 
classified has benign, which may be related with an enhancing of immune defence mechanism. 
A recurring theme is the emergent importance of variants in non-coding regions 
because it has been shown that non-coding regions can be involved in diverse biological 
functions [416]. In the human genome, non-coding variants may have several regulatory 
functions, including interaction with TFBS and miRNA target sites, creating splice sites and 
acting as exonic splicing [417], which may affect gene expression. Thus, in our intensive in 
silico analyses, we found alterations at all these levels.  
Previous studies showed that a SNP located at TFBS may have multiple effects: (1) 
often, a SNP does not change TF and binding site interaction nor alters gene expression, since 
a TF may recognize many binding sites, (2) in other cases, a SNP can increase or decrease 
binding ability, leading to allele-specific gene expression and (3) more rarely, a SNP can 
eliminate the natural binding site or create a new binding site [418]. However, SNPs within the 
regulatory elements of a gene may alter TFBS, affecting the strength of enhancers and 
promoters, which may result in dysregulation of gene expression [418]. In C1QC gene, we 
found one variant and other in LD that may change binding of TFs (NERF1a and CAT8). 
NERF1a contribute to the decrease of transcriptional levels, promoting a downregulation of 
C1QC gene expression and may be a risk factor for TTR-FAP Val30Met patients, while CAT8 
seems to have an opposite effect, which may lead to better glucose delivery in the brain, and 
possibly may play a protective role. In addition, we found one variant in MEK1 gene that can 
alter binding of the TF, promoting upregulation of this gene. Similarly, we found a variant in LD 
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in the AR gene that may alter TFBS, promoting upregulation of this gene in the female late-
onset group. 
Additionally, splicing, by removing introns from the primary transcripts of genes, as well 
as alternative splicing, whereby a single gene produces various mRNAs and protein isoforms 
with different functions, are other fundamental processes in gene expression [419]. SNPs 
located within two bp of an intron–exon junction, or located at exonic splicing enhancer (ESE) 
or exonic splicing silencer (ESS)-binding sites, affecting 5’ and 3’ splice sites, branch sites and 
polyadenylation signals, may disrupt mRNA splicing and severely affect protein function [420]. 
It may cause several hereditary diseases, as approximately 15% of mutations affect pre-mRNA 
splicing patterns [421]. Mutations that disrupt any DNA sequence motifs, intronic and exonic 
elements, regulatory factors and spatial signal pathway may deregulate splicing machinery 
and may be direct causal agents of disease or contribute to the determinants of disease 
susceptibility or modulator of disease severity [419, 422]. Using FuncPred, we found two 
variants in the C1QA that cause alterations in ESE and ESS motifs, possibly affecting the 
splicing machinery, which was further explored using HSF and ESEfinder software to detect 
specific alterations in splice sites and modifications on ESE motifs. As it was detected 
alterations in conformation or creation of new splice sites, this may explain the association of 
these variants with disease later-onset. Regarding MEK1 gene, we found one variant in LD 
that may affect splicing regulatory factors, which may interfere with the regulation of MEK1 
expression, decreasing AO. 
miRNAs play an important role in pathogenesis of several human diseases, including 
neurological disorders [423-426], and regulate a variety of cellular processes through the post-
transcriptional repression of gene expression [427]. Overall, these in silico approaches provide 
data for miRNA target detection and insight into the role of miRNAs in the gene expression. 
Thus, SNPs can affect miRNA binding when localized in miRNA target sites and may eliminate 
an existing binding site or create an erroneous binding site. A number of studies have shown 
that SNPs in 3’ UTR can alter putative miRNA targeting activity, affecting gene expression 
levels [428-430]. In TTR-FAP Val30Met, it was previously described that the presence of a 3’ 
UTR variant on the V30M haplotype in Swedish carriers may function as a potential miRNA 
binding site leading to downregulation of mutated TTR allele expression, which can explain the 
low penetrance and an increase in AO of the disease in Swedish patients [114]. However, 
Norgren et al., 2012 showed through an in vitro study that the SNP found in the 3’ UTR of the 
TTR did not affect TTR mRNA expression, and therefore this may not be the mechanism that 
explains the decreased penetrance or AO in the Swedish population [431]. The algorithms 
used to assess miRNA targets sites for SNPs were MicroInspector and PITA and to cross 
analysis of all miRNAs, RNAhybrid and RegRNA were used. In our study, we applied different 
algorithms, miRWalk and mirDIP, because these combine the results of different software. 
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Using FuncPred for the MEK1 gene, we also found one variant in LD that may affect miRNA 
binding sites and possibly may influence the regulation of MEK1 expression. The identification 
of these SNPs could be useful as molecular biomarker for disease diagnosis and prediction of 
therapeutic response, as has already been suggested in other amyloid-related disorders. [432]. 
 Therefore, these studies have shown that in silico analysis using different 
bioinformatics tools provide an excellent framework to validate our findings, since they give a 
fast, efficient and reliable data, but a critical analysis is required because different software 
may have different algorithms and thresholds [433].  
 
5.2.4. Importance of gene-gene interactions 
 
As a first approach, we tested only the main effects of the variants found for each 
candidate-gene in AO variability of TTR-FAP Val30Met. However, there is recognition in the 
literature of a large complexity in genetic variation involving multiple genes and with several 
levels of interaction [434]. Therefore, we also focused in gene-gene interactions underlying 
this trait, which may be very important to understand the global structure and function of 
genetic pathways and the evolutionary dynamic of complex genetic mechanisms associated 
with AO [434]. Previous studies provide evidence of two gene-gene interactions that increase 
AD risk [435] and also interactions that may influence the risk for PD [118].  
Initially, gene-gene interactions were thought to play a major role in susceptibility to 
human common diseases, since it results in the combination of multiple interacting genetic 
variants at different genes, and environmental factors for disease manifestation [436, 437]. 
However, interaction analysis may also have an important function in Mendelian diseases that 
display large phenotypic heterogeneity [310]. 
Several statistical methods and software have been developed to consider interaction 
analysis between loci [438-441], due to limitations of parametric-statistical methods for 
detection of interactions between genes. Whereas some are more focused on increasing the 
power to detect effects, others were developed to detect interactions that are informative about 
the biological and biochemical pathways. In this study, we used the multifactor-dimensionality 
reduction (MDR) method, which it is effective in multilocus data reduction, to improve the 
identification of SNP combinations involved in disease risk [251]. Moreover, this approach is: 
(1) non-parametric (values of statistical parameter are not based on any hypothesis) and (2) 
genetic model-free (any particular inheritance model is assumed). Previous studies have 
demonstrated that MDR has sufficient power to detect high-order interactions even in the 
absence of any statistically significant main effects and in relatively small sample sizes [442, 
443]. In addition, combination of cross-validation and permutation testing help to decrease the 
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false positive results [443, 444]. Therefore, analysing gene-gene interactions according to the 
pathway or taking into account disease markers already described, through this method 
allowed us to find highly significant interactions between variants of several genes, which may 
act together in the modulation of AO variation in TTR-FAP Val30Met patients, further 
supporting our results. 
Contrary to Soares et al., 2005, in our sample we did not find any strong interaction 
between APCS and RBP4 genes, leading us to hypothesis that these two genes do not act 
together as genetic modifiers of AO in TTR-FAP Val30Met. This finding is supported by the 
fact that there is no biochemical or biological evidence described justifying the relation between 
both genes. Furthermore, we found highly significant interactions for variants of C1QA-C1QC 
and NGAL-MMP-9, as would be expected, since C1q molecular structure is composed by three 
polypeptide chains (A, B, C) that associate to form a heterotrimeric collagen-like triple helix 
[445] and NGAL forms a complex with MMP-9 [362]. Thus, this reinforces our statistical 
findings and indicates that these genes may have a stronger effect acting together as genetic 
modifiers. 
 
5.3. Mitochondrial DNA copy number as a potential biomarker of 
TTR-FAP Val30Met 
 
Each human cell contains hundred to several thousand mitochondria, each carrying 2-
10 copies of mtDNA [180]. Consequently, mtDNA copy number may differ according to type of 
the cell and tissue, which may be altered with cell differentiation, hormones and exercise [446]. 
Previous studies have demonstrated that mitochondrial biogenesis, mediated through mtDNA 
copy number, is crucial in the development of many disorders, including neurodegenerative 
diseases [302, 447]. In PD, the role of mitochondria is quite evident and might be directly 
involved in the mechanism of this disease, while in AD, the function of mitochondria is more 
indirect and mitochondrial dysfunction probably occurs in later stages [448]. Also, Jenkins et 
al., 1993, have suggested that mtDNA sequence variants may interact with the HD mutation 
and affect disease AO [449]. 
 Moreover, as mtDNA is almost exclusively transmitted through the maternal lineage 
[166], the measurement of mtDNA copy number may also be a good marker to assess the 
gender-related differences in AO depending on the gender of the transmitted parent and of the 
offspring. Therefore, our hypothesis was that mtDNA content might function as a potential 
modifier factor of AO variability in TTR-FAP Val30Met and as an important biomarker to 
unravelling the biological mechanisms underlying to this pathology. 
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 Following this strategy, we were able to find, for the first time, a significant association 
between mtDNA copy number of peripheral blood leukocytes and V30M TTR carriers.  
Individuals carrying the V30M TTR variant (patients and asymptomatic carriers) have a 
significantly higher mean mtDNA copy number than controls. Furthermore, the highest mtDNA 
copy number mean per cell was observed in early-onset patients. Importantly, early-onset 
offspring showed a significant increase in the mtDNA copy number, when compared with their 
late AO parents. However, these results contrast with studies in other diseases such as HD 
[301] and PD [302], in which the mtDNA copy number by cells decreased in disease-causing 
variant carriers, possibly revealing a compensatory effect. 
In these diseases such as in AD, oligomer forms are known to initiate the cascade of 
pathogenic events [448, 450], it is speculated that the mechanism resulting in 
neurodegeneration in TTR-FAP Val30Met is similar. Thus, in the presence of TTR oligomer 
and/or aggregates, which might be toxic for cells, the mitochondrial and ER function, may be 
impaired, leading to mitochondrial dysfunction. Consequently, it may increase formation of 
oxidative species as result of imbalance between the increased production of ROS and limited 
anti-oxidant defences [451]. A previous study suggested that endogenous or exogenous 
oxidative stress may increase the mtDNA content and it may function as an early molecular 
event [303]. Thus, an increase of the levels of mtDNA and cytochrome c-oxidase (the terminal 
enzyme complex of the respiratory chain) in the cytoplasm and decreasing the number of 
mitochondria in the tissues, may lead to the formation of more TTR aggregates. Taken 
together, this initiated a vicious cycle, further enhancing mitochondrial dysfunction and 
decreasing the energetic metabolism [306, 448]. It is conceivable that to increase 
mitochondrial biogenesis in response to severe mitochondrial dysfunction may lead to 
production of a compensatory response to maintain normal mitochondrial function, thereby 
increasing mtDNA copy number possibly due to decreased cytochrome c oxidase activity [303, 
447]. Therefore, this complex may act in both neurodegeneration and neuroprotection [452]. 
Importantly, the transmitting-parent analysis allowing us to suggests that early-onset offspring 
possibly receive from their affected mother a mitochondrial risk effect, modulating AO. 
However, regarding gender-related differences observed in TTR-FAP Val30Met 
patients, we did not find any association with mtDNA copy number, suggesting that mtDNA 
copy number does not seem have a gender-linked effect, similar to what was observed in other 
diseases [308, 309], and it may be under the control of nuclear genes, inherited from either the 
mother or the father. 
Therefore, these findings suggest that mtDNA copy number seems to have a significant 
effect in AO variability, particularly, when parent-offspring transmission is taken into account, 
leading us to hypothesize that a mitochondrial deregulation seems to play a key role in TTR-
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FAP Val30Met pathogenesis, since an increased mtDNA copy number is associated with 
earlier TTR-FAP Val30Met events. 
 
5.4. An integrated perspective of biological mechanisms involved in 
AO of TTR-FAP Val30Met 
 
During this project, we found various candidate-genes involved in some TTR 
associated pathways, all contributing to TTR-FAP Val30Met pathology, and more importantly 
contributing to AO modulation, delaying or anticipating symptoms onset. 
Extracellular TTR amyloid deposition triggered by V30M variant can affect several 
tissues and organs, mainly the PNS, and may lead to neuronal toxicity and death [453]. Clinical 
and experimental studies have shown that early non-fibrillary TTR aggregates in TTR-FAP 
Val30Met nerves may be the most toxic forms [454, 455] and, therefore they have been 
recognized as the essential factors to unravel molecular signalling mechanisms related to 
neurodegeneration [37, 133, 456]. These arguments lead us to suggest that AO differences 
within of same family and, particularly, between generations caused by the same V30M 
variant, may be associated with diverse biological and molecular mechanisms correlated with 
the aggregation state. 
In AD, Aβ is known to cause an increase in the mitochondrial dysfunction, apoptosis 
and activation of caspases, which induce ER stress, interfere with Ca2+ homeostasis and alter 
MAP kinase signalling [457]. Similarly, these same alterations have been described in TTR 
and, particularly, in TTR-FAP Val30Met [133, 291, 455]. Furthermore, a recent study with a 
mouse model of TTR-FAP Val30Met have shown that genetic background seems to modulate 
amyloidogenesis through the involvement of several factors in the formation of misfolded 
proteins and amyloid deposition, TTR and disease markers including ER stress, apoptosis and 
complement activation [458]. 
 
TTR aggregates, MEK-ERK MAP kinases pathway genes and other 
players 
 
The interaction of low-molecular-mass TTR aggregates with the membrane lipids or 
specific receptors may lead to Ca2+ deregulation or to activation MEK-ERK MAPK signalling 
cascade [37, 459]. This will lead to activation of TF that may have the ability to induce 
increased expression of different molecules causing, oxidative stress, inflammatory response 
Discussion 
 
123 
 
and mitochondrial dysfunction, consequently resulting in apoptotic pathways. [37, 218, 456]. 
Thus, RBP4 may have a protective role in this process since the RBP4-retinol complex binds 
to TTR, leading to stabilization of TTR tetramer, preventing dissociation in TTR monomers and 
oligomers, which are toxic for cells, and contributing to normal signal transduction pathways 
and a later AO. Therefore, this may also prevent abnormal activation of MEK-ERK MAPK 
signalling cascade. 
Furthermore, MEK1/2 genes, which are associated with ERK1/2 genes, belong to a 
classic genomic signalling pathway that may increase and/or decrease gene expression, 
associated with cell survival. Activation of this cascade is triggered by several extra- and 
intracellular stimulus as growth factors, pro-inflammatory cytokines, hormones and various 
oxidative stress and ER stress factors (including protein misfolded and aggregates), which 
may lead to transcription of inflammatory cytokines and oxidative stress-related molecules, 
resulting in ECM genes deregulation [218]. The association of MEK1/2 with ECM genes (BGN, 
NGAL and MMP-9) is essential for tissue homeostasis as well as peripheral nerve regeneration 
[360]. Therefore, variants found in MEK1/2 genes may induce an increased or decreased gene 
expression of BGN, NGAL and MMP-9, contributing to delaying or anticipating disease 
symptoms. Subsequently, TTR aggregates besides ECM-related components, also include in 
its constitution other elements as APCS, which is present in all amyloid deposits [460]. Thus, 
the binding of APCS and ECM genes with amyloid fibrils may have an inhibitory effect on the 
toxic response, leading to stabilization of fibrils, preventing proteolytic degradation [238], which 
may delay the onset of the disease. 
Interestingly, this cascade of events may also interfere with inflammatory processes 
through the release of inflammatory factors, such as pro-inflammatory cytokines, which may 
be involved in attenuation of injury mechanism. Thus, interactions of MEK1/2, BGN, NGAL and 
MMP-9 genes with C1Q complement genes (C1QA and C1QC), which have a major role in 
the immune defence mechanism, may have a strong synergistic interaction as we observed in 
the gene-gene interaction analysis. Additionally, NGAL forms a complex with MMP-9 [362] and 
on its turn, C1q molecule is formed by three polypeptide chains (A, B, C) associated between 
them, leading to an increased gene expression. Consequently, the interaction of these genes 
with HSP27, that functions mainly as a molecular chaperone, promoting the release of 
inflammatory stimulus, inducing expression of TNF-α and IL1-β cytokines, causing an 
increased expression of these genes and may, ultimately, contribute to a later AO. 
Additionally, YWHAZ gene may also interact with MEK-ERK MAPK signalling genes 
contributing to increase the protective effect in the toxicity induced by TTR aggregates. 
Therefore, one can speculate that variants in these genes may possibly be associated with a 
later AO. 
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Interaction of AR gene with MEK/ERK and HSPs genes 
 
Regarding AR, encoding a sex-steroid hormone, there is increasing evidence that it 
may also be involved in MAPK/ERK signalling, since androgens are known to activate several 
signalling pathways in neuronal and non-neuronal cells. This event may lead to activation of 
MAPK/ERK signalling through intracellular AR, which has been shown to positively regulate 
cell survival against apoptosis [461]. Thus, the interaction between AR and MAPK/ERK 
signalling cascade genes may be essential to neuroprotection, which may predict that variants 
found in these genes, associated with a later AO, may play a neuroprotective role in males 
and females.  
In addition, there is evidence in the literature that AR gene can also interact with HSPs, 
when a stress event occurs and, this last one on its turn, interacts with MAPK/ERK signalling 
cascade genes, probably also contributing to cellular protection. HSP play an important role in 
protein folding and quality control, as well as in regulating cellular homeostasis and survival 
[462]. This way, the joint effect of these genes may further increase the protective effect, 
allowing us to suppose that variants associated with late-onset strengthen this interaction, 
whereas variants associated with early-onset can induce an early neuroprotective intracellular 
stress response by increasing HSP27 expression, activating the mechanisms of cell defence 
to prevent neurodegeneration. 
 
ATXN2 gene, Ca2+ homeostasis and mitochondrial dysfunction 
 
Interestingly, previous studies have shown that TTR aggregates may bind to the 
plasma membrane inducing cytotoxicity and leading to an increased membrane fluidity [459]. 
In addition, TTR aggregates may also cause disruption of the cellular membrane increasing 
Ca2+ influx from the extracellular medium and Ca2+ efflux from the ER causing ER stress, 
resulting in Ca2+ deregulation and, consequently, mitochondrial dysfunction [218]. 
Concerning ATXN2, this gene is involved in many cellular processes, including Ca2+ 
homeostasis (crucial to normal functioning of the cell and signal transduction) and 
mitochondrial activity. Thus, the association of the (CAG)23-28 alleles at the ATXN2 locus with 
TTR aggregates and the Ca2+ channels, namely L-and N-type voltage-gated calcium channels 
(VGCCs), may lead to an increased Ca2+ influx, promoting ROS and abnormal signal 
transduction, that result in oxidative stress [463]. Accumulation of ROS can induce Ca2+ 
deregulation and also mitochondrial dysfunction. Combining previously published studies with 
our data, (CAG)23-28 alleles at the ATXN2 locus may contribute to accelerate amyloid deposition 
and result in an earlier AO.  
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In summary, the interaction of all these different genes and pathways may play an 
important function in the TTR-FAP Val30Met pathology, and more importantly, modulate AO 
as a consequence of a deregulation of all these mechanisms.  
 
5.5. Strengths of our study 
 
In this study, we found several different variants that explain part of AO variability. We 
are confident on the results since we had a special concern with the design and analysis in 
this project. Furthermore, there are some key points as described below that strengthen the 
results found. 
 
1. Sample size 
 
We have one of the largest sample collections available worldwide (gathering over 
2000 patients, belonging to more than 500 families) for a rare disease. This is a major 
advantage because it allows us to have a large statistical power to identify genetic modifiers 
related with AO variation in TTR-FAP Val30Met. 
 
2. Reliable of definition of AO 
 
AO (age at which the first sensorimotor symptoms of TTR-FAP Val30Met occur) is the 
most commonly used phenotype in study for the identification of TTR-FAP Val30Met modifiers. 
There is some criticism to the use of AO, since some authors argue that its determination is 
not always easy and can be one of the limitations of these studies. However, in our study, we 
have a high degree of confidence in this information because over 75 years the patients have 
been clinically well characterized by a medical team specialized in TTR-FAP Val30Met, always 
using the same criteria. We cannot guarantee that other studies in other populations have used 
the same criteria, and this can be a source of bias leading to different results.   
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3. Family-centred approach 
 
Furthermore, the family-centred approach that we used to study the AO variation of 
TTR-FAP Val30Met prevents population stratification, unlike case-control studies. In addition, 
we revealed different results compared to the previous case-control studies, reinforcing the 
previous results and further strengthening our knowledge in the investigation of AO, which can 
be applied to the study of other genes. In addition, the analysis of common genetic background 
among individuals of same family allowed us to investigate population-specific and common 
genetic variants between different populations, which affects the ability to confirm a modifier 
effect.    
 
4. Using a powerful statistical and in silico analysis  
 
The statistical analysis that we used focused on parametric tests, which have an 
increased statistical power when compared with non-parametric tests. Furthermore, to account 
for non-independency of AO between members of the same family and the correlated nature 
of data we used GEE [233, 464]. This quite powerful statistical method has gained popularity, 
since it is computationally efficient and easy to integrate data. This method uses a multi-level 
or hierarchical modelling where the correction between the repeated measurements within the 
same family is assumed and several covariates can be included in the model [464]. 
Furthermore, GEE has a greater power to detect a statistically significant effect than other 
similar methods [465]. In addition, we paid special attention to multiple testing corrections to 
prevent type-I errors and we applied a large diversity of in silico analysis, which were helpful 
to decipher the regulatory mechanisms associated with AO variation. 
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Using different approaches, this study focused on one major topic to understand better 
the AO variability and the role of the molecular mechanisms in the TTR-FAP Val30Met. The 
main conclusions of our studies are: 
 
1. We confirmed the involvement of the APCS, RBP4, C1QA and C1QC genes as 
modifiers of AO variation. This study has also provided new insight, since we found 
variants different from those described in previous studies associated with earlier and 
later AO. These results also strengthen the fact that different genetic background 
between populations can result in different disease pathologic mechanisms. 
2. We were able to unravel, for the first time, new candidate-genes involved in signal 
transduction pathways associated with AO variability in TTR-FAP Val30Met Portuguese 
patients (BGN - in the female group, NGAL, MEK1, MEK2, HSP27 and YWHAZ). These 
findings revealed new pathological mechanisms that may have important clinical 
implications, in the genetic counselling and follow-up of disease-causing variant 
carriers. In addition, activation or inhibition of the variants of these genes may be useful 
for the development of novel therapeutic approaches. 
3. The gender-related differences regarding AO may be related to sex-linked genes, since 
we have found, for the first time, genes encoding sex-steroid hormones (AR) and/or 
located on the X-chromosome (AR and BGN) significantly associated with AO both in 
males and in females, confirming previous epidemiological findings. 
4. The presence of, at least, a normal CAG repetitive tract with a length higher than 
(CAG)22, ((CAG)23-28), in the ATXN2 gene may modify AO in TTR-FAP Val30Met, 
leading to a decrease in AO, showing that not only SNPs are associated with AO 
variation, but also oligonucleotide repeats. 
5. The assessment of functional implications using in silico analyses through different 
bioinformatics tools was important to validate our results and to disentangle new 
biological and molecular mechanisms. This way, we have found interesting and 
unreported findings that could influence the regulation of gene expression regarding 
TFBS, splicing regulatory factors and miRNA binding sites, which might have impact in 
AO and phenotypic variability. 
6. We found a strong genetic interaction between C1QA and C1QC genes in TTR-FAP 
Val30Met late-onset patients and NGAL and MMP-9, allowing us to conclude that these 
genes may act together as AO genetic modifiers and can have a stronger effect in AO 
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than when acting independently. Therefore, this shows that gene-gene interactions 
might be important in AO variation, modulating this trait that is considered a complex 
trait. 
 
7. The mtDNA copy number of peripheral blood leukocytes was associated with V30M 
TTR variant carriers, allowing us to suggest that the mitochondrial dysfunction is 
associated with TTR-FAP Val30Met mechanisms, and may function as a biomarker of 
the disease. 
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In this study, we have found very interesting and promising results that led to 
understand genetic factors involved in AO variability, which behaves as a complex phenotype, 
with several factors involved interacting and that may have a great impact to TTR-FAP 
Val30Met patients and in other amyloid-related disorders. However, there is still much to 
unveil.  
In the future, we intend: 
 
1. To replicate these findings, using this approach, in other populations such as Spain, 
Japan and Sweden, to compare and confirm the mechanisms involved in AO variability; 
 
2. To continue to disentangle further genetic modifiers related to AO variability in TTR-
FAP Val30Met, identifying and characterizing functionally new candidate-genes, to 
deepen our results and provide more insights into the underlying mechanisms involved; 
 
3. To unravel rare genetic variants associated with AO variability and, then to assess 
possible regulatory function of the variants found, using exhaustive in silico analyses 
and in vivo studies; 
 
4. To investigate the genetic interaction between the significant candidate-genes found 
associated with AO and TTR gene to assess whether the join effect of these genes is 
stronger than individual effects only; 
 
5. To further explore interactions of SNPs with (CAG)23-28 alleles at the ATXN2 locus to 
assess whether it has a significant effect in the modulation of AO; 
 
6. During this project, it was not possible to have access to patients' tissue biopsies as 
previous intended. However, we still aim to study in the future the involvement of the 
epigenetic modifications in liver biopsies of transplanted TTR-FAP Val30Met early- and 
late-onset patients in order to investigate their effect in AO variation and in gender 
differences; 
 
7. To apply the information gathered about mRNA splicing alterations in therapeutic 
approach as antisense oligonucleotides; 
 
8. To use next generation sequencing technologies in TTR-FAP Val30Met patients to 
identify high risk alleles in AO at novel genes in order to establish genetic profiles.
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Appendix 1 
 
Complement C1q genes as genetic modifiers of age-at-onset variability in FAP 
ATTRV30M 
Authors: Andreia Dias1,2, Diana Santos1,3, Teresa Coelho4, Miguel Alves-Ferreira1,3, Jorge 
Sequeiros1,3, Isabel Alonso1,3, Alda Sousa1,3, Carolina  Lemos1,3 
1UnIGENe, IBMC - Instituto de Biologia Celular e Molecular, i3S,  
2Faculdade de Ciências, and  
3ICBAS; Univ. Porto; and 4 UCA - Unidade Corino de Andrade, CHP – Centro Hospitalar do 
Porto 
 
Abstract 
Introduction: Familial amyloid polyneuropathy (FAP ATTRV30M) is an autosomal dominant 
disease and the most frequent mutation in the TTR gene in Portugal is V30M. FAP ATTRV30M 
shows a wide variation in age-at-onset (AO) [19-82 years, in the Portuguese population], 
including within some families, offspring often showing anticipation in AO when compared to 
their parents. Our aim was unravel if C1QA and C1QC genes might act as genetic modifiers 
of AO. 
Methods: We analysed 267 patients (117 families) and performed an intensive in silico 
analysis to assess miRNAs, splicing sites and transcription factor binding sites (TFBS) 
alterations. We also explored gene-gene interactions.  
Results: We found two statistically significant variants for C1QA gene: GA genotype (p<0.001) 
of rs201693493 and CT genotype (p<0.001) of rs149050968 were associated with later AO (> 
50 years) (increasing the mean AO in 16 and 10 years, respectively). In silico analysis 
demonstrated that rs201693493 may alter splicing activity.  Regarding C1QC, we found four 
statistically significant variants: GA genotype (p = 0.003) of rs2935537, CT/TT genotype (p = 
0.037) of rs15940, GA genotype (p < 0.001) of rs201241346 and GA genotype (p < 0.001) of 
rs200952686. The first three variants were associated with earlier AO (≤ 40 years) decreasing 
mean AO to 5 and 11 years, while the last one was associated with late-onset, leading to an 
increase of 32 years in mean AO. In silico analysis showed that rs2935537 may change 
NERF1a factor binding. 
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Discussion: Some variants in C1QA and C1QC were associated with late-onset and they can 
have a protective role in FAP ATTRV30M. Three variants in C1QC were associated with an 
early-onset acting as risk factors. A strong interaction between C1QA and C1QC was 
found.  Therefore, our results are important to understand differences in AO between family 
members, with possible implications in genetic counselling.  
 
ARiA VI Symposium, Advanced Research in TTR-Amyloidosis VI, Vienna, Austria, 
2017.  
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Appendix 2 
 
The hidden story behind gender differences in familial amyloid polyneuropathy (FAP) 
ATTRV30M 
 
Authors: Santos D1,2; Coelho T3; Alves-Ferreira M1,2; Sequeiros J1,2; Alonso I1,2; Grazina M4; 
Sousa A1,2; Lemos C1, 
1Instituto de Investigação e Inovação em Saúde (I3S); and UnIGENe, IBMC – Institute for 
Molecular and Cell Biology, Univ. Porto; 
 2ICBAS, Instituto Ciências Biomédicas Abel Salazar, Univ. Porto;  
3Unidade Corino de Andrade (UCA), Centro Hospitalar do Porto (CHP), Porto, Portugal; 
4Center for Neuroscience and Cell Biology, Univ. Coimbra - FMUC 
 
Abstract 
 
Background: Familial amyloid polyneuropathy (FAP ATTRV30M) is an autosomal dominant 
systemic amyloidosis, due to a point mutation in the transthyretin (TTR) gene (chr18q12.1). 
The most frequent, V30M is associated with several clusters. Among Portuguese families, FAP 
shows a wide variation in in age-at-onset (AO) [19-82 yrs] and this variability is also apparent 
between generations. Also, significant differences in AO regarding gender are known in 
Portuguese series, where women were found to have a later-onset than men. Moreover, 
mother-son pairs showed larger anticipation (> 10 yrs) while the father-daughter pairs only 
showed residual anticipation. Therefore, to unravel these gender-related differences in AO, we 
studied three candidate-genes (AR, HSD17B1 and BGN) linked to sex-steroid hormones or X-
linked as genetic modifiers of AO. We also evaluated if mitochondrial DNA (mtDNA) copy 
number is associated with AO. 
 
Methods: We analysed a DNA sample of 318 Portuguese patients (106 families) 
corresponding to 152 males and 166 females. Additionally, asymptomatic carriers and non-
carriers were also included in the study. Polymorphisms in candidate genes were genotyped 
by several standard techniques and mtDNA copy number was assessed using appropriate 
software for analysis.  
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Results: Our patients’ sample shows a mean AO of around 39 years, but mean AO in males 
(37.28) is lower than in females (40.52), as already described in the literature. Moreover, we 
found some polymorphisms significantly associated with AO variation. For the AR gene, in the 
male group, three polymorphisms were associated with an early AO, while in the female group, 
four were associated with both an early and later AO. Regarding parental transmission in this 
gene, for rs5919392, we found that e affected mothers transmitted the T allele more often than 
expected (which is associated with an early-onset).  For HSD17B1 gene, we did not find any 
significant results. Concerning BGN gene, in the male group no significant results were found 
associated with AO but in the female group, one polymorphism was associated with a later 
AO. Regarding mtDNA copy number, there are significant gender differences when we 
compared controls and patients groups. Patients present an mtDNA copy number higher than 
controls. We also found significant differences in the female group when we compared late 
and early patients. 
Conclusions: This study revealed for the first time the contribution of the AR and BGN genes 
as AO modifiers both in males and females. Moreover, it was important to show that mtDNA 
copy number is associated with FAP. Therefore, we showed that FAP expresses differently in 
males and females. These results are significant to improve clinical management, with 
important implications in genetic counselling and therapeutic strategies.  
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